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Trap by Pain
ACTIONS
Oxycodone is a semi-synthetic narcotic analgesic with actions qualitatively 
similar to those of morphine, particularly involving the central nervous 
system and organs composed of smooth muscle. The principal therapeutic 
actions are analgesia and sedation. Oxycodone retains at least one half of 
its analgesic activity when administered orally. In addition to caffeine. 
Percocet and Percocet-Demi also contain the non-narcotic antipyretic anal­
gesic acetaminophen, which exerts its effects in a manner similar to the 
salicylates, but without the anti-inflammatory or uricosuric properties. 
Acetaminophen is rapidly and almost completely absorbed in the gastro­
intestinal tract: peak plasma levels are reached within ten minutes to 
one hour.
IN D ICA TIO N S
Relief of moderate to moderately severe pain (Percocet), or relief of mild to 
moderate pain (Percocet-Demi), with or without fever, especially in patients 
who are allergic to acetylsalicylic acid or for whom acetylsalicylic acid is 
contraindicated.
CO N TR A IN D IC A TIO NS
Status asthmaticus, pre-existing respiratory depression or convulsive states, 
hypersensitivity to oxycodone, acetaminophen, or caffeine.
Unlike acetylsalicylic acid, acetaminophen is not contraindicated in pa­
tients with peptic ulcer or gout.
W ARNINGS
Oxycodone can produce drug dependence of the morphine type and has the 
potential for being abused. Psychic dependence, physical dependence and 
tolerance may develop upon repeated administration, as with other oral nar­
cotic medication. May impair the mental and/or physical abilities required 
for the performance of potentially hazardous tasks, such as driving a car or 
operating machinery. Patients should be cautioned accordingly. Additive 
CNS depression may occur in patients receiving other narcotic analgesics, 
general anesthetics, monoamine oxidase inhibitors, tricyclic antidepres­
sants, phenothiazines or other tranquilizers, sedative-hypnotics or alcohol.
If combined therapy is contemplated, the dose of one or more of the agents 
should be reduced. Safe use in pregnancy has not been established 
relative to possible adverse effects on fetal development, therefore Per­
cocet or Percocet-Demi should not be used in pregnant women unless, in 
the judgment of the physician, the potential benefits outweigh the possible 
hazards. The administration of Percocet or Percocet-Demi to obstetrical 
patients in labor may be associated with respiratory depression of the new­
born. Percocet should not be administered to infants or children, although 
Percocet-Demi may be considered for children of six years or older.
PRECAUTIONS
The respiratory depressant effects of narcotics and their capacity to elevate 
cerebrospinal fluid pressure may be markedly exaggerated in the presence 
of head injury, other intracranial lesions or a pre-existing elevated in­
tracranial pressure. The diagnosis or clinical course in patients with head 
injuries or with acute abdominal conditions may be obscured by narcotic 
drugs. Give cautiously to elderly or debilitated patients due to the risk of 
cardiac or respiratory depression, as well as to patients with hemorrhage, 
severe impairment of hepatic, respiratory or renal function, hypothyroidism, 
Addison's disease, prostatic hypertrophy or urethral stricture. Narcotic 
analgesics should only be employed for the treatment of headaches when 
no other treatment is effective, in order to minimize risk of psychological 
and physical dependence.
ADVERSE REACTIONS
Light-headedness, dizziness, sedation, nausea and vomiting may occur, as 
well as euphoria, dysphoria, constipation and pruritus.
D R U G  INTERACTIONS
May be additive with other CNS depressants.
M AN A G EM EN T OF OVERDOSAGE
Signs and symptoms: Respiratory depression, extreme somnolence progress­
ing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and 
sometimes bradycardia and hypotension. In severe cases, apnea, circulatory 
collapse, cardiac arrest and death may occur. Acute acetaminophen intoxi­
cation is characterized by anorexia, nausea, vomiting and sweating within 
two or three hours of ingestion, and possibly cyanosis with methemo­
globinemia; enlargement and tenderness of liver, accompanied by 
abnormally high liver function tests, occur within 48 hours, followed by 
jaundice, coagulation defects, myocardiopathy, encephalopathy, renal 
failure and death due to hepatic necrosis. A dose of 10 g of acetaminophen 
is intoxicating, possibly fatal in excess of 15 g. Hepatic toxicity occurs when 
the plasma levels reach 300 p g /m l within four hours of ingestion. 
Treatment: Re-establish adequate respiratory exchange. Naloxone, nalor­
phine or levallorphan are specific antidotes against narcotic-induced 
respiratory depression. An appropriate dose of antagonist should be ad­
ministered preferably intravenously, and repeated as needed to maintain 
adequate respiration; the patient should be kept under continued 
surveillance. Instructions in the package insert provided by the manufac­
turer should be carefully followed. Do not administer an antagonist in the 
absence of clinically significant respiratory or cardiovascular depression. 
Employ oxygen, intravenous fluids, vasopressors and other supportive 
measures as indicated. Gastric emptying by emesis or lavage may be 
helpful. Hemodialysis carried out within ten hours of ingestion may be of 
some value. Plasma levels of acetaminophen should be determined.
DOSAGE A N D  ADMINISTRATION
Percocet Tablets: Usual adult dose is one tablet every six hours, as needed 
for pain.
Percocet-Demi Tablets: Usual adult dose is one or two tablets every six 
hours. Children twelve years and older: half a tablet every six hours.
Children six to twelve years: a quarter of a tablet every six hours. Not in­
dicated for children under six years of age.
Dosage should be adjusted according to the severity of the pain and the 
patient’s response.
DOSAGE FORMS
Percocet Tablets: Bottles of 40,100 and 500 white, scored tablets, each 
containing oxycodone hydrochloride 4.5 mg, oxycodone terephthalate 0.38 
mg, acetaminophen 325 mg, caffeine 32 mg 
Percocet-Demi Tablets: Bottles of 40,100 and 500 blue quadrisected 
tablets, each containing oxycodone hydrochloride 2.25 mg, oxycodone 
terephthalate 0.19 mg, acetaminophen 325 mg, caffeine 32 mg.
Complete prescribing information available on request.
Peicocel
fits the pain and the patient
Only Percocet combines acetaminophen with the 
effectiveness of oxycodone, to provide relief of moderate 
to moderately severe pain.
A single dose of Percocet begins to act within 15—30 
minutes, and may provide up to six hours of soothing relief.
£ndo Laboratories
7 0 0 0  Park Avenue,
Montreal, P.Q. H3N 1X1
Subsidiary of E.l. Dupont de Nemours Co. (Inc.)
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Le journal canadien de chirurgie
(613) 731-9331
The Canadian Journal of Surgery is published by the Cana­
dian Medical Association and sponsored by the Royal Col­
lege of Physicians and Surgeons of Canada. The establish­
ment of editorial policy is the responsibility of the Royal Col­
lege. The objectives of the Journal, endorsed by the Council 
of the College, are: (1) to contribute to the effective continu­
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QUILL ON SCALPEL
This section provides a medium through which Canadian surgeons can declare themselves, briefly 
and informally, on the day-to-day affairs of surgery.
Management of Postirradiation Thyroid 
Nodules—Too Much or Too Little?
There is little doubt that people sub­
jected to irradiation of the neck in 
childhood, either by external beam 
radiotherapy for conditions of the 
tonsils, adenoids, thymus, lymph nodes 
or skin1 or from radioactive fallout,2 
are prone to diseases of the thyroid 
gland many years later. Palpable ab­
normalities of the thyroid are found in 
25% to 30% of such asymptomatic 
individuals who are recalled for rou­
tine examination.3'6 Thyroid cancer is 
reportedly found in 30% to 45% of 
those explored surgically.3'7 These high 
figures are not based on the presence 
of clinically evident cancers but on 
reports of specimens in which all or 
almost all of the thyroid was removed 
and sectioned closely. The cancers 
found are usually papillary in type 
and when they are adequately excised 
the patient’s prognosis is excellent.8 
Many of the cancers are not found in 
the nodule for which the operation 
was performed but elsewhere in the 
gland. In up to 80% of reported cases, 
the cancer is “occult”, a lesion rarely.
i f  C V C i ,  V.aU311tg UCaill W 1 I C 1 1  C A C 1 S C U
from patients with nonirradiated 
glands who have been followed up for 
periods of over 25 years.910
The identification of such a high- 
risk group of patients in whom the 
thyroid cancer if often multicentric, 
and the frequent finding of occult 
lesions in locations other than the 
palpably suspect area have led to 
considerable controversy and differ­
ing opinions on the optimal sur­
gical management. Total thyroidec­
tomy with its increased risk of recur­
rent laryngeal nerve damage and post­
operative hypoparathyroidism11 has 
been practised by many surgeons3'7'12 
while a conservative approach consist­
ing of partial thyroidectomy plus sup­
pression by feeding thyroid is ad­
vocated by some.8 The roles of scan­
ning3'7’13 and needle aspiration biopsy14
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in the early detection and diagnosis of 
radiation-related thyroid abnormalities, 
and of thyroxine suppression and use 
of radioactive iodine in the postoper­
ative treatment remain equally con­
troversial.1517
Getaz and colleagues, in this issue 
(page 558) report on 85 patients who 
had previously received irradiation to 
the head and neck. They were given 
thyroid hormones orally for the treat­
ment of palpable nodules detected in 
a screening program, a finding gener­
ally considered an indication for im­
mediate surgical exploration.1 The 
authors suggest that there is a group 
of patients whose nodules will disap­
pear completely or partially with sup­
pression therapy, the implication being 
that these patients will not require 
surgical intervention. This conclusion, 
although attractive, is not necessarily 
supported by their data.
Although operation was recom­
mended for all 61 patients who did 
not show a complete response, only 
21 consented. The authors do not in­
d ic a t e  the c a tc g u iy  o f  i c s p u iis iv e n e s s  
for each of these 21 patients. At least 
one carcinoma was in a partial re­
sponder. Therefore, at best, the con­
servative approach must be confined 
to those who are complete respond­
ers—in this case only 28% of the 
total. In one patient who achieved an 
initial complete response the condi­
tion later progressed and a carcinoma 
was found.
The authors correctly reaffirm 
the importance of close follow-up 
in this group of patients. Unfor­
tunately, nowhere in their manuscript 
do they report the period of time 
allowed or required to achieve a com­
plete response with suppression ther­
apy or the duration of follow-up of 
patients in their study. They found 
malignant thyroid lesions in approxi­
mately 30% of patients operated
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upon. This rate is consistent with 
those reported by most thyroid clinics 
in the United States. Presumably, 30% 
of their 40 patients who refused 
operation have carcinoma. Carcino­
ma may also exist in 30% of those 
who had a complete response of 
the palpable nodularity, since histol­
ogic examination of these glands 
was not carried out and we are not 
told whether the carcinomas that 
were found were in the nodules 
clinically palpated and suspect. 
Many clinics use thyroid feeding in 
all patients exposed to neck irradia­
tion in the absence of dominant 
nodularity on the assumption that such 
therapy will prevent the subsequent 
growth of nodules and possibly even 
cause regression of occult carcinomas. 
Results of animal studies have led to 
the theory that suppression of thyroid 
stimulating hormone (TSH) by ex­
ogenous thyroid hormone can pre­
vent the development of thyroid 
neoplasms.18'20 This conclusion has 
proved to be valid in irradiated 
i a i s  and m ic e , but has not 
been demonstrated conclusively in 
man. Nevertheless, many believe that 
the improved survival reported in pa­
tients with thyroid carcinoma who 
have been subjected to conservative 
resection is related to the beneficial 
effects of thyroid feeding on other 
remaining foci and occult lesions.8'10 
Again, close follow-up in this group 
of patients is emphasized. In other 
circumstances, suppression therapy 
with exogenous thyroxine has allowed 
previously indistinct nodules to be­
come clinically more apparent by sup­
pressing the surrounding normal tis­
sue.
Getaz and coworkers attempt to 
compare their result using triiodothy­
ronine (T3) and dessicated thyroid in 
irradiated glands with those of 
Shimaoka and Sokal21 who compared
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the suppressive effect of thyroxine 
(TO and T3 in nonirradiated glands. 
Any such comparison is obviously 
fallacious and no valid conclusions 
can be drawn. Unfortunately, TSH 
levels and corresponding thyroid doses 
are not reported although presumably 
they were estimated. Probably there 
is no difference between the use of 
T.s, T„ or dessicated thyroid as long as 
the dose is large enough to obtain suf­
ficient suppression of TSH and the 
drug product is from a reliable source 
with high quality control.
Although aspiration cytology was 
apparently performed on all nodules, 
the data are not reported. Getaz and 
colleagues suggest that patients with 
thyroiditis may respond to suppression 
but fail to report on any correlation 
between the cytologic findings and 
the response to suppression. The very 
high rate of Hashimoto's disease and 
other forms of thyroiditis occurring in 
the excised glands has been com­
mented upon by other authors. 
Swelstad and colleagues7 found that 
70% of irradiated patients with carci­
noma had associated benign condi­
tions of the thyroid, especially thy­
roiditis.
The role of needle biopsy, whether 
core, cell block or smear, is worthy of 
further comment. Twenty years ago, 
the diagnosis of carcinoma of the 
thyroid was a challenge to most 
pathologists. They needed full per­
manent sections of the capsule and tu­
mour before they could make a deci­
sion. Initially, needle biopsy was used 
only rarely in cases of solitary 
nodules.22-23 Few pathologists would 
risk a decision on a minute specimen. 
Moreover, the technique was rarely 
used to confirm a suspicious diagnosis 
of carcinoma for fear that cancer cells 
might be seeded along the needle tract. 
In recent years, increasing emphasis 
has been placed on cytologic diag­
nosis with the result that now pathol­
ogists can decide on the basis of an 
aspiration biopsy whether a tumour 
is malignant. Since a thyroid nodule 
is usually all benign or all malignant, 
there is little possibility of being 
misled by a nonrepresentative speci­
men. The myth of seeding tumour 
cells along the needle tract has been 
dispelled and the accuracy and safety 
of needle biopsy has now been con­
firmed by several large studies.24'28 It 
should, therefore, be just as effective 
a diagnostic aid in patients with 
previous irradiation as in patients 
without such a history, assuming that 
one wishes to know only the histology 
of the palpable nodule.14 Its use must
be limited to institutions where special 
expertise in the use of this technique 
has been developed. The specimen 
must be interpreted by a pathologist 
who is thoroughly acquainted with the 
pathology of the thyroid gland and 
experienced in the evaluation of needle 
biopsy material and cytologic tech­
niques.
In summary, sufficient time has 
elapsed and numbers of cases have 
accumulated for us to reconsider our 
management of patients with radia­
tion-related thyroid disease. It seems 
reasonable to consider a trial of thy­
roid suppression therapy in these pa­
tients, even those with palpable ab­
normalities of the thyroid gland, in 
the expectation that 25% to 30% will 
show complete response and disap­
pearance of the palpable abnormal­
ities as reported by Getaz and col­
leagues. Confidence in this approach 
might be strengthened further by an 
initial needle biopsy of the palpable 
nodules that fail to show neoplasm, as 
strongly advocated by Crile, Esselstyn 
and Hawk.14 Clearly, continued close 
follow-up is necessary and the parent 
must be maintained on suppressive 
doses of thyroxine indefinitely. Period­
ic examinations should assess the 
state of the gland by palpation and 
the adequacy of thyroid therapy by 
measuring TSH levels and by ensuring 
that the dosage is not producing 
chronic hyperthyroidism. One must 
recognize that up to 30% of these 
glands may harbour an occult car­
cinoma; however, it is believed that 
the patient’s welfare will not be en­
dangered if consideration of surgery 
is delayed until a nodule can 
be palpated. In the event that oper­
ation is needed, the procedures 
selected should be dictated by 
the pathological findings and clinical 
assessment at the time as for any car­
cinoma of the thyroid which is not 
radiation-related.12 The frequent oc­
currence of multifocal and occult le­
sions and the common finding of car­
cinomatous foci in areas other than 
the palpable abnormality should not 
necessarily lead to automatic total thy­
roidectomy except by surgeons special­
ized in thyroid surgery and with de­
monstrated proficiency in this opera­
tion. On the other hand, it must be 
recognized that when surgery is con­
servative the problem remains: the 
thyroid or at least part of it is still in 
the neck and the patient must be 
closely followed up indefinitely. Also 
if reoperation becomes necessary it is 
often hazardous because of fibrosis 
and scarring. Nevertheless, the re­
latively benign natural history of these 
carcinomas encourages a conservative 
surgical approach.
M arvin I. W ex ler , m  sc , m d , c m , 
fa cs, frcs  [c]
Department of surgery,
Royal Victoria Hospital,
McGill University,
Montreal, PQ
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Remuneration of Part-Time Faculty for 
Undergraduate Surgical Teaching
Members of university faculties have 
responsibilities for teaching, in re­
search and administration, in clinical 
departments of the faculty of medicine 
and in the day-to-day care of patients. 
The fourth function is intimately re­
lated to the teaching of students, in­
terns and residents in hospitals affi­
liated with the university. The degree 
of responsibility in each category 
depends on department requirements 
and personal commitment by the fa­
culty member.
Only a few years ago all clinical 
teaching was provided gratis by doc­
tors in private practice. The physi­
cians' donation of time and effort to 
the undergraduate was looked upon 
as an academic privilege. Now, in­
creasing numbers of geographical full­
time staff are being taken on by uni­
versity-affiliated hospitals and are 
being paid a salary for teaching and 
other activities. Part-time clinicians, 
however, continue to shoulder a sub­
stantial portion of the teaching load. 
For this they receive little or no finan­
cial recognition.
Teaching programs in the under­
graduate curriculum are expanding 
because of the rapid growth of med­
ical scientific knowledge and increas­
ing complexity and diversity of med­
ical technology. In the clinical years, 
the trend is towards more individuali- 
ized student-teacher contact. Increas­
ingly smaller groups of undergraduates 
meet with individual members of the 
faculty. As students advance, the 
teaching pattern changes from class 
lectures to seminars, tutorials and case 
presentations. In addition to such as­
signed teaching, faculty members
provide preceptorial teaching on the 
wards, at the outpatient clinics and 
in the operating rooms. All faculty 
members, working full time or part 
time, participate in undergraduate 
case-study programs that bring stu­
dents into contact with clinicians of 
widely varying knowledge and ex­
perience.
With the introduction of govern­
ment-financed universal “free” hos­
pital care in Canada about 10 years 
before government-financed universal 
“free” medical care, a great impetus 
was given to hospital-based health 
care. This increased the emphasis on 
the hospital-based specialist. That trend 
now appears to be decreasing and the 
need to train more community-based 
physicians is being recognized. Com­
munity-based part-time faculty mem­
bers have an essential role in clinical 
teaching within the university and in 
preparing trainees for medical and 
surgical practice outside the univer­
sity.
Teaching by the university faculty 
cannot be provided without cost 
to the department’s budget or to the 
physicians' time. Whether it is 
provided on a university campus or in 
a teaching hospital by geographical 
full-time or part-time staff, teaching 
deserves an appropriate monetary re­
ward. Members of the medical profes­
sion who are on the attending and 
academic staff at teaching hospitals 
welcome active participation in teach­
ing programs of the university. How­
ever, commitment to teaching by part- 
time faculty should be coupled with 
a reasonable financial commitment by 
the university. To date, there has been
little in the way of specific financial 
remuneration for the teaching pro­
vided by part-time faculty. At one 
time, when no clinical teachers were 
paid, teaching without financial re­
muneration was at least equitable. At 
present, some are paid and others are 
not.
While the office practice overhead 
of part-time clinical teachers increases 
yearly there is only marginal im­
provement in payment for professional 
services. No such financial disadvan­
tages apply to the geographical full­
time faculty.
Academic surgeons in private prac­
tice give up valuable time from their 
practices to teach in the university. 
Since the federal government has 
assumed financial responsibility for 
so many social services that were 
formerly voluntary, such “subsidiza­
tion” has ceased to be appropriate. 
Government now pays for the serv­
ices provided by doctors for the med­
ical care that they give to patients. 
It is therefore logical that, through the 
university, the government should re­
imburse clinical teachers for their 
contribution to the university curri­
culum.
All teaching that is recognized in a 
university curriculum should be paid 
for from the faculty budget. This bud­
get should support all teaching equit­
ably, whether it is provided by full­
time or part-time faculty.
T. Kenneth T horlakson, md, frcs,
FRCS[c ] , FACS
Surgeon general,
Division of general surgery,
Winnipeg Clinic,
Winnipeg, Man.
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CORRESPONDENCE
Effects of Oral Contraceptives 
on the Liver
To the coeditors.—I read with in­
terest Dixit’s review article con­
cerning the liver and oral contra­
ceptives (Can J Surg 23: 222, 1980), 
and I think attention should be drawn 
to one or two possibly erroneous gen­
eralizations and inaccuracies.
The author refers to both oral con­
traceptives and menopausal replace­
ment medications and lists a group of 
general long-term effects which he de­
scribes as being “common”. In fact, 
their rate of occurrence is quite low. 
Endometrial carcinoma has been re­
ported to be associated with estrone 
sulfate therapy but not with combined 
estrogen-progesterone oral contra­
ceptives; however, Silverberg and 
Makowski1 reported several cases of 
endometrial carcinoma associated with 
the use of the sequential oral contra­
ceptive Oracon, a product containing 
dimethisterone. Sequential agents are 
no longer used and indeed it is pos­
sible that combination agents may have 
a protective effect vis-a-vis endome­
trial carcinoma.2 Further, it is con­
fusing to state that estrogen may be 
causally associated with carcinoma of 
the cervix; this was not the intent of 
the quoted article.3
All currently used oral contracep­
tives contain 19-nortestosterones but 
substituted progesterones have been 
used in the past. The progestins that 
have been used are numerous but 
should include norithisterone and 
d-norgestrel, the latter being one of 
the most widely used synthetic pro­
gestins. Estrogens are currently used 
in doses as low as 0.02 mg, and 0.035- 
mg doses are usual.
The plasma coagulation proteins 
are indeed elevated (page 225) but in 
addition to those mentioned, factors 
V and VIII should have been in­
cluded.
In the section on changes in preg­
nancy (page 226), “increased serum 
fibrinogen” is mentioned. Surely the 
author means “plasma fibrinogen”, as
Contributions to the Correspondence sec­
tion are welcomed. They should be type­
written and double spaced.
serum is totally devoid of that partic­
ular protein.
This very comprehensive review 
emphasizes the effect of these potent 
agents on hepatic function in general. 
In view of the elevation of coagulation 
protein levels produced by oral con­
traceptives (and the consequent ten­
dency to hypercoagulability), it might 
be interesting to ask general surgeons 
how frequently they discontinue oral 
contraceptive medication before they 
perform elective surgery.
A shley T. C oopland, m d , frcs[c]
Associate clinical professor,
Yale University School of Medicine, 
Director, Department of obstetrics 
and gynecology,
Waterbury Hospital Health Center, 
Waterbury, Conn.
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To the coeditors.—In response to Dr. 
Coopland's letter I wish to clarify 
some of the points he has raised.
The use of the term “common” in 
relation to adverse effects, was in­
tended to refer to those conditions 
most readily recognized, rather than 
to frequency of occurrence. The in­
cidence of serious adverse effects is 
without doubt “low” but nevertheless 
is important. The use of oral contra­
ceptives is associated with a four­
fold increase in the occurrence of 
thromboembolic disease. The pre­
valence of deep venous thrombosis is 
dose-related but even the smallest 
effective dose is not free of risk. 
About 40% of healthy women taking 
oral contraceptives show retention of 
bromsulfalein. If the infusion techni­
que is used, almost all women using 
oral contraceptives show increased 
retention. In 53% of women taking 
oral contraceptives, raised blood pres­
sure will be recorded on one visit.
and in about 30% on more than one 
visit. The biochemical effects of the 
oral contraceptives are reversible and, 
in most cases, transient.
I still regard oral contraceptives as 
a reasonably safe method of contra­
ception.
Estrogen prescribed for menopausal 
symptoms is of questionable benefit 
and is associated with an increased 
risk of endometrial carcinoma. Se­
quential oral contraceptives have been 
discontinued in Canada and the 
United States for nearly 3 years. 
Whereas endometrial carcinoma is 
rarely seen in women under 40 years 
of age, it has been reported in women 
of this age group who have taken 
sequential oral contraceptives. The 
biological effects of estrogens, regard­
less of the indications for use, gen­
erally remain the same and were there­
fore included in my review.
While it is correct that plasma coa­
gulation proteins are elevated, factors 
V and VIII were not mentioned in 
the articles quoted, hence the omis­
sion. Factor VIII is produced by the 
reticuloendothelial system. Premarin, 
which has been used in the past for 
controlling postoperative bleeding is 
no longer recommended for this in­
dication.
Dr. Coopland is correct in pointing 
out that “serum fibrinogen” should 
have been “plasma fibrinogen”.
I know of no general surgeon who 
discontinues oral contraceptives in 
women before they undergo elective 
surgical procedures. Although it 
sounds logical, to my knowledge there 
has been no publication to date sup­
porting this view. Perhaps the posto­
perative venous thrombosis and oral 
contraceptive hypercoagulability do 
not have an additive effect. The 
history of oral contraceptive use is 
not always recorded before general 
surgical procedures. Should a study 
of this aspect of contraceptive use be 
undertaken, the results might prove 
most interesting.
S.P. Dixit, frc s , fr c s[c], facs
Department of surgery,
Woodstock General Hospital,
Woodstock, Ont.
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Gallstones: Current Concepts of Pathogenesis and
Medical Dissolution
E ldon A. Shaffer, md, frcp[c], facp
Gallstone disease constitutes a major 
health problem in the western world, 
despite a successful form of surgical 
therapy, cholecystectomy. The past 
decade has witnessed considerable 
advances in our understanding of 
the physiochemical changes in bile 
that lead to cholesterol gallstone 
formation. This knowledge has resulted 
in a rational basis for identifying 
agents that could dissolve gallstones 
and for defining conditions that 
predispose to gallstone formation 
which might be eliminated or treated 
prophylactically. This review examines 
the concepts of gallstone formation 
and indicates the current status of 
medical therapy.
La lithiase biliaire represente un 
probleme majeur de sante dans le 
monde occidental en depit du succes 
du traitement chirurgical, la chole- 
cystectomie. Au cours de la derniere 
decennie, on a ete temoin de 
progres considerables dans les 
connaissances des changements de la 
chimie physiologique de la bile qui 
preside a la formation de calculs de 
cholesterol. Cette connaissance a 
permis d'etablir les fondements 
logiques de I'identification des 
substances capables de dissoudre les 
calculs biliaires, et de la definition 
des desordres qui predisposent a la 
formation des calculs biliaires, 
desordres qui peuvent etre elimines 
ou traites preventivement. Cette 
revue examine les notions sur la 
formation des calculs biliaires et 
indique I’etat actuel du traitement 
medical.
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Disease is very old, and nothing about it has changed. It is we who change, as we learn to recognize what was for­merly imperceptible.
Jean Martin Charcot
Gallstones have afflicted mankind 
since antiquity,' but their treatment 
has received little attention. Ingel- finger2 first emphasized the impor­
tance and economic burden of this 
seemingly mundane digestive condi­tion in 1968. Since then, calculous 
disease of the biliary tract has become 
recognized in Canada as a major cause of hospitalization, accounting for about 130 000 admissions, result­
ing in 80 000 cholecystectomies, an­nually.'1 Cholecystectomy is one of the 
most frequently performed abdominal operations, particularly in Canada," 
although in Sweden the frequency of cholecystectomy is decreasing." 
This may reflect either a greater ten­
dency of the Canadian population to suffer from biliary tract disease, im­
proved diagnostic expertise or better 
health-care delivery. It could also 
imply that therapeutic usefulness has 
been exceeded and eventually might 
lead to excessive mortality.6'7 Care 
must be taken not to misinterpret the 
number of deaths attributed to chole­cystectomy.8 The annual mortality 
from gallbladder disease in Canada is less than 0.5% (about 580 deaths).3 
The morbidity, annual cost (estimated at $280 000 000 in Canada) and the 
drain on surgical facilities9 make cal­culous biliary tract disease a major health problem.
Epidemiologic studies documenting the occurrence of cholelithiasis have been based mainly on clinical and autopsy information which contain both selection and detection bias. Such a data base underestimates the true frequency and obscures any valid associations by failing to identify asymptomatic disease. A random sur­
vey by cholecystography or, even 
better, by ultrasonography (because it
is not invasive) of a living population 
at risk most accurately determines 
prevalence.10 Such studies are more 
accurate than others because the pre­
sence of gallstones is detected in both 
symptomatic and asymptomatic pa­tients, especially if an entire popula­
tion is examined. The true prevalence 
has been examined in this manner only on a Pima Indian reservation in Arizona"1 and in Micmac Indian 
women in Nova Scotia.12 These women have an extraordinarily high rate of 
gallbladder disease which starts in 
the third decade of life. The reported frequency of gallstones in different countries derived from autopsy studies 
varies widely, from being very rare in 
the Masai tribe of East Africa and Canadian Eskimos to being very common (more than 30%) in northern 
Europeans. The rate for North Amer­ican white people ranges from 10% to 30%.10
The natural history of gallstones is also poorly defined. Most patients are 
asymptomatic; only one third to one 
half have been reported to experience 
symptoms during a 10- to 20-year period.” Further, a radiologic survey 
in a Welsh industrial town demon­
strated that the dyspeptic symptoms 
commonly associated with gallstones 
did not discriminate between those with and those without gallbladder 
disease.13 The frequency of these clin­
ically “silent gallstones” is therefore difficult to determine since a dilemma exists in formulating a clinical defini­tion of asymptomatic cases that are 
found fortuitously.1" 16 Why was the radiologic examination done in the first place? What about gallstones discovered incidentally during an ab­dominal operation? The tendency to cause symptoms appears unrelated to size, number or type of gallstone present.17 The silent gallstone therefore is probably not part of a specific 
lesion but represents the asymptomatic 
stage of cholelithiasis. Because our 
knowledge of the natural course of
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this disease is deficient, the indications 
for cholecystectomy in such cases are 
not absolutely clear. The older patient 
with relatively asymptomatic calculous 
disease can present a particular dilem­
ma for the surgeon. The danger of 
a nonoperative approach is the pos­
sible development of acute cholecys­
titis with its high mortality and mor­
bidity. The warning features in such 
elderly patients are premonitory symp­
toms18 or the development of a radio- 
logically nonfunctioning gallbladder.19 
The diabetic patient with cholelithiasis 
also presents a problem for the sur­
geon.20,21 Although the risk-benefit 
ratio of cholecystectomy is not fully 
known in patients without symptoms 
these guides, such as age, radiologic 
function of the gallbladder and dia­
betes, can serve as an indication for 
operation.22
Human gallstones fall generally into 
two chemical categories, pigment 
stones and cholesterol stones.23
Pigment Gallstones
Pigment stones are composed of 
bile pigment, calcium and a matrix of 
organic material. They contain only 
trace amounts (less than 20%) of 
cholesterol. These small, irregular, 
dark (black, brown or green) stones 
are amorphous. They result from 
abnormal metabolism of bile pigment. 
Those present in the gallbladder look 
like tarry concretions, whereas stones 
forming in the common duct resemble 
reddish brown mud. Most (67%) 
radiopaque stones are of the pigment 
variety; their calcium content is high.24 
From a different perspective, 50% 
of pigment stones are opaque roent- 
genographically.
Pigment stones have been known 
for years to be common in Asiatic 
people. They also constitute 10% to 
20% of gallstones in Occidentals.23,25,20 
Certain disease states, particularly al­
coholic cirrhosis27,28 and chronic hemo­
lysis,29 are associated with pigment 
lithiasis. If these small gallstones pro­
duce biliary obstruction, the ensuing 
clinical picture can create a complex 
management problem. Even the red­
dish brown biliary “sludge”, which 
frequently complicates stasis and 
common-duct strictures, consists of 
pigment material. Intraductal pigment 
lithiasis is common in the Orient, and 
often there are no stones in the gall­
bladder.30
Pigment stones may be classified 
into two types: bile pigment-calcium 
stones and pure pigment stones.31'33
Bile Pigment-Calcium (or Calcium
Bilirubinate) Stones
These are commonly associated 
with bacterial infection and can be 
found anywhere in the biliary system 
including the intrahepatic tree. The 
black pigment in concretions from the 
gallbladder and the reddish brown 
material found in the common duct 
are only sparingly soluble in most 
organic solvents, making chemical an­
alysis difficult and inexact. The one 
definite characteristic is a relatively 
high bilirubin and low cholesterol 
content.
The possible mechanisms by which 
these gallstones form include: secre­
tion of an abnormal pigment that 
readily precipitates in bile, excessive 
hepatic secretion of normal pigment 
which surpasses its solubility in bile, 
or extrahepatic conversion of a nor­
mal constituent into an insoluble pre­
cipitate. Maki31 developed the last 
thesis to explain the genesis of calcium 
bilirubinate stones in Asiatics who 
commonly have parasitic infections 
(e.g., Ascaris lumbricoides, Clonorchis 
sinensis) that cause stasis and bac­
terial infection within the biliary tract 
(Fig. 1). Bilirubin is a tetrapyrrole that 
is normally esterified in the liver and 
secreted into bile as a water-soluble 
glucuronide (bilirubin diglucuronide), 
perhaps in conjunction with biliary 
lipids. The enzyme ^-glucuronidase 
can hydrolyze conjugated bilirubin 
into free (unconjugated) bilirubin and 
glucuronic acid. The normal biliary 
tree is free of this lysosomal enzyme 
and even contains an inhibitor of 
^-glucuronidase, D-glucaric acid (glu- 
caro-1,4-lactone).34 Coliform infec­
tions of the biliary tree, however, 
can elaborate /J-glucuronidase. The 
ensuing hydrolytic sequence trans­
forms the diconjugated bilirubin into 
a monoconjugated form and finally 
into unconjugated bilirubin.32 The 
free bilirubin then combines with the 
available calcium in bile to produce 
insoluble calcium bilirubinate. These 
tetrapyrrole units aggregate to form 
a biopolymer resulting in the forma­
tion of a pigment gallstone.33'35 That is, 
calcium bilirubinate stones result from 
chemical alteration of conjugated bili­
rubin within the biliary tree producing 
an insoluble product that then poly­
merizes. Such a sequence theoretically 
could be aborted by dietary mani­
pulation to increase glucaric acid in 
bile and so reduce ^-glucuronidase 
activity.34 The deconjugating enzyme 
may also come from the gallbladder 
epithelium itself.36 In fact, spontaneous 
nonenzymatic hydrolysis could be in­
itiated by stasis in the biliary tract and 
then compounded by bacterial infec­
tion. This hypothesis is much more 
attractive because in the Occident in­
fection has never been established as 
the primary event in gallstone dis­
ease.37,38
Pure Pigment Stones
Stones of this type contain heavy 
metals and pigment other than bili­
rubin. The gallbladder is the usual 
site of stone formation.39 Pure pig­
ment stones can occur in hemolytic 
states, but are relatively uncommon, 
even in Japan.26,31,33 Their formation 
(Fig. 1) involves precipitation of cal­
cium carbonate or phosphate in con­
junction with some calcium biliru-
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FIG. 1—Mechanism of pigment stone formation.
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binate. Stasis with altered pH may be 
conducive to the precipitation of such 
calcium salts. Copper and iron also 
can be involved as a complex with 
bilirubin derivatives.39
The true importance of pigment 
stones in the West may be much 
greater than their relatively low 
prevalence indicates. Almost every 
cholesterol gallstone has a pigment 
centre, indicating that pigment also 
plays a role in cholesterol stone forma­
tion and growth.40 The central deposits 
consist of calcium bilirubinate as a 
protein-pigment complex often con­
taining copper, mixed with calcium 
phosphate and carbonate,41 and may 
thus serve as a nidus for subsequent 
precipitation of cholesterol from bile 
supersaturated with cholesterol.
C holesterol Gallstones
The composition of these stones is 
predominantly (more than 70%) 
cholesterol. Their formation involves 
abnormal cholesterol and bile-salt me­
tabolism. In fact, cholesterol means
FIG. 2— Enterohepatic circulation of 
bile salts.
FIG. 3— Synthesis of primary bile 
acids, cholic acid and chenodeoxycholic 
acid, in liver. Solid arrow indicates site 
of first reaction, hydroxylation of 
cholesterol at 7 position; this step is 
rate-limiting for overall conversion of 
cholesterol into bile salts.
bile solid. Even the so-called “pure 
cholesterol” gallstone frequently has 
some pigment at its centre, while the 
“mixed cholesterol” stone also con­
tains bile pigment, bile acids, calcium 
salts and a protein matrix. The pure 
cholesterol stone tends to be a large, 
pale solitaire. Mixed stones are usually 
smaller (diameter less than 2 cm) and 
have a round or faceted surface de­
pending upon the pressure of adjacent 
stones. Their surface may be dark 
brown, but in the cut section yellow­
ish crystalline cholesterol is seen. If 
enough calcium is present, these stones 
can be radiopaque (33%), but 80% 
to 86% of lucent stones consist of 
cholesterol.24,42
Cholesterol is the major component 
of most gallstones found in the people 
of the Americas, Europe, India and 
Africa.43 In lapan the percentage of 
cholesterol gallstones is increasing 
especially in urban areas, perhaps re­
flecting dietary and environmental 
changes.25,34 To understand the me­
chanism of cholesterol gallstone for­
mation and the basis for medical dis­
solution, one must first appreciate 
biliary physiology and how cholesterol 
is rendered soluble in bile.
Physiology and Physical
Chemistry of Bile
Bile formation begins in the bile 
canaliculus, mainly in response to 
the secretion of bile salts.44,45 Bile salts, 
the most abundant organic solute, are 
the driving force behind bile flow and 
the principal determinant of bile com­
position. They are synthesized ex­
clusively in the liver from cholesterol. 
Degradation occurs solely in the in­
testine, the only excretory route being 
fecal. Bile salts undergo an entero­
hepatic circulation (Fig. 2).46,47 
Secreted by the liver, they are stored 
mainly in the gallbladder during the 
interdigestive period. In the jejunum, 
bile salts act as detergents to promote 
fat absorption; their active absorption 
occurs later in the terminal ileum. 
After they have been absorbed into the 
portal vein, bile salts return to the 
liver, where they are effectively 
cleared and secreted again into bile. 
The major source for hepatic secre­
tion during the day is bile salts recir­
culated from the intestine, with only 
a small portion derived from de novo 
synthesis. Gallbladder storage and in­
testinal transit are the slow points in 
this circuit, whereas hepatic clearance 
and intestinal absorption are rapid 
and efficient. The total mass of bile 
salts within the enterohepatic circula­
tion represents the bile-salt pool. The
size of this pool multiplied by the rate 
at which it cycles gives the bile-salt 
secretion rate. This efficient recycling 
system allows a small pool of bile salts 
(about 50 mg/ kg body weight) to re­
circulate 5 to 15 times a day, while 
losing only a small portion (3 to 10 
mg/kg body weight).46 With each cir­
cuit, only 3% to 5% of bile salts are 
lost. These small losses are accurately 
replaced by hepatic synthesis from 
cholesterol, maintaining a stable bile- 
salt pool.
Bile-salt synthesis is regulated by 
the rate at which bile salts return to 
the liver in a negative feedback man­
ner: a low rate stimulates synthesis, a 
high rate inhibits it. Loss of the bile- 
salt pool, such as through a T tube 
postoperatively, decreases the rate of 
bile-salt return to the liver. The liver 
responds by augmenting synthesis. 
Complete interruption of the entero­
hepatic circulation, a maximal stim­
ulus, can increase synthesis 10-fold 
(about 5 g/d) in man.48 The rate-limit­
ing enzyme in the overall biotrans­
formation of cholesterol to bile salts 
is cholesterol 7a-hydroxylase (Fig. 
3).49 The activity of this enzyme is 
controlled quantitatively by the total 
mass of bile salts returning through 
the portal vein. Qualitatively no dif­
ferences exist between the individual 
species of bile salts.50,51 After the ad­
dition of the hydroxyl group at the 7 
position (nuclear hydroxylation), the 
subsequent steps involve two basic 
pathways. If a second hydroxylation 
occurs at the 12 position producing a 
compound with three OH groups (3a, 
7a, 12a-triol), shortening of the side 
chain (side-chain degradation) results 
in the formation of cholic acid. If 
hydroxylation at the 12 position does 
not occur, the two OH compound 
(3a , 7a-diol) ends up as chenodeoxy­
cholic acid. Bile salts are then con­
jugated with either glycine or taurine 
before being secreted into bile. Normal 
human bile has a molar ratio of gly­
cine to taurine of about 3:1.
Conjugated bile salts undergo fur­
ther metabolic processing in the in­
testine, especially the ileum and colon. 
Here the high bacterial content can 
greatly alter the bile-salt molecule 
(Fig. 4). Deconjugation first breaks 
the peptide linkage, yielding free bile 
acids.*52 Dehydroxylation then re­
moves the hydroxyl group from the
*“Bile acid” should be applied to un­
conjugated or free bile acids. “Bile 
salt” the generic term, refers to those 
bile acids conjugated with glycine or 
taurine or the bile alcohols esterified 
with a sulfate group.52
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7 position of the primary bile acid. 
Cholic acid (with OH groups at the 
3, 7 and 12 positions) is converted 
into deoxycholic acid (with two OH 
groups at the 3 and 12 positions). 
Chenodeoxycholic acid (with OH 
groups at the 3 and 7 positions) is 
transformed into lithocholic acid (with 
one OH group at the 3 position). Con­
siderable dehydroxylation must occur 
in healthy individuals because human 
bile normally contains more than 25% 
of the total bile salts in the secondary 
form, chiefly as deoxycholic acid. 
Deoxycholic acid and any free primary 
bile acids are passively reabsorbed 
from the colon and reconjugated in 
the liver before being resecreted into 
bile. Lithocholic acid with only one 
polar OH group is insoluble in water 
and so remains unabsorbed in the in­
testinal lumen (as a stone or concre­
tion, hence the prefix “litho”), bound 
to bacteria or unabsorbed plant fibre. 
Intestinal transformation of cheno­
deoxycholic acid (3«, 7a-dihydroxy- 
cholanic acid) can also produce urso­
deoxycholic acid (3a, 7a-dihydroxy- 
cholanic acid), which represents 1% 
to 5% of all bile acids in bile.* Those 
bile salts synthesized in the liver are 
termed “primary”, whereas their bac­
terial metabolites are “secondary”.
Cholesterol and bile-salt meta­
bolisms are closely intertwined.5'1 Bile 
salts are formed in the liver from 
cholesterol and are its water-soluble 
excretory products. Unlike most ani­
mals, man tends to excrete cholesterol 
as such, with comparatively limited 
conversion to bile salts. Man absorbs 
dietary cholesterol rather poorly and 
any increase in the absorption of 
cholesterol is not necessarily associated 
with increased conversion into bile 
salts. The liver is the principal site 
for cholesterol production, with the 
small intestine assuming a lesser role 
under normal conditions.54"56 Choles­
terol synthesis begins from the carbon 
acetate fragments in an activated 
form, acetyl-CoA (Fig. 5). Successive 
condensation of three molecules of 
acetyl-CoA forms /"j-hydroxy-^-me- 
thylglutaryl-CoA (HMG-CoA). HMG- 
CoA is then reduced to mevalonate, 
the first unique step in cholesterol 
synthesis. The microsomal enzyme 
controlling this key reaction, HMG- 
CoA reductase, is rate-limiting for 
the total sequence in cholesterogenesis. 
The final product, cholesterol, consists
*Chenodeoxycholic acid was first iso­
lated from goose bile (Greek chen, 
goose), while ursodeoxycholic acid was 
originally found in bear bile (Latin ursus, 
bear).
of 27 carbon atoms. As noted previ­
ously, its catabolism to bile acids with 
24 carbon atoms is rate-limited by the 
enzyme, cholesterol 7a-hydroxylase. 
The control of cholesterol and bile- 
salt synthesis is therefore governed by 
two key enzymes: HMG-CoA reduc­
tase and cholesterol 7a-hydroxylase. 
The activity of HMG-CoA reductase 
is turned off by increased cholesterol 
return to the liver and may also be 
suppressed by a high return of bile 
salts.57 As bile salts are necessary for 
cholesterol absorption and can influ­
ence cholesterol catabolism to bile 
salts, it is difficult to know whether 
their effect on cholesterol metabolism 
is direct or indirect.58 Certainly long­
term administration of bile acids ap­
pears to suppress cholesterol and bile 
synthesis by decreasing the two rate- 
limiting enzymes. Chenodeoxycholic 
acid has a greater inhibitory effect on 
HMG-CoA reductase than on choles­
terol 7a-hydroxylase, suppressing 
cholesterol synthesis to a greater extent 
than bile-salt synthesis. The opposite 
is true of cholic acid.59 The suppres­
sive effect of chenodeoxycholic acid 
on cholesterol synthesis may be me­
diated through enhanced intestinal 
absorption of cholesterol.58 The 
amount of cholesterol being converted 
to bile salts also may play an indirect 
role. Under conditions in which the 
administration of bile acid had sup­
pressed bile-salt synthesis, the in­
creased cholesterol returning to the 
liver would not be readily diverted 
into bile salts but rather would in­
hibit cholesterol synthesis. The regula­
tion of hepatic cholesterol synthesis is 
therefore complex, being influenced 
by many variables such as total 
caloric intake, stress and even diurnal 
light cycling.60 The two mechanisms 
responsible for adjusting the rate of 
hepatic cholesterol synthesis are: (a)
PRIMARY
CHOLIC ACID 
(3a, 7a, 12a)
CHENODEOXYCHOLIC ACID 
(3a, 7a)
DECONJUGATION
I t
FREE BILE ACIDS
SECONDARY
7O-DEHYDR0XYLATI0N
DEOXYCHOLIC ACID LITHOCHOLIC ACID
(3a. 12a) (3a)
FIG. 4— Deconjugation and dehy- 
droxylation of primary bile salts in in' 
testine.
the amount of cholesterol entering the 
body through the gastrointestinal tract 
and (b) the amount of sterol lost from 
the body as bile acids. Elsewhere, the 
nonhepatic cells in the body possess 
a cell surface receptor that specifically 
binds low-density lipoprotein (LDL) 
which is the major cholesterol-carry­
ing protein in human plasma. Once 
bound to the receptor, at least in 
human fibroblasts, LDL enters the 
cell and is transferred to lysosomes 
where both its protein and cholesterol 
ester components are removed by acid 
hydrolases. The resultant free choles­
terol is then able to reduce endogenous 
cholesterol synthesis by suppressing 
the activity of HMG-CoA reductase. 
The liberated cholesterol inside the 
cell also neatly prevents any excessive 
uptake of LDL-cholesterol by sup­
pressing the synthesis of the cell sur­
face LDL receptor.61 Hepatic choles­
terol synthesis, however, is predomin­
antly controlled by dietary cholesterol 
which reaches the liver in the form 
of chylomicron remnants rather than 
by endogenous cholesterol contained 
in LDL. In fact, free cholesterol 
from plasma high-density lipoprotein 
(HDL) and newly synthesized choles­
terol within the liver appear to be the 
principle substrate for transformation 
of cholesterol into bile salts and may 
be the source of cholesterol secreted 
into bile.62"64
ACETVL-CoA
I
♦
HMG-CoA
(HMG-CoA reductase)
MEVALONATE
I
I
C H O L E S T E R O L -
(70 hydroxylase)
I
*
BILE SALTS.
FIG. 5— Cholesterol metabolism in 
liver. Key steps in cholesterol synthesis 
and major degradation product, bile 
salts, are depicted. Broken lines indicate 
possible sites of feedback inhibition.
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The phospholipids in bile and plas­
ma are synthesized only in the liver. 
Despite a similar origin, the phospho­
lipid secreted into bile is a lecithin 
whose fatty acids (palmitic and linoleic 
acids) differ from other hepatic leci­
thins and from that in the plasma. 
The synthesis of lecithin and its secre­
tion into bile occur consecutively, both 
events being dependent on bile-salt 
secretion.65 Once in the intestinal 
lumen, lecithin undergoes partial hy­
drolysis to lysolecithin and fatty acids, 
which are absorbed. Its products are 
not substantially reused as a source 
of bile lecithin, so that there is little 
enterohepatic circulation of lecithin.66 
The choline moiety may be preserved 
for de novo hepatic synthesis.67
The flux of bile salts through the 
hepatocyte and into the bile canali­
culus profoundly influences the secre­
tion of lecithin and cholesterol.65,68,69 
The secretion rate of bile salts, as 
noted previously, is governed by the 
size of the bile-salt pool and the rate 
at which it circulates enterohepatically. 
Cholesterol output into bile is gen­
erally coupled to the rate of bile-salt 
secretion, while a close association 
exists between lecithin and bile-salt 
secretion. The relation between these 
three is not fixed but is curvilinear. 
At low rates of bile-salt secretion, 
there is little secretion of lecithin.
Cholesterol secretion is also low but 
less so than the other two, so that the 
amount of cholesterol in bile com­
pared with the other two rises. Con­
versely, at high rates of bile-salt secre­
tion, the lecithin and cholesterol out­
puts plateau and the relative propor­
tion of cholesterol diminishes. The rate 
of bile-salt secretion is thus the prin­
cipal determinant of biliary lipid com­
position, but several modifying fac­
tors exist.45 For example, patients with 
significant liver disease have a low 
rate of bile-salt secretion but also a 
low rate of cholesterol secretion. 
Hence, their bile does not contain a 
relative excess of cholesterol despite 
the low bile-salt output (Shaffer EA: 
Unpublished observations). Moreover, 
lecithin and cholesterol output can 
be reduced by certain organic anions 
and chemicals without any effect on 
bile-salt secretion.70 The control of 
biliary cholesterol secretion is further 
complicated by the important role of 
the liver in cholesterol metabolism. 
Cholesterol secretion is increased in 
obese people, presumably because of 
the increased cholesterol synthesis 
associated with obesity.69 Cholesterol 
secretion into bile has been reported 
to correlate directly with hepatic 
cholesterol synthesis (as measured by 
the activity of HMG-CoA reductase)71 
but inversely with bile-salt synthesis.72
The control of biliary cholesterol sec­
retion in terms of cholesterol and bile- 
salt synthesis is complicated by the 
heterogeneous sources of free choles­
terol destined for export into bile and 
for the synthesis of bile salts; from 
HDL-cholesterol in plasma and from 
newly synthesized cholesterol in the 
liver.62'64 The rate of hepatic uptake 
of chylomicron cholesterol, the size of 
the intrahepatic pool and the rate of 
hepatic cholesterol synthesis probably 
do not regulate biliary cholesterol out­
put73 and HMG-CoA reductase ac­
tivity may not truly reflect the overall 
rate of cholesterol synthesis.74 Hence, 
the determinants of cholesterol syn­
thesis and secretion are not clear and 
a variety of external factors such as 
drugs and diet can influence its out­
put into bile.75
Bile from healthy persons is a 
homogeneous liquid, whereas that 
from patients with cholesterol chole­
lithiasis contains additional cholesterol 
in a crystalline form that has pre­
cipitated from solution.40,76 The pre­
sence of cholesterol in solution and 
as solid crystals, indicates that the 
solubility of cholesterol in bile is 
limited. Cholesterol is virtually in­
soluble in water, yet human bile nor­
mally contains about 10 mmol/1 cho­
lesterol in solution. Bile is mainly 
water, with solids accounting for only 
5 to 10 g/dl (w/v). More than 90% 
of the total solids in bile consist of 
three organic components: bile salts, 
lecithin and free cholesterol. The con­
ventional chemical formulae depicted 
in the upper portion of Fig. 6 are less 
informative than the schematic draw­
ings in the lower panel which repre­
sent the physical state of the mole­
cules at an oil-water interface.77 Each 
substance is “amphiphilic” (loving both 
sides), part of the molecule being 
attracted to water and part to fat. 
At the oil-water interface, the water- 
soluble parts are oriented into the 
aqueous phase (downwards in Fig. 6) 
while the oil-soluble parts are in the 
oil phase (upwards in Fig. 6). 
Cholesterol has a single hydroxyl 
group which is water soluble. 
The remainder of the molecule is the 
water-insoluble (oil-soluble) 27-carbon 
steroid ring. This single OH group 
cannot possibly pull the bulky hydro­
carbon moiety down into the water. 
Therefore, cholesterol has only sur­
face solubility on water and negligible 
solubility within water. Lecithin (or 
phosphatidyl choline) contains a phos- 
phoryl choline group— 0 P ( 0 3)—CH2- 
CH»N + (CHs)j—that, being hydrophi­
lic, seeks water. The other portion
FIG. 6—Chemical formula and physical state of cholesterol, lecithin and bile 
salts at oil—water interface. Upper part of figure shows chemical formulae of cho­
lesterol, lecithin and sodium taurocholate. In lecithin, R and R' represent long-chain 
fatty acids attached to glycerol skeleton by ester linkage. Lower part is schematic re­
presentation of molecules. Shaded parts represent hydrophobic steroid nuclei of cho­
lesterol and bile salt. Closed circles or ovals represent hydroxyl or ester groups, 
respectively. +  and — represent positively and negatively charged groups. Wavy 
lines- are lipid-soluble hydrocarbon alkyl chains of lecithin.
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of lecithin, the two long-chain fatty 
acids esterified through glycerol (R 
and R'), is hydrophobic and seeks oil. 
The phosphoryl choline and ester 
groups therefore lie below the water 
surface, whereas the long hydrocarbon 
chains point upwards into the oil phase 
like a tuning fork (Fig. 6). Lecithin is 
insoluble in water and forms crystals 
of bimolecular leaflets, the hydrophilic 
ends sticking into the water and hydro- 
phobic ends being adjacent to one an­
other. Water penetrates between the 
hydrophilic phosphoryl choline groups 
causing the crystals to swell, forming 
“liquid crystals”. Cholesterol possesses 
the ability to interdigitate between the 
lecithin molecules with its hydroxyl 
group sticking into the water layer and 
the rest of the molecule buried deep 
in the fatty acid, hydrocarbon interior 
of the lecithin bilayer.77 In contrast, 
bile salts are quite soluble with their 
polar hydroxy] groups and taurine (or 
glycine) conjugates attracted into 
water. In aqueous solution above a 
limiting concentration (the “critical 
micellar concentration”), bile salts ag­
gregate by association of their hydro- 
phobic sides, forming “simple mi­
celles”.78 Lecithin can be dissolved by 
these bile-salt aggregates, creating 
“mixed micelles”. This results in bi­
layer discs appearing like stout drums 
with a water-soluble coating and a 
water-insoluble core. Cholesterol can 
then be dissolved within the hydro- 
phobic core between the fatty acid 
chains of lecithin. Water is associated 
with the polar groups of lecithin, act­
ing to swell the micelles making it 
possible to incorporate more choles­
terol than could be contained by sim­
ple bile-salt micelles alone. Thus, bile 
salts are biologically active detergents 
which, in cooperation with lecithin, 
keep cholesterol in solution. The phy­
sical coupling of these biliary lipids 
and their secretion into bile may occur 
at or near the canalicular membrane, 
either within the membrane during 
translocation or adjacent to the mem­
brane in the newly formed bile.77
The solubility of cholesterol in 
mixed micellar solutions is limited. 
Physicochemical studies have shown 
that the capacity of these micelles to 
dissolve cholesterol is primarily re­
lated to the relative amounts of bile 
salts and lecithin.76'711 Because there are 
three components, triangular coor­
dinates best represent the bile-salt— 
lecithin-cholesterol mixture in bile 
(Fig. 7). Any combination of these 
three ingredients can be represented 
on the triangle in terms of the relative 
molar percentage of each component. 
Thus point X in Fig. 7 represents a
solution with 60% bile salts, 15% 
cholesterol and 25% lecithin. Similar­
ly, a point in the centre of the triangle 
would represent bile with 33.3% of 
each component. Admirand and 
Small76 defined the limits of choles­
terol solubility in bile-salt-lecithin 
micellar solutions of different relative 
proportions and represented the phy­
sical properties of the resultant mix­
tures on a triangular phase diagram. 
The system chosen contained 90% 
water and 10% bile salts plus lecithin 
and cholesterol, similar to the solid 
content of human gallbladder bile. 
Out of all possible combinations of 
bile salts, lecithin and cholesterol they 
found only a small zone in which the 
bile composition was micellar. The 
solid line in Fig. 7 defines the bound­
aries of the micellar zone and repre­
sents the maximal solubility of choles­
terol in varying mixtures of bile salts 
and lecithin. Any bile having a com­
position above this solid line (say at 
point X) would contain excess choles­
terol in either a supersaturated or 
precipitated form. Supersaturated bile 
contains the cholesterol in a single, 
liquid phase, or as a two-phase system 
of liquid bile plus solid crystalline 
cholesterol. If very rich in lecithin, a 
three-phase system could be present 
as liquid bile, cholesterol crystals and 
mixed liquid crystals. Excess choles­
terol readily precipitates out of such 
a supersaturated solution over a 
relatively short period. Hence, in this 
thermodynamically unstable bile, 
termed “labile”, crystallization occurs 
spontaneously. Many biological solu­
tions that are supersaturated do not 
necessarily continue to precipitate 
their excess solute until an absolute 
equilibrium is established, at least dur­
ing the finite period of observation. 
Precipitation may be extremely slow, 
often requiring a nucleating agent to 
initiate and hasten the process. Such a 
solution represented by the shaded 
area in Fig. 7 contains a slight excess 
of cholesterol and exhibits a certain 
stability, not readily precipitating 
cholesterol crystals unless seeded, and 
termed a “metastable” solution.80 The 
absolutely true equilibrium (the 
broken line below the metastable zone 
continuous with the solid line on the 
right of Fig. 7) defines the “stable” 
micellar zone.79'82 The commonly ac­
cepted “effective” line of cholesterol 
solubility is best defined by the whole 
solid line in Fig. 7 which includes the 
area of metastable supersaturation. 
The “true” limits exclude the meta­
stable area. The physical chemistry 
of cholesterol solubility in bile is even 
more complex in vitro, depending on
a subtle variety of conditions, but for 
physiologic bile at 37°C the major 
determinants are the bile-salt to leci­
thin ratio and the total lipid concentra­
tion. A group of cholesterol solubility 
curves determined for each total lipid 
concentration has shown that, con­
trary to popular notion, concentrated 
bile holds more cholesterol than dilute 
bile.79 Precise tables are now available 
defining the limits of maximal choles­
terol solubility in human bile.83
When the relative molar compo­
sition of human bile is plotted on the 
triangular phase diagram, patients 
with cholesterol gallstones have a 
biliary lipid composition different 
from that of patients without choles­
terol gallstones10,48,76'84'85 (Fig. 8). There 
is even a close relation in various 
populations between the prevalence 
of gallstones and the frequency of 
supersaturated bile in subjects without 
overt gallstones.86 A discrepancy still 
exists: there is no consistent decrease 
in the cholesterol-holding capacity of 
bile from patients with gallstones when 
compared with bile from subjects 
without gallstones. Much overlap 
exists.87 The problem was further com­
pounded when Hegardt and Dam81 and 
Holzbach and colleagues82 found that 
the micellar phase at true equilibrium 
was smaller than that reported by 
Admirand and Small.76 Most of these 
discrepancies have been resolved by 
Carey and Small.79 They meticulously 
redefined the true solubility charac­
teristics of cholesterol in micellar 
solutions and applied their findings 
to humans. Their results demonstrated 
that all patients with cholesterol gall­
stones have supersaturated bile, even 
though metastable supersaturation was 
frequent in both normal and abnormal 
biles. The common denominator for 
cholesterol precipitation was the ab­
solute degree of cholesterol super­
saturation.79 The prerequisite for
FIG. 7— Triangular phase diagram 
for plotting relative molar concentrations 
of three major components of bile (bile 
salts, lecithin and cholesterol).
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cholesterol gallstone formation then is 
supersaturated bile.
Stages of Cholesterol Gallstone
Formation
Cholelithiasis is the end stage of 
a long process that begins with a me­
tabolic defect causing the formation 
of chemically abnormal or “litho- 
genic” bile (the chemical stage),77 
proceeds to a physical change of state 
in which microscopic crystals precipi­
tate from solution (the physical stage) 
and ultimately results in growth to a 
macroscopic stone (the growth stage). 
Gallstones produce symptoms by 
blocking the cystic or common duct, 
or by irritating the gallbladder.
The chemical stage.—The liver has 
clearly been identified as the source 
of lithogenic bile and gallstone dis­
ease has become known as a subtle 
disorder of liver metabolism84 (Fig. 
8). The liver might produce such bile 
either by decreased secretion of the 
solubilizing agents, bile salts or leci­
thin, or by an increased secretion of 
cholesterol, or both. In fact, the he­
patic defect involves several mechan- 
ims, perhaps representing several dis-
FIG. 8— Lipid composition of bile 
obtained at operation. Triangle represents 
tbree-coinponent system for describing 
biliary lipid composition in bile. Mean 
compositions for (a) hepatic and (b) gall­
bladder biles are represented by closed 
circle for patients with cholesterol gall­
stones, open circle for patients with pig­
ment gallstones and closed triangle for 
those without hepatobjjiary disease. 
Areas bounded represent x ±  1 SEM for 
each component; that for cholesterol 
gallstone patients is shaded. Cholesterol 
saturation of hepatic and gallbladder 
bile from cholesterol gallstone patients 
clearly differed from corresponding biles 
in other two groups. In each case, hepa­
tic bile was more saturated with choles­
terol than gallbladder bile, indicating 
that liver was source of abnormal gall­
bladder bile.
eases69 (Table I88-90). Nonobese patients 
with cholesterol gallstones have a 
decreased bile-salt pool,91 which cycles 
to produce a reduced bile-salt and leci­
thin secretion rate.69 The basic prob­
lem appears to be inadequate hepatic 
synthesis; the liver does not sense the 
small circulating bile-salt pool. A dif­
ferent abnormality of bile-salt meta­
bolism occurs with ileal dysfunction. 
Loss of the site for active transport 
results in significant bile-salt malab­
sorption, and fecal losses exceed any 
compensatory increase in hepatic syn­
thesis. The bile-salt pool then 
decreases, secretion is low and bile 
becomes supersaturated. This mechan­
ism probably accounts for the in­
creased prevalence of gallstones in 
patients who have ileal disease or who 
have undergone ileal resection.92 The 
principal problem in morbidly obese 
persons is excessive secretion of 
cholesterol rather than a deficiency 
of bile salts.90 Most overweight pa­
tients with cholesterol gallstones prob­
ably fall between these two extremes. 
They likely have a combined defect: a 
reduced bile-salt pool and secretion 
rate, and increased cholesterol secre­
tion. This correlates with reports of in­
creased HMG-CoA reductase activity 
(implying enhanced hepatic cholestero- 
genesis) and decreased cholesterol 7a- 
hydroxylase levels (suggesting im­
paired bile-salt synthesis) in patients 
with gallstones,93,94 but these results 
must be interpreted cautiously because 
of methodologic limitations.73,74
The age at which this critical 
process begins is uncertain, but in 
young North American Indian women 
who are at high risk of stone forma­
tion, lithogenic bile develops during 
early puberty.95,96 The mechanism re­
sponsible is a combination of increas­
ing obesity in these teenage girls (with 
presumed increased cholesterol secre­
tion) without any corresponding aug­
mentation of their bile-salt pool, which 
their male counterparts demonstrate.
Older Chilean women also show in­
creasingly abnormal bile with age,97 
but this is not related to a decrease in 
the size of the bile-salt pool. Rather, 
obesity appears to be a factor here, 
so that increased cholesterol secretion 
may be responsible.
The physical stage.—This second 
stage occurs with a change in gall­
bladder bile from a liquid, super­
saturated with cholesterol, to a two- 
phase system consisting of liquid bile 
plus cholesterol crystals. There are 
two possible situations. If the abnormal 
bile is labile with a great excess of 
cholesterol in a clear solution (that is, 
above the metastable-labile line, say at 
point X in Fig. 7), cholesterol crystals 
spontaneously and readily precipitate. 
This is “homogeneous nucleation” be­
cause cholesterol molecules randomly 
coalesce to form cholesterol micro­
crystals without the influence of other 
solids. If the supersaturated bile is me­
tastable with just a slight excess of 
cholesterol (in the shaded area in Fig. 
7), the excess cholesterol can preci­
pitate over a long period but usually 
requires seeding by a crystal of the 
same substance or by a crystal of a 
different substance with a similar phy­
sical configuration. This is “heterogen­
eous nucleation”, because precipitation 
occurs around a particle other than a 
pure cholesterol crystal.98 A variety 
of nucleating agents may initiate or 
hasten crystal formation, including 
desquamated epithelial cells, calcium 
salts, precipitated bile acids and for­
eign bodies. But once precipitation 
starts, the solid crystals themselves 
provide the seed for further nuclea­
tion of cholesterol. The presence or 
role of inhibitors in bile has not been 
explored. The end result is that the 
precipitated cholesterol is deposited 
in an oriented, tightly-packed manner 
as microcrystals, a process known as 
epitaxy.99
The growth stage.—The third stage 
consists of retention of these micro-
T a b le  1— S pectrum  o f  L ith o g e n ic  B i le  F o rm a tio n  
in  C h o le s te ro l G a lls to n e  D is e a s e
P a t ie n t
B i le -s a lt  
pool s ize
B i le - s a l t
s e c re t io n
L e c ith in
s e c re tio n
C h o le s te ro l
s e c re t io n
T h in * D ecreased D e c re a s e d D e c re a s e d N o rm a l
S lig h t ly  obese 7 7 7 7
O b ese  In d ia n s ) 7 ±  D e c re a s e d N o rm a l In c re a s e d
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crystals in the gallbladder, their aggre­
gation and subsequent growth produ­
cing a macroscopic stone. Events in 
the gallbladder are central to this 
stage of gallstone formation.85 Reten­
tion of the crystalline material, for 
example, is critical and undoubtedly 
occurs because the gallbladder never 
completely empties.100 Mucopolysac­
charides secreted by the gallbladder 
mucosa may be another factor.101 They 
can form a gel, trapping crystals or 
small stones and preventing them from 
leaving the gallbladder. Crystals grow 
in layers by aggregation and by epi­
taxy. The layer sequence may be bi- 
phasic with alternate depositions of 
cholesterol and calcium bilirubinate- 
protein complexes.41 These complexes 
may act as a cementing material hold­
ing the layers of cholesterol crystals 
together where epitaxy has not oc­
curred. Gallstones then develop either 
homogeneously as a simple stone, or 
by adherence of simple stones forming 
complex mulberry stones.102
The resultant stone by damaging 
the gallbladder epithelium may alter 
mucosal permeability to the biliary 
constituents with a relatively rapid 
loss of bile salts,103 rendering the bile 
more unstable. Irritation of the gall­
bladder or obstruction of the duct 
system, or both, ultimately leads to 
cholecystitis with clinical symptoms.
Loss of the gallbladder surgically48,69 
or functionally in terms of roentgeno- 
graphic filling104 causes a definite im­
provement in biliary lipid composition. 
The reduction in cholesterol satura­
tion, however, may not be sufficient 
to effect a return to completely normal 
bile, especially in obese patients. The 
beneficial effect of cholecystectomy 
comes from an increased rate of bile- 
salt (and secondarily, lecithin) secre­
tion. The small bile-salt pool cycles 
more rapidly around the enterohepatic 
circulation to increase bile-salt flux 
through the liver and ameliorate bile 
composition (Fig. 9). This finding has 
further emphasized the role of the 
gallbladder in cholesterol gallstone 
formation.85 The primary defect may 
be the hepatic production of abnormal 
bile, but the presence of the gall­
bladder and its effect on the entero­
hepatic circulation is necessary to 
elicit the liver defect.
Contributing Factors
Once the solubility characteristics of 
cholesterol in bile were established, a 
more critical approach to those con­
ditions clinically and epidemiologically 
associated with cholelithiasis was 
feasible. Most of these states can be 
linked directly to the occurrence of
supersaturated bile. The risk factors 
identified so far include obesity, diet, 
female sex hormones, genetic and 
ethnic factors, gastrointestinal disease 
and hyperlipoproteinemia.
Obesity.—This common problem 
has been epidemiologically linked with 
gallstone disease. The mechanism re­
sponsible for the production of satu­
rated bile is excessive biliary secretion 
of cholesterol, most likely related to 
the increased cholesterol synthesis that 
occurs in obese persons.69,105,106 During 
active weight reduction, bile saturation 
may increase in some patients but once 
weight is stabilized at a reduced level, 
bile composition improves.
Diet.—This has long been im­
plicated, but the most obvious risk 
factor so far has been a high-caloric 
diet leading to obesity. Other dietary 
features that have been suggested are: 
high-caloric value,107 polyunsaturated 
fats,108 high cholesterol,109 high carbo­
hydrate110 and low vegetable fibre.111
Female sex hormones.— Estrogens 
in particular adversely affect biliary 
lipid composition and predispose the 
patient to cholesterol gallstone dis­
ease.112 When administered exogenous­
ly estrogens reduce bile-salt synthesis 
and secretion in animals113,114 and 
reduce the size of the chenodeoxycho- 
lic acid pool in man.115 Their litho- 
genic effect is more likely related to 
increased secretion of cholester- 
ol,105,106 perhaps related in some 
ethnic groups to obesity.96,97 The effect 
of progesterone on gallbladder con­
traction and the role of the sluggish 
gallbladder is unknown.85
Genetic and ethnic factors.—A 
genetic predisposition to cholelithiasis 
is based on detecting familial aggrega­
tion, both in terms of clinical disease 
and formation of lithogenic bile.116 The 
prevalence of cholelithiasis also cor­
responds to the biliary lipid compo­
sition of the racial group or geographic 
region; gallstones and abnormal bile 
are particularly common (up to 70%) 
in native Indians of North America 
and people from South America and 
northern Europe. In contrast, the 
Masai tribe of East Africa have low 
serum cholesterol levels despite a high- 
fat diet and high cholesterol absorp­
tion, and are quite free of both gall­
stones and atherosclerosis.117 These 
tall, thin people seem to possess an 
effective and unusual negative feed­
back control of their endogenous 
cholesterol synthesis which compen­
sates for the influx of dietary choles­
terol.
Gastrointestinal disease.-—Any gas­
trointestinal condition that causes 
malabsorption of bile acid (because of
ileal disease or as a result of ileal re­
section) can lead to fecal losses that 
may outstrip compensatory increases 
in hepatic synthesis. The result is 
depletion of the bile-salt pool, reduced 
bile-salt secretion and eventually, in­
creased cholesterol saturation.92 Cystic 
fibrosis with pancreatic insufficiency 
also results in malabsorption of bile 
salts, production of lithogenic bile and 
gallstones.118
Hyperlipoproteinemia-—Hyperlipo­
proteinemia may be associated with 
deranged bile-salt metabolism, but the 
importance of this has not been 
established.119 Hypercholesterolemia, 
itself, does not heighten the propensity 
to cholesterol gallstone formation, de­
spite the increased serum cholesterol 
largely as low-density lipoprotein, the 
increased total body cholesterol and 
the abnormality in conversion of 
cholesterol to bile salts. Biliary lipid 
secretion is normal in patients with 
familial hypercholesterolemia (type 
Ila hyperlipoproteinemia) and therapy 
directed at correcting the disorder in 
bile-salt metabolism and also creating 
a net cholesterol loss has failed.120 
In hypertriglyceridemia (type IV hy­
perlipoproteinemia), the bile-acid pool 
is large, yet many hypertriglyceridemic 
patients have cholelithiasis.121 Their 
problem is further compounded by 
the fact that many are also obese. Un­
fortunately, therapy in the form of 
diet or drugs generally increases the 
risk of gallstone formation.122,123 A diet 
high in polyunsaturated fat, for exam­
ple, increases the frequency of gall­
stones108 in some patients with hyper­
triglyceridemia by increasing biliary 
cholesterol secretion and bile satura-
FIG. 9— Schematic representation of 
effect of cholecystectomy on entero­
hepatic circulation of bile salts. After 
cholecystectomy enterohepatic cycling 
increases because bile-salt pool is never 
trapped in gallbladder. Bile-salt pool may 
be reduced but this is offset by rapid cy­
cling which causes increased bile-salt and 
also phospholipid secretion. Increased cy­
cling with increased exposure of bile salts 
to intestinal degradation results in high 
proportion of secondary bile acids. In­
testinal reabsorption of these secondary 
bile acids can occur proximally, possibly 
creating jejunohepatic shunt to speed up 
enterohepatic circulation further.
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tion.124 Clofibrate, a drug used to treat 
several types of hyperlipidemia, ap­
pears to mobilize cholesterol stores 
out of the tissues and to increase its 
secretion into bile.125 It also impairs 
bile-salt synthesis.112 The net result 
is lithogenic bile.126 The same may 
hold true for nicotinic acid.127 Chole­
styramine resin, which binds bile acids, 
is sometimes administered orally to 
block intestinal absorption, partially 
interrupt the enterohepatic circulation, 
reduce bile-salt return to the liver and 
so enhance the conversion of choles­
terol into bile salts.128 Used in hyper- 
cholesterolemic patients to drain body 
cholesterol, cholestyramine probably 
has no effect on cholesterol saturation 
in bile, except to alter bile acid com­
position by trapping deoxycholic and 
chenodeoxycholic acid in the intestine 
with a compensatory rise in cholic 
acid.105,106 When given to patients with 
ileal dysfunction for therapy of their 
bile acid-induced diarrhea, cholesty­
ramine could magnify the bile-salt ab­
sorption, deplete the bile-salt pool, de­
spite enhanced hepatic synthesis and 
worsen biliary lipid composition. Such 
an effect has not been documented in 
man, although this resin can produce 
abnormal bile and gallstones in 
baboons.129 At lower dosages, cholesty­
ramine may have the opposite effect 
in humans with hyperlipidemias127 or 
gallstones.1™ If this is so, the most 
likely mechanism is that originally 
postulated by Strasberg, Petrunka and 
Ilson;72 cholestyramine removes some 
bile salt from the enterohepatic cir­
culation, stimulating synthesis from 
cholesterol and so reducing hepatic 
cholesterol secretion.
Medical Dissolution
Before the advent of modern sur­
gery, when the physician possessed 
only simple remedies, it was hardly 
surprising that numerous diets, potions 
and herbs were used in attempts to 
dissolve gallstones.1 As surgical tech­
niques improved and the number of 
operative deaths decreased, the in­
centive to find a medical cure for 
cholelithiasis evaporated. The de­
finitive treatment of gallstones is cur­
rently surgical and will likely remain 
so. A new era began, however, when 
gallstone formation came under scien­
tific scrutiny. The application of fun­
damental knowledge has led to real 
potential for medical prophylaxis and 
dissolution. Several extensive reviews 
on medical therapy have been pub­
lished,131"134 but I shall present a brief 
summary.
It was first demonstrated over 40 
years ago that exogenous administra­
tion of bile salts caused gallstones to 
disappear radiologically.135 This study 
was by no means definitive and curi­
ously part of the rationale for its use 
was its properties as a cathartic! Not 
only was dyspepsia improved, but the 
roentgenographic “shadows” tended 
to vanish. When the physicochemical 
basis for gallstone formation was un­
covered76 and a metabolic basis— 
insufficient bile salts91—known, the 
next logical step was to administer 
bile salts orally. The breakthrough 
came when Thistle and Schoenfield126 
were able to improve bile composition 
with chenodeoxycholic acid in patients 
with overt gallstones and also in sub­
jects at high risk for the develop­
ment of gallstones.95 Subsequent clin­
ical trials proved that chenodeoxy­
cholic acid promoted gallstone dis­
solution.136,137 Even more pertinently, 
it soon became clear that this bile salt 
was specific—the other two major bile 
salts in man, cholic acid and deoxy­
cholic acid, did not work.50,126,138,139
The efficacy of chenodeoxycholic 
acid in dissolving radiolucent gall­
stones has now been fairly well 
established.140'142 In a dosage of 12 to 
15 mg/ kg daily it will dissolve 
approximately 80% of radiolucent 
gallstones. Low-dose therapy and 
intermittent therapy, however do 
not adequately revert bile to an 
unsaturated state.143,144 Bedtime admi­
nistration of chenodeoxycholic acid145 
and a diet low in cholesterol146 en­
hance the desaturating effect, but not 
plant sterols which block cholesterol 
absorption.147 Since the rate of gall­
stone dissolution presumably depends
on the degree of cholesterol unsatura­
tion, dissolution would be accelerated 
by bedtime administration of cheno­
deoxycholic acid combined with a low 
cholesterol diet.148
Not all stones dissolve on therapy. 
The 20%  failure rate may represent 
the fact that not all radiolucent gall­
stones consist predominantly of choles­
terol.24’42 Radiopaque stones are vir­
tually unresponsive as most are pig­
ment gallstones. Improved criteria for 
detecting patients with cholesterol gall­
stones should result from analysis of 
cholesterol saturation in duodenal 
bile149 and might therefore identify 
probable responders. The number and 
especially the size of the gallstones are 
definite factors in determining the 
duration of therapy necessary for dis­
solution.133 Complete dissolution of 
small stones (diameter less than 5 mm) 
usually occurs within 6 to 12 months. 
Large stones may be resistant; a small 
surface relative to a large mass 
provides less exposure to the de- 
saturated bile. Most stones larger than 
1 cm in diameter require more than 2 
years to dissolve, while very large 
stones (diameter more than 2 cm) 
mav never respond. Stones that ap­
pear to float on oral cholecystography 
may be more amenable to dissolution. 
Obesity is a relative problem overcome 
by administering larger than normal 
doses (18 to 20 mg/kg daily).150 Thus 
certain determinants of efficacy are 
now clear (Table II), the most impor­
tant being gallstone type.141
Potential adverse effects, especially 
that of hepatotoxicity, were recognized 
early.151 Chenodeoxycholic acid is nor­
mally transformed by intestinal bac­
teria into lithocholic acid, a known 
hepatotoxin.152 Subhuman primate 
studies have found that chenodeoxy­
cholic acid therapy produces severe 
hepatic lesions.153,154 Man, however, 
appears to be protected from hepatic 
toxicity; only transient elevations of 
serum transaminase levels have been 
reported.131 Humans are quite capable 
of adding a sulfate moiety to litho­
cholic acid rendering it less toxic 
and little is reabsorbed into the en­
terohepatic circulation.155’156 Fears that 
chronic therapy could also disturb 
cholesterol metabolism, leading to 
cholesterol accumulation within the 
body,151 were proven unfounded.157 In 
fact, chenodeoxycholic acid lowers 
serum triglyceride levels but not those 
of cholesterol.158 This indicates that 
chenodeoxycholic acid could be useful 
when combined with clofibrate in 
lowering serum triglyceride levels 
while offsetting the adverse effect of 
clofibrate on cholesterol saturation of
Table II -  Factors in Successful Gallstone Dissolution 
w ith Chenodeoxycholic Acid
Factor Good Bad
Patient weight 
On oral cholecystography 
Stone size 
Gallstone type
Gallbladder
Normal 
< 1  cm
Radiolucent (80% are cholesterol) 
Floating (?)
Well visualized
Obese 
> 2  cm
Radiopaque,* calcified rim 
Nonvisualized*
’ Medical dissolution contraindicated.
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bile.159 Despite their property of break­
ing the gastric mucosal barrier, bile 
salts administered orally have not been 
associated with the development of 
gastritis. Biliary colic, however, has 
occurred, presumably from passage of 
partially dissolved stones into the 
common duct,1'17160 but most investi­
gators have generally noted a lessen­
ing of symptoms. Hence, chenodeoxy- 
cholic acid therapy is not suitable for 
patients with biliary colic, acute chole­
cystitis or cholangitis. It is most effect­
ive in patients with mild symptoms, a 
functioning gallbladder and an un­
obstructed biliary tract. Its chief side 
effect is diarrhea, which is dose-re­
lated. The most distressing problem 
is the likelihood of recurrence when 
therapy is stopped.193 Because the un­
derlying metabolic disorder has not 
been permanently corrected in most 
cases (unless an obvious risk factor is 
eliminated, such as obesity or estrogen 
therapy), gallstones can form again. 
Because the risk of recurrence is life­
long, a safe form of long-term pro­
phylactic therapy is needed. Despite 
these problems, chenodeoxycholic 
acid has been used in some 10 000 
patients and has been on the British 
market since early 1978. It is safe and 
effective.
The most intriguing aspect of this 
gallstone story is why and how only 
chenodeoxycholic acid works. Cholic 
acid and deoxycholic acid do not. 
Although the major bile salts of man 
have similar properties and structure, 
the liver must be capable of interpret­
ing the subtle differences that do exist. 
Even now we do not fully understand 
the mechanism of action. Repletion of 
the bile-salt pool was initially thought 
to be the sole factor136 but oral ther­
apy with cholic acid, the other primary 
bile salt in man, did not benefit biliary 
lipid composition or secretion.50 Deo­
xycholic acid similarly had no real 
effect on cholesterol saturation or 
secretion.51,139 The key difference ap­
pears to be a greater suppression of 
cholesterol synthesis (reduced HMG- 
CoA) by chenodeoxycholic acid, re­
sulting in reduced cholesterol secretion 
into bile.50,161,162 Patients with choles­
terol gallstones tend to have increased 
HMG-CoA reductase levels93 which 
return towards normal with cheno­
deoxycholic acid therapy.94 Whether 
or not chenodeoxycholic acid acts by 
reducing hepatic cholesterol synthesis 
and secretion into bile, the net effect 
is bile with less cholesterol relative to 
bile salts and lecithin. The principal 
benefit of chenodeoxycholic acid 
could even be attributed to a meta­
bolite, such as ursodeoxycholic acid.163
Increased levels of this 7/3 epimer are 
found in patients treated with cheno­
deoxycholic acid. Acting upon this, a 
Japanese group has recently demon­
strated that oral ursodeoxycholic acid, 
alone, is capable of dissolving stones.164 
Its effective daily dose may even be 
lower at 8 to 11 mg/ kg.165 This major 
constituent of biliary bile acids in the 
bear has been widely used for cen­
turies in Japan and China as a general 
remedy for liver ailments. Hence, its 
safety may already have been proven. 
As an added benefit, ursodeoxycholic 
acid does not cause diarrhea, but 
being manufactured from cheno­
deoxycholic acid it costs more. Its 
mechanism of action is probably sim­
ilar to that of chenodeoxycholic acid. 
Curiously the solvent characteristics of 
ursodeoxycholic acid in vitro differ: 
a little ursodeoxycholic acid is good 
but more can lessen the cholesterol 
holding capacity of bile. Further stu­
dies are required on its efficacy, phar­
macokinetics and mechanism of ac­
tion.134
Alternative therapeutic agents are 
also being actively investigated. Pheno- 
barbital, for example, is a known in­
ducer of microsomal enzymes in the 
liver and causes marked changes in 
hepatic structure and function. Obser­
vations in the monkey have shown that 
phenobarbital increases bile flow, bile 
salt synthesis, pool size and secre­
tion.166 The resultant improvement in 
biliary lipid composition makes it a 
logical choice for drug therapy in 
patients with cholelithiasis. Unfor­
tunately it also stimulates cholestero- 
genesis. Phenobarbital administration 
in some clinical studies has decreased 
cholesterol saturation, but so far 
has not effectively dissolved gall­
stones.160,167 Moreover, it does not en­
hance the desaturation effect of cheno­
deoxycholic acid.168 A surge of interest 
has been created, resulting in a ple­
thora of studies of various drugs. Of 
these, lecithin and a-glycerophosphate 
need further investigation whereas 
older drugs, such as Zanchol169 and 
Rowachol170 merit re-evaluation.
The role of dietary manipulation, 
particularly in the form of a high- 
fibre diet, could yield a very exciting 
therapeutic modality. Burkitt, Walker 
and Painter,171 have postulated that 
the low frequency of gallstones and 
atherosclerosis in parts of Africa and 
Asia is the result of the high-fibre 
content in the diet of these popula­
tions. Dietary fibres are structural 
components of plant cell walls which 
cannot be digested within the in­
testinal tract of man.172 Studies on the 
effect of a high-fibre diet have so far
been uncontrolled and inconclu­
sive.173,174 Bran may be effective in 
desaturating bile of patients with 
supersaturated bile175 or with overt 
gallstones176,177 but it is not sufficiently 
effective to dissolve the stones. The 
beneficial effect of these dietary fibres 
may be mediated by their binding of 
bile acids in the intestinal lumen, re­
ducing their absorption and return to 
the liver, increasing bile-salt synthesis 
and so decreasing biliary cholesterol 
secretion.172 Once better designed stu­
dies using chemically purer forms of 
fibre have identified the most potent 
component and defined an optimal 
dose, then a natural plant material 
could easily become the basis for long­
term gallstone prophylaxis: to prevent 
recurrences in patients whose gall­
stones have been dissolved medically 
and for those with abnormal bile at 
high risk of stone formation.
The knowledge that biophysical 
and metabolic investigations have im­
parted over the past decade to the pa­
thogenesis of gallstones has created 
the field of medical management. 
Medical dissolution of cholesterol gall­
stones has become a reality and is 
likely to become an increasingly im­
portant mode of therapy in the future. 
Cholecystectomy is currently excellent
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treatment for most patients with cal­
culous biliary tract disease. The re­
lative merits of medical dissolution 
versus surgery, especially in patients 
with minimal symptoms, should there­
fore provide an interesting debate in 
the next decade. Only careful obser­
vations and cost-effectiveness studies 
will demonstrate the practical feasibil­
ity of medical therapy. Meanwhile, 
research efforts should be directed 
towards other goals: the detection of 
people at risk, which presently re­
quires aspiration of bile through a 
duodenal tube for analysis; a more 
complete understanding of cholesterol 
gallstone formation and dissolution, 
which should yield future therapeutic 
agents; better comprehension of the 
calcified pigment stone, which so far 
has eluded accurate description or 
dissolution; and safe, acceptable ther­
apy to prevent recurrence in patients 
who have undergone gallstone dis­
solution.
I thank Mrs. Linda Ward for her 
secretarial assistance. Figs. 3, 4 and 5 
are reproduced by permission from 
Shaffer EA, Small DM: Gallstone 
disease: problems and management, in 
R avitch MM, et al (eds): Current
Problems in Surgery, copyright © 1976 
by Year Book Medical Publishers, Inc., 
Chicago, and Figs. 8 and 9 from 
Shaffer EA: The role of the gallblad­
der in gallstone formation, in Gall­
stones, F isher MM, Goresky CA, 
Shaffer EA, et al (eds), Plenum Pr, 
New York, 1979, p 223
References
1. Rains AJE1: Causes, in Gallstones. 
CC Thomas, Springfield, 111., 1964, 
P 1
2. Ingelfinger FJ: Digestive disease 
as a national problem. V. Gall­
stones. Gastroenterology 55: 102, 
1968
3. F isher MM: Perspectives on gall­
stones. in Gallstones, F isher. MM. 
G oresky CA. Shaffer EA. et al 
(eds). Plenum Pr. New York. 1979. 
P 1
4. Plant ICD, Percy I, Bates T, et 
al: Incidence of gallbladder disease 
in Canada, England and France. 
Lancet 2: 249, 1973
5. Vayda E: A comparison of surgical 
rates in Canada and in England and 
Wales. N EngI J Med 289: 1224, 
1973
6. Bunker IP, Wennberg JE: Opera­
tion rates, mortality statistics and 
the quality of life (E). Ibid, p 1249
7. Ingelfinger FJ: Misuse of infor­
mation printed in the Journal (E ). 
N Engl J Med 294: 667, 1976
8. Ahlberg J, Ewerth S, H ellers G,
et al: Decreasing frequency of
cholecystectomies in the counties 
of Stockholm and Uppsala, Sweden. 
Acta Chir Scand 144 (suppl 482): 
21, 1978
9. G lenn F: Calculous biliary tract 
disease an increasing burden on 
surgical facilities (F.). Ann Surg 
171: 163, 1970
10. Shaffer EA, Small DM: Gall­
stone disease: pathogenesis and
management. Curr Probl Surg 13: 
3. 1976
11. Sampliner RE, Bennett PH, 
Comess LJ, et al: Gallbladder dis­
ease in Pima Indians. Demonstra­
tion of high prevalence and early 
onset by cholecystography. N Engl 
J Med 283: 1358, 1970
12. Williams CN, Johnston JL, 
Weldon KLM: Prevalence of gall­
stones and gallbladder disease in 
Canadian Micmac Indian women. 
Can Med Assoc J 117: 758, 1977
13. Bainton D, D avies GT, Evans KT,
et al: Gallbladder disease. Pre­
valence in a South Wales industrial 
town. N Engl J Med 294: 1147, 
1976
14. Comfort MW, Gray HK, Wilson 
JM: The silent gallstone: 10 to 20 
year follow-up study of 112 cases. 
Ann Surg 128: 931, 1948
15. Robertson HE: Silent gallstones. 
Gastroenterology 5: 345, 1945
16. When do gallstones matter? (E). 
Lancet 1: 1061, 1976
17. Bouchier IAD, Rhodes K, Brien 
M: A study of symptomatic and 
“silent” gallstone. Scand J Gastro­
enterol 3: 299, 1968
18. Sato T, Matsushiro T : Surgical 
indications in patients with silent 
gallstones. Am J Surg 128: 368, 
1974
19. Wenckert A, Robertson B: The 
natural course of gallstone disease: 
eleven-year review of 781 nonoper- 
ated cases. Gastroenterology 50: 
376, 1966
20. Turrill FL, McCarron MM,
Mikkelsen WP: Gallstones and
diabetes: an ominous association. 
Am J Surg 102: 184, 1961
21. Mundth EA: Cholecystitis and dia­
betes mellitus. N Engl J Med 267: 
642, 1962
22. Dangers of silent gallstones (E). Br 
Med J 1: 415, 1975
23. Trotman BW, Ostrow JD, 
Soloway RD: Pigment vs choles­
terol cholelithiasis: comparison of 
stone and bile composition. Am J 
Dig Dis 19: 585, 1974
24. Trotman BW, Petrella EJ, 
Soloway RD, et al: Evaluation of 
radiographic lucency or opaqueness 
of gallstones as a means of identify­
ing cholesterol or pigment stones. 
Correlation of lucency or opaque­
ness with calcium and mineral. 
Gastroenterology 68: 1563, 1975
25. Miyake H, Johnston CG: Gall­
stones: ethnological studies. Diges­
tion 1: 219, 1968
26. Soloway RD, Trotman BW. 
Ostrow JD: Pigment gallstones. 
Gastroenterology 72: 167, 1977
27. Bouchier IAD: Postmortem study 
of the frequency of gallstones in 
patients with cirrhosis of the liver. 
Gut 10: 705, 1969
28. Nicholas P. Rinaudo PA, Conn 
HO: Increased incidence of chole­
lithiasis in Laennec's cirrhosis. A 
postmortem evaluation of patho­
genesis. Gastroenterology 63: 112. 
1972
29. Weens HS: Cholelithiasis in sickle 
cell anemia. Ann Intern Med 22: 
182, 1945
30. Caroli J : Diseases of the intrahepa­
tic biliary tree. Clin Gastroenterol 
2: 147, 1973
31. Maki T: Pathogenesis of calcium 
bilirubinate gallstone: role of E. 
coli, /3-glucuronidase and coagula­
tion by inorganic ions, polyelectro­
lytes and agitation. Ann Surg 164: 
90, 1966
32. Masuda H, Nakayama F: Com­
position of bile pigment in gall­
stones and bile and their etiological 
significance. J Lab Clin Med 93: 
353, 1979
33. Trotman BW: Insights into pig­
ment stone disease (E). Ibid, p 349
34. Matsushiro T, Suzuki N, Sato T, 
et al: Effects of diet on glucaric 
acid concentration in bile and the 
formation of calcium bilirubinate 
gallstones. Gastroenterology 72: 
630, 1977
35. Wosiewitz U, Schroebler S: On 
the chemistry of “black” pigment 
stones from the gallbladder. Clin 
Client Acta 89: 1, 1978
36. Ballantyne B, Wood WG: Bio­
chemical and histochemical observa­
tions on /3-glucuronidase in the 
mammalian gallbladder. Am J 
Dig Dis 13: 551, 1968
37. Scott AJ: Bacteria and disease of 
the biliary tract. Gut 12: 487, 1971
38. Goodhart GL, Levison ME, 
T rotman BW, et al: Pigment vs 
cholesterol cholelithiasis: bacteriol­
ogy of gallbladder, stone, bile and 
tissue correlated with biliary lipid 
analysis. Am J Dig Dis 23: 877, 
1978
39. Suzuki N. N akamura Y, Kobaya- 
shi N, et al: On metal elements in 
pure pigment gallstones. Tolioku 
Exp Med 116: 233, 1975
40. Small DM: Gallstones. N  Engl J 
Med 279: 588, 1968
41. Been JM, Bills PM, Lewis D: 
Microstructure of gallstones. Gas­
troenterology 76: 548, 1979
42. Bell GD, Dowling RH, Whitney 
B, et al: The value of radiology in 
predicting gallstone type when 
selecting patients for medical treat­
ment. Gut 16: 359, 1975
43. Sutor DJ, Wooley SE: A statis­
tical survey of the composition of 
gall-stones in eight countries. Gut 
12: 55, 1971
44. Boyer JL, Bloomer JR: Canali­
cular bile secretion in man-studies 
utilizing the biliary clearance of 
(C-14) mannitol. J Clin Invest 54: 
773, 1974
45. Strasberg SM: Mechanisms of
solute secretion into bile, in Gall­
stones, F isher MM, Goresky CA, 
Shaffer EA, et al (eds), Plenum 
Pr, New York, 1979, p 47
46. Small DM. Dowling RH. Redin­
ger RN: The enterohepatic circula­
tion of bile salts. Arch Intern Med 
130: 552. 1972
47. H ofmann AF: The enterohepatic 
circulations of bile acids in man: a 
maturation of concepts, in Gall­
stones, F isher MM, Goresky CA, 
Shaffer EA, et al (eds), Plenum 
Pr, New York, 1979, pp 89-105
48. Shaffer EA, Braasch JW, Small 
DM: Bile composition at and after 
surgery in normal persons and pa­
tients with gallstones. Influence of 
cholecystectomy. N Engl J Med 
287: 1317, 1972
528 VOLUME 23, NO. 6, NOVEMBER 1980 /  THE CANADIAN JOURNAL OF SURGERY
49. Shefer S, Hauser S, Bekersky I, 
et al: Feedback regulation of bile 
acid synthesis in the rat. J Lipid 
Res 10: 646, 1969
50. LaRusso NF, Hoffman NE, 
Hofmann AF, et al: Effect of 
primary bile acid ingestion on 
bile acid metabolism and biliary 
lipid secretion in gallstone patients. 
Gastroenterology 69: 1301, 1975
51. LaRusso NF, Szczepanik PA 
Hofmann AF: Effect of deoxy- 
cholic acid ingestion on bile acid 
metabolism and biliary lipid secre­
tion in normal subjects. Gastroen­
terology 72: 132, 1977
52. Hofmann AF, Small DM: Deter­
gent properties of bile salts: corre­
lation with physiological function. 
Atinu Rev Med 18: 333, 1967
53. Wilson JD: The role of bile acids 
in the overall regulation of steroid 
metabolism. Arch Intern Med 130: 
493, 1972
54. Dietschy JD, Wilson JD: Regula­
tion of cholesterol metabolism 
(first of three parts). N Engl J 
Med 282: 1128, 1970
55. Idem: Regulation of cholesterol
metabolism (second of three parts). 
Ibid, p 1179
56. Idem: Regulation of cholesterol
metabolism (third of three parts). 
Ibid, p 1241
57. Shefer S, Hauser S, Lapar V, 
et al: Regulatory effects of sterols 
and bile acids on hepatic 3-hydroxy- 
3-methylglutaryl CoA reductase and 
cholesterol 7 a-hydroxylase in the 
rat. J Lipid Res 14: 573, 1973
58. Nervi FO, Dietschy JM: The 
mechanisms of and the interrela­
tionship between bile acid and chy­
lomicron-mediated regulation of 
hepatic cholesterol synthesis in liver 
of rat. J Clin Invest 61: 895. 1978
59. Schoenfield LJ, Bonorris GG, 
Ganz P: Induced alterations in the 
rate-limiting enzymes of hepatic 
cholesterol and bile acid synthesis 
in the hamster. J Lab Clin Med 82: 
858, 1973
60. Andersen JM, Dietschy JM: Re­
gulation of sterol synthesis in 16 
tissues of rat. 1. Effect of diurnal 
light cycling, fasting, stress, mani­
pulation of enterohepatic circula­
tion, and administration of chylomi­
crons and triton. J Bio! Client 252: 
3646. 1977
61. Brown MS, Goldstein JL: Recep­
tor-mediated control of cholesterol 
metabolism. Science 191: 150, 1976
62. Schwartz CC, Berman M, Vlah-
cevic ZR, et al: Multicompart-
mental analysis of cholesterol me­
tabolism in man—characterization 
of the hepatic bile acid and biliary 
cholesterol precursor sites. J Clin 
Invest 61: 408, 1978
63. Schwartz CC, H alloran LG, 
Vlahcevic ZR, et al: Preferential 
utilization of free cholesterol from 
high-density lipoproteins for biliary 
cholesterol secretion in man. Sci­
ence 200: 62, 1978
64. H alloran LG, Schwartz CC, 
Vlahcevic ZR, et al: Evidence for 
high-density lipoprotein-free choles­
terol as the primary precursor for 
bile-acid synthesis in man. Surgery 
84: 1, 1978
65. Nilsson S, Schersten T: Impor­
tance of bile acids for phospholipid 
secretion into human hepatic bile. 
Gastroenterology 57: 525, 1969
66. Saunders DR: Insignificance of the 
enterobiliary circulation of lecithin 
in man. Gastroenterology 59: 848, 
1970
67. Robins SJ: Recirculation and re­
utilization of micellar bile lecithin. 
Am J Physio! 229: 598, 1975
68. Wheeler HO, King KK: Biliary 
excretion of lecithin and cholesterol 
in the dog. J Clin Invest 51: 1337, 
1972
69. Shaffer EA, Small DM: Biliary 
lipid secretion in cholesterol gall­
stone disease-effect of cholecys­
tectomy and obesity. J Clin Invest 
59: 828, 1977
70. Shaffer EA, Preshaw RM: The 
effect of bromosulphthalein (BSP) 
on biliary lipid secretion (abstr). 
Gastroenterology 75: 987, 1978
71. Key PH, Bonorris GG, Coyne MJ, 
et al: Hepatic cholesterol synthesis: 
a determinant of cholesterol secre­
tion in gallstone patients (abstr). 
Gastroenterology 72 (pt 2): 1182,
1977
72. Strasberg SM, Petrunka CN, 
Ilson RG: Effect of bile acid syn­
thesis rate on cholesterol secretion 
rate in the steady state. Gastro­
enterology 71: 1067, 1976
73. T urley SD, Dietschy JM: Regula­
tion of biliary cholesterol output in 
the rat: dissociation from the rate 
of cholesterol synthesis and the 
size of the cholesterol ester pool 
in the liver (abstr). Gastroen­
terology 74 (pt 2): 1106, 1978
74. N ervi FO, Carrella M, Dietschy 
JM: Dissociation of /3-hydroxy-/3- 
methyglutaryl-CoA reductase ac­
tivity from the overall rate of cho­
lesterol synthesis in the liver fol­
lowing the intravenous administra­
tion of lipid. J Biol Client 251: 
3831, 1976
75. Grundy SM, Mok HYI: Effects 
of diets and drugs on biliary 
cholesterol secretion in man, in 
Gallstones, Fisher MM, Goresky 
CA, Shaffer EA, et al (eds), 
Plenum Pr, New York, 1979, p 283
76. Admirand WH, Small DM: The 
physicochemical basis of cholesterol 
gallstone formation in man. J Clin 
Invest 47: 1043, 1968
77. Small DM: The formation of gall­
stones, in Advances in Internal 
Medicine, v 16, Stollerman GH 
(ed), Year Bk Med, Chicago, 1970, 
p 243
78. Carey MC, Small DM: Micelle 
formation by bile salts. Physical- 
chemical and thermodynamic consi­
derations. Arch Intern Med 130: 
506, 1972
79. Idem: Physical chemistry of choles­
terol solubility in bile-relationship 
to gallstone formation and dissolu­
tion in man. J Clin Invest 61: 998,
1978
80. Holzbach RT, Par CYC: Metasta­
ble supersaturation. Physicochemical 
studies provide new insights into 
formation of renal and biliary tract 
stones. Am J Med 56: 141, 1974
81. H egardt FG, Dam H: The solu­
bility of cholesterol in aqueous 
solutions of bile salts and lecithin. 
Z Ernaehrungswiss 10: 223, 1971
82. H olzbach RT, Marsh M, Olszew­
ski M, et al: Cholesterol solubility 
in bile. Evidence that supersaturated 
bile is frequent in healthy man. 
J d in  Invest 52: 1467, 1973
83. C arey MC: Critical tables for cal­
culating the cholesterol saturation 
of native bile. J Lipid Res 19: 945,
1978
84. Small DM, Rapo S: Source of 
abnormal bile in patients with 
cholesterol gallstones. N  Engl J  
Med 283: 53, 1970
85. Shaffer EA: The role of the gall­
bladder in gallstone formation, in 
Gallstones, F isher MM, G oresky 
CA, Shaffer EA, et al (eds), 
Plenum Pr, New York, 1979, p 223
86. Redinger RN, Small DM: Bile 
composition, bile salt metabolism 
and gallstones. Arch Intern Med 
130: 618, 1972
87. Strasberg SM, F isher MM: Patho­
genesis of human cholesterol chole­
lithiasis. Can Med Assoc J 112: 
484, 1975
88. G rundy SM, Metzger AL, Adler 
RD: Mechanisms of lithogenic bile 
formation in American Indian 
women with cholesterol gallstones. 
J Clin Invest 51: 3026, 1972
89. G rundy SM, Duane WC, Adler
RD. et al: Biliary lipid outputs
in young women with cholesterol 
gallstones. Metabolism 23: 67, 1974
90. Bennion LJ, Grundy SM: Effects 
of obesity and caloric intake on 
biliary lipid metabolism in man. 
J Clin Invest 56: 996, 1975
91. Vlahcevic ZR, Bell CC j r , 
Buhac I, et al: Diminished bile 
acid pool in patients with gallstones. 
Gastroenterology 59: 165, 1970
92. Dowling RH, Bell GD, White J : 
Lithogenic bile in patients with ileal 
dysfunction. Gut 13: 415, 1972
93. Salen G, N icolau G, Shefer S, 
et al: Hepatic cholesterol meta­
bolism in patients with gallstones. 
Gastroenterology 69: 676, 1975
94. Coyne MJ, Bonorris GG, G old­
stein LI, et al: Effects of cheno- 
deoxycholic acid and phenobarbital 
on the rate-limiting enzymes of he­
patic cholesterol and bile acid syn­
thesis in patients with gallstones. 
J Lab Clin Med 87: 281, 1976
95. T histle JL, Schoenfield LJ: Li­
thogenic bile among young Indian 
women. Lithogenic potential de­
creased with chenodeoxycholic acid. 
N  Engl J Med 284: 177, 1971
96. Bennion LJ, Knowler WC, Mott 
DM, et al: Development of litho­
genic bile during puberty in Pima 
Indians. N Engl J Med 300: 873,
1979
97. Valdivieso V, Palma R, Wunkhaus 
R, et al: Effect of aging on biliary 
lipid composition and bile acid me­
tabolism in normal Chilean women. 
Gastroenterology 74: 871, 1978
98. Walton AG: Formation and
Properties of Precipitates, Wiley, 
New York, 1967
99. Lonsdale K: Epitaxy as a growth 
factor in urinary calculi and gall­
stones. Nature 217: 56, 1968
100. Spellman SJ, Shaffer EA, 
Rosenthall L: Gallbladder emp­
tying in response to cholecystokinin. 
A cholescintigraphic study. Gastro­
enterology 77: 115, 1979
VOLUME 23, NO. 6, NOVEMBER 1980 /  THE CANADIAN JOURNAL OF SURGERY 529
101. Bouchier IAD, Freston JW: The 
aetiology of gallstones. Lancet 1: 
340, 1968
102. OSUGA T, PoRTMAN OW, MlTA- 
mura K, et al: A morphologic 
study of gallstone development in 
the squirrel monkey. Lab Invest 30: 
486, 1974
103. Ostrow JD: Absorption of organic 
compounds by the injured gall­
bladder. J Lab Clin Med 78: 255, 
1971
104. Redinger RN: The effect of loss 
of gallbladder function on biliary 
lipid composition in subjects with 
cholesterol gallstones. Gastroen­
terology 71: 470, 1976
105. Bennion LJ, Grundy SM: Risk 
factors for the development of 
cholelithiasis in man (first of two 
parts). N Engl J Med 299: 1161, 
1978
106. Idem: Risk factors for the develop­
ment of cholelithiasis in man (sec­
ond of two parts). Ibid, p 1221
107. Sarle H, Hauton J, Planche NE, 
et al: Diet, cholesterol gallstones 
and composition of the bile. Am J 
Dig Dis 15: 251, 1970
108. Sturdevant RAL, Pearce ML, 
D ayton S: Increased prevalence of 
cholelithiasis in men ingesting a 
serum-cholesterol-lowering diet. N 
Engl J Med 288: 24, 1973
109. D enBesten L, Connor WE, Bell 
S: The effect of dietary cholesterol 
on the composition of human bile. 
Surgery 73: 266, 1973
110. Johnston JL, Williams CN,
Weldon KLM: Nutrient intake
and meal patterns of Micmac In­
dian and Caucasian women in 
Shubenacadie, NS. Can Med Assoc 
J 116: 1356, 1977
111. BurkittDP: Some diseases charac­
teristic of modern Western civiliza­
tion. Br Med J 1: 274, 1973
112. Pertsemlidis D, Panveliwalla D, 
Ahrens EH j r : Effects of clofib- 
rate and estrogen-progestin combi­
nation on fasting biliary lipids and 
cholic acid kinetics in man. Gastro­
enterology 66: 565, 1974
113. Lynn J, Williams L, O’Brien J, et 
al: Effects of estrogen upon bile: 
implications with respect to gall­
stone formation. Ann Surg 178: 
514, 1973
114. D avis RA, Kern F j r : Effects of 
ethinyl estradiol and phenobarbital 
on bile acid synthesis and biliary 
bile acid and cholesterol excretion. 
Gastroenterology 70: 1130, 1976
115. Bennion LJ, Ginsberg RL, G ar- 
nick MB, et al: Effects of oral 
contraceptives on the gallbladder 
bile of normal women. N  Engl J 
Med 294: 189, 1976
116. Danzinger RG, Gordon H, 
Schoenfield LJ, et al: Lithogenic 
bile in siblings of young women 
with cholelithiasis. Mayo Clin Proc 
47: 762, 1972
117. Biss K, H o KJ, Mikkelson B, et 
al: Some unique biologic character­
istics of the Masai of East Africa. 
N Engl J Med 284: 694, 1971
118. Roy CC, Weber AM, Morin CL, 
et al: Abnormal biliary lipid com­
position in cystic fibrosis. Effect of 
pancreatic enzymes. N Engl J Med 
297: 1301, 1977
119. H ellstrom K, Einarrson K: Bile
“Zinacef
CEFUROXIME SODIUM INJECTION
Prescribing Information:
Indications and Clinical uses: ZINACEF may be indicated for the 
treatment of the following infections when caused by susceptible 
organisms: lower respiratory tract, urinary tract and soft tissue 
infections.
Appropriate culture and susceptibility studies should be performed 
to determ ine the s u s c e p tib ility  of the causa tive  organism  to 
ZINACEF. Therapy may be started while awaiting the results of these 
tests, however, modification of the treatment may be required once 
these results become available.
C linical studies have shown ZINACEF to be effective against infec­
tions caused by sensitive strains of:
Gram positive cocci - Staphylococcus aureus
Streptococci (excluding S. faecalis)
Gram negative rods -  Hemophilus influenzae 
Escherichia coli 
Proteus mirabilis 
Klebsiella spp.
Contraindications: Hypersensitivity to cephalosporins.
Warnings: Before therapy with ZINACEF is instituted, careful inquiry 
should be made concerning previous hypersensitivity reactions to 
cephalosporins, penicillins or other drugs ZINACEF should be given 
only with caution to penicillin-sensitive patients 
There is some clin ica l and laboratory evidence of partia l cross­
allergenicity of the cephalosporins and penicillins. Patients have 
been reported to have had severe reactions (including anaphylaxis) 
to both types of drugs.
Any patient who has demonstrated some form of allergy, particularly 
to drugs, should receive antibiotics, including ZINACEF. with cau­
tion. If an allergic reaction to ZINACEF occurs, administration of the 
drug should be discontinued. Serious acute hypersensitivity reac­
tions may require treatment with epinephrine and other emergency 
measures.
Precautions: The safety of ZINACEF in the treatment of infections 
during pregnancy has not been established. If the administration of 
ZINACEF is considered to be necessary, its use requires that the po­
tential benefits be weighed against possible hazards to the patient 
and to the fetus. Animal studies have shown ZINACEF to affect bone 
calcification in the fetus and to show maternal toxicity in the rabbit. 
The safety of ZINACEF for the treatment of infections in infants, 
children and nursing mothers, has not been established.
Prolonged use of ZINACEF may result in the overgrowth of non- 
susceptible organisms. Careful observation of the patient is there­
fore essential, and if superinfection should occur during therapy, 
appropriate measures should be taken. Should an organism become 
resistant during antib io tic therapy, another antib io tic should be 
substituted.
Patients w ith renal or hepatic im pairm ent should be carefully 
monitored during therapy w ith ZINACEF. Patients with impaired 
renal function should be placed on the special dosage recom­
mended under DOSAGE AND ADMINISTRATION, because normal 
doses in these individuals are likely to produce excessive serum 
concentrations.
Studies suggest that the concurrent use of potent diuretics, such as 
furosemide and ethacrynic acid, may increase the risk of renal tox­
icity with cephalosporins.
ZINACEF may interfere w ith  Benedict’s and Fehling's tests for 
glycosuria. It may cause false negative reactions in the ferricyamde 
test, and possibly, may cause an erroneously high reading in the 
alkaline picrate test for creatinine.
Adverse reactions: The following reactions have been observed 
during treatment with ZINACEF.
Hypersensitivity: rash and eosinophilia. Anaphylaxis, pruritus and 
drug fever have also been observed with cephalosporin therapy. 
Local reactions: thrombophlebitis, stiffness at the site of injection 
and inflammatory reactions at the site of injection. Some degree of 
pain, after intram uscular injections when using water as the d i­
luent, has been observed.
Blood, increased erythrocyte sedimentation rate and decreased 
hemoglobin. Some patients developed a positive direct Coombs test. 
Renal: increases in BUN and serum creatinine.
Hepatic: transient increases in serum bilirubin, transaminases and 
alkaline phosphatase.
Others: drowsiness, loose stools, faint feeling, sweating, palpita­
tions and Candida intertrigo.
Symptoms and treatment of overdose: Other than general suppor­
tive treatm ent, no specific antidote is known. Excessive serum 
levels of cefuroxime can be reduced by dialysis. For treatment of 
hypersensitivity reactions, see WARNINGS.
Dosage and administration: Adults: the intramuscular dose is 750 
mg three times daily and the intravenous dose is 750 mg or 1.5 g 
three times daily.
For most infections the usual recommended dosage is 750 mg every 
8 hours (2.25 g/day) and may be administered either l/M or I/V.
For severe or life-threatening infections, the higher dose is sug­
gested. For infections of the lower respiratory tract, caused by gram­
negative organisms, the higher dose may also be required. Anti­
biotic therapy for infections caused by B-hemolytic streptococci 
should be continued for at least 10 days.
There is insufficient evidence for recommending the use of ZINACEF 
in children or in nursing mothers.
Dosage in adults with impaired renal function: ZINACEF may be 
used for patients with impaired renal function but a reduced dosage 
must be employed and serum levels of cefuroxime may need to be 
monitored. The following Table shows the dosage recommendations.
Serum creatinine Glomerular filtration rate Dose of ZINACEF
(mg/mL) (mL/min)* (mg)
2.0 -  3.5 2 0 -5 0 500 t.i.d.
3 5 -  6.0 1 0 -2 0 500 b id
> 6 .0 <  10 500 q.d.
T o r  more precise calculations, whenever possible, the glomerular 
filtration rate should be used.
Patients on dialysis should receive an additional dose of 500 mg at 
the end of dialysis.
Preparation of solutions: For intramuscular use: Add 3.2 m l of 
Water for Injection to a vial containing 750 mg of ZINACEF and 
shake gently to produce an opaque suspension. The total volume 
obtained is approximately 3.7 mL.
For intravenous use: When a single bolus injection is prepared. 750 
mg of ZINACEF is dissolved in 7 mL of Water for Injection, which pro­
vides a volume of approximately 7.5 mL. Reconstitution of 1.5 g of 
ZINACEF is done by adding 19 mL of Water for Injection, thereby ob­
ta in ing an approximate volume of 20 mL.
For short intravenous infusion, 1,5 g of ZINACEF is dissolved in
49 mL of Water for Injection, resulting in an approximate volume of
50 mL.
Administration: Intramuscular: ZINACEF should be injected into a 
large muscle mass to m inimize pain. As the preparation is in 
suspension form, a 21 gauge needle should be used 
Intravenous: ZINACEF may be administered intravenously either by 
a bolus injection or by a short intravenous infusion over a period of 
approximately 30 minutes.
For continuous intravenous infusions, a solution of ZINACEF (1.5 g 
dissolved in 19 mL of Water for Injection) may be added to a suitable 
bottle containing an appropriate intravenous infusion fluid in the 
amount calculated to give the desired antibiotic dose. 
Compatibility: Reconstituted primary solutions of ZINACEF may be 
further diluted with Sodium Chloride Injection B.P. 0.9% w/v. 5% 
w/v Dextrose Injection B.P. or Compound Sodium Lactate Injection 
B.P. (Hartmanns Solution).
NOTE: The pH of 2.74% w/v Sodium Bicarbonate Injection B.P con­
siderably affects the colour of the solution, therefore, this solution is 
not recommended for the dilution of ZINACEF However, if required, 
for patients receiving Sodium Bicarbonate Injection by infusion, the 
ZINACEF may be introduced into the tube of the set.
NOTE ZINACEF should not be mixed with aminoglycoside antibiotics 
(e g. gentamicin sulfate, tobramycin sulfate, amikacin sulfate) be­
cause of potential interaction.
Stability: The dry powder in vials should be stored below 25°C and 
protected from light.
Suspensions of ZINACEF for intramuscular injection and aqueous 
solutions for intravenous injection retain their potency for 6 hours if 
kept below 25°C. and for 48 hours if refrigerated. More dilute solu­
tions, i.e. 1.5 g in 50 mL Water for Injection, retain their potency for 
at least 12 hours if kept below 25°C. and for 36 hours when re­
frigerated. Some increase in the intensity of colour may occur on 
storage.
Dosage forms: ZINACEF is available for intramuscular or direct in­
travenous injection in 18 mL vials containing cefuroxime sodium 
powder equivalent to 750 mg of cefuroxime, in packs of five.
For intravenous injection, 30 mL vials contain cefuroxime sodium 
powder equivalent to 1.5 g of cefuroxime, in individual packs.
For intravenous infusion. ZINACEF is available in 75 mL vials con­
taining cefuroxime sodium powder equivalent to 1.5 g of cefuroxime. 
in individual packs.
Product Monograph available on request.
References.
1) Product Monograph
2) Adapted from Proc. Roy. Soc. Med. (1977) 70, Suppl. 9, p.7 and 
Product Monograph
3) Proc. Roy. Soc. Med. (1977) 70, Suppl. 9, p.26
Glaxo Laboratories
A GLAXO CANADA LIMITED COMPANY
Toronto, Ontario Montreal, Quebec LE 11505-8003
PAAB
CCPP
4
4
4
◄
4
-<
530 VOLUME 23, NO. 6, NOVEMBER 1980 /  THE CANADIAN JOURNAL OF SURGERY
LL .Q
u j ooco
N ilm ia flB le F T e ii
gkT/sgsl8lfBCitfs]gils
tVSMi < MsE »?si i  kM&fsfiFij
iiTsST :W  iiilfel f i l l  & iHKI i
f V l M w i
i j  ITiTiTi^T^Sl
i i S f i r r i r l l  f •£?•] i  * ls l«  I t  1 l i t  1  s M  i  i  i i s i
■slSh R S I i I!?S3 S T a i ^ f !  H I
acid metabolism in hyperlipopro- 
teinaemia. Clin Gastroenterol 6: 
103, 1977
120. T angedahl TN, H ofmann AF, 
Kottke BA: Biliary lipid secretion 
in hypercholesterolemia. J Lipid 
Res 20: 125, 1979
121. Ahlberg J, A ngelin B, E inarsson 
K, et al: Prevalence of gallbladder 
disease in hyperlipoproteinemia. 
Dig Dis Sci 24: 459, 1979
122. Coronary Drug Research Project: 
Gallbladder disease as a side effect 
of drugs influencing lipid meta­
bolism. Experience in the coronary 
drug project. N Engl J Med 296, 
1185, 1977
123. Grundy SM, Biliary lipids, gall­
stones and treatment of hyperlipi- 
daemia (E). Eur J Clin Invest 9: 
179, 1979
124. Idem: Effects of polyunsaturated 
fats on lipid metabolism in patients 
with hypertriglyceridemia. J Clin 
Invest 55: 269, 1975
125. G rundy SM, A hrens EH j r , 
Salen G, et al: Mechanisms of 
action of clofibrate on cholesterol 
metabolism in patients with hyper­
lipidemia. J Lipid Res 13: 531, 
1972
126. Thistle JL, Schoenfield LJ: In­
duced alterations in composition of 
bile of persons having cholelithiasis. 
Gastroenterology 61: 488, 1971
127. Angelin B, E inarrson K, L eijd  
B: Biliary lipid composition dur­
ing treatment with different hypo- 
lipidaemic drugs. Eur J Clin Invest 
9: 185, 1979
128. G rundy SM: Treatment of hyper­
cholesterolemia by interference 
with bile acid metabolism. Arch 
Intern Med 130: 638, 1972
129. R edinger RN, G race DM: Choles­
terol gallstones and biliary lipid 
metabolism in the primate. Gastro­
enterology 74: 201, 1978
130. Redinger RN, K utty PK: The 
effect of cholestyramine on biliary 
lipid metabolism in man (abstr). 
Gastroenterology 77: 208, 1979
131. H ofmann AF, P aumgartner G
(eds): Chenodeoxycholic Acid
Therapy of Gallstones, FK Schat- 
tauer, Stuttgart, 1974
132. G oldstein LI, Schoenfield LJ: 
Gallstones: pathogenesis and med­
ical treatment, in Advances in In­
ternal Medicine, v 20, Stollerman 
GH (ed), Year Bk Med, Chicago, 
1975, p 89
133. D owling RH: Chenodeoxycholic
acid therapy of gallstones. Clin Gas­
troenterol 6: 141, 1977
134. P earlman BJ, M arks JW, 
Bonorris GG, et al: Gallstone dis­
solution—a progress report. Clin 
Gastroenterol 8: 123, 1979
135. Rewbridge AG: Disappearance of 
gallstone shadows following pro­
longed administration of bile salts. 
Surgery 1: 395, 1937
136. D anzinger RG, H ofmann AF, 
Schoenfield LJ, et al: Dissolution 
of cholesterol gallstones by cheno­
deoxycholic acid. N Engl J Med 
286: 1. 1972
137. Bell GD, W hitney B, D owling 
RH: Gallstone dissolution in man 
using chenodeoxycholic acid. Lancet 
2: 1213, 1972
138. T histle JL, H ofmann AF: Effica­
cy and specificity of chenodeoxy­
cholic acid therapy for dissolving 
gallstones. N Engl J Med 289: 655, 
1973
139. Ahlberg J, Angelin B, Einarrson 
K, et al: Influence of deoxycholic 
acid on biliary lipids in man. Clin 
Sci Mol Med 53: 249, 1977
140. Thistle JL, H ofmann AF, Ott BJ, 
et al: Chenotherapy for gallstone 
dissolution. I. Efficacy and safety. 
JAMA 239: 1041, 1978
141. Hofmann AF, Thistle JL, Klein 
PD, et al: Chenotherapy for gall­
stone dissolution. II. Induced 
changes in bile composition and 
gallstone response. Ibid, p 1138
142. Iser JH. Dowling RH, Mok HYI, 
et al: Chenodeoxycholic acid treat­
ment of gallstones. A follow-up re­
port and analysis of factors influ­
encing response to therapy. N Engl 
J Med 293: 378, 1975
143. Iser JH, Murphy GM, Dowling 
RH : Speed of change in biliary 
lipids and bile acids with cheno­
deoxycholic acid—is intermittent 
therapy feasible? Gut 18: 7, 1977
144. Marks JW, Bonorris GG, Chung 
A, et al: Feasibility of low-dose and 
intermittent chenodeoxycholic acid 
therapy of gallstones. Am J Dig Dis 
22: 856, 1977
145. Maudgal DP, Bird R, Northfield 
TC: Optimal timing of doses of 
chenic acid in patients with gall 
stones. Br Med J 1: 922, 1979
146. Maudgal DP, Bird R, Blackwood 
WS, et al: Low-cholesterol diet: 
enhancement of effect of CDCA in 
patients with gall stones. Br Med J 
2: 851, 1978
147. Tangedahl TN, T histle JL, 
Hofmann AF, et al: Effect of (3- 
sitosterol alone or in combination 
with chenic acid on cholesterol 
saturation of bile and cholesterol 
absorption in gallstone patients. 
Gastroenterology 76: 1341, 1979
148. Maudgal DP, N orthfield TC: 
Acceleration of gallstone dissolu­
tion with bedtime chenic acid plus 
low cholesterol diet (abstr). Gut 
20: A461, 1979
149. Bruusgaard A, Malver E, Peder­
sen LR, et al: Criteria for selection 
of patients for medical treatment 
(chenodeoxycholic acid therapy) of 
gallstones. Scand J Gastroenterol 
12: 97, 1977
150. Iser JH, Maton PN, Murphy GM, 
et al: Resistance to chenodeoxy­
cholic acid (CDCA) treatment in 
obese patients with gallstones. Br 
Med J 1: 1509, 1978
151. Small DM: Prestone gallstone dis­
ease—is therapy safe? (E). N Engl 
J Med 284: 214, 1971
152. Palmer RH: Bile acids, liver in­
jury, and liver disease. Arch Intern 
Med 130: 606, 1972
153. Morrissey RP, McSherry CK,
Swarm RL, et al: Toxicity of
chenodeoxycholic acid in non­
human primate. Surgery 77: 851, 
1975
154. Dyrska H, Salen G, Zaki FG, 
et al: Hepatic toxicity in the rhesus 
monkey treated with chenodeoxy­
cholic acid for 6 months: biochem­
ical and ultrastructural studies. 
Gastroenterology 70: 93, 1976
155. Allan RN, Thistle JL, Hofmann
AF, et al: Lithocholate metabolism 
during chenotherapy for gallstone 
dissolution. 1. Serum levels of sul- 
phated and unsulphated litho- 
cholates. Gut 17: 405, 1976
156. Idem: Lithocholate metabolism
during chenotherapy for gallstone 
dissolution. 2. Absorption and sul- 
phation. Ibid, p 413
157. Pedersen L, Arnfred T, Thaysen 
EH: Cholesterol kinetics in patients 
with cholesterol gallstones before 
and during chenodeoxycholic acid 
treatment. Scand J Gastroenterol 
9: 787, 1974
158. Bell GD, Lewis B. Petrie A, et 
al: Serum lipids in cholelithiasis: 
effects of chenodeoxycholic acid 
therapy. Br Med J 3: 520, 1973
159. Bateson MC, R oss PE, Murison J, 
et al: Reversal of clofibrate-induced 
cholesterol oversaturation of bile 
with chenodeoxycholic acid. Br Med 
J 1: 1171. 1978
160. Coyne MJ, Bonorris GG, C hung
A, et al: Treatment of gallstones 
with chenodeoxycholic acid and 
phenobarbital. N EngI J Med 292: 
604, 1975
161. N orthfield TC, LaRusso NF, 
H ofmann AF, et al: Biliary lipid 
output during three meals and an 
overnight fast. II. Effect of cheno­
deoxycholic acid treatment in gall­
stone patients. Gut 16: 12, 1975
162. A dler RD, Bennion LJ, D uane 
WC, et al: Effects of low dose 
chenodeoxycholic acid feeding on 
biliary lipid metabolism. Gastroen­
terology 68: 326, 1975
163. Carey MC: Cheno and urso: What 
the goose and the bear have in 
common (E). N Engl J Med 293: 
1255, 1975
164. N akagawa S, M akino I, Ishaki T, 
et al: Dissolution of cholesterol 
gallstones by ursodeoxycholic acid. 
Lancet 2: 367, 1977
165. Stiehl A, Czygan P, K ommerell
B, et al: Ursodeoxycholic acid ver­
sus chenodeoxycholic acid. Compa­
rison of their effects on bile acid 
and bile lipid composition in pa­
tients with cholesterol gallstones. 
Gastroenterology 75: 1016, 1978
166. R edinger RN, Small DM: Primate 
biliary physiology. VIII. The effect 
of phenobarbital upon bile salt syn­
thesis and pool size, biliary lipid 
secretion, and bile composition. J 
Clin Invest 52: 161, 1973
167. Vlahcevic ZR, G regory DH, 
Swell L: Phenobarbital and choles­
terol gallstone dissolution (E). Am 
J Dig Dis 21: 429, 1977
168. Marks JW, Sherman JH, Bonorris 
GG, et al: Gallstone dissolution by 
chenodeoxycholic acid and pheno­
barbital. Am J Gastroenterol 69: 
160, 1978
169. Zimm on  DS, K erner MB, A aron 
BM, et al: The effect of a hydro­
choleretic agent (Zanchol) on bil­
iary lipids in post cholecystectomy 
patients. Gastroenterology 70: 640, 
1976
170. Bell GD: Medical treatment of 
gallstones. J R Coll Phvsicians Lond 
13: 47, 1979
171. Burkitt DP, Walker ARP, 
Painter NS: Dietary fiber and dis­
ease. JAMA 229: 1068, 1974
continued on page 557
532 VOLUME 23, NO. 6, NOVEMBER 1980 /  THE CANADIAN JOURNAL OF SURGERY
The Successor 
to Silk.
A  Success Story.
SCIRGILON®, the suture with the feel and knot security of silk 
and the inertness and strength of a synthetic.
Better than Silk
•  Stronger.
•  Longer flex life.
•  Less tissue reaction.
•  More prolonged in vivo tensile 
strength.
•  No brooming.
Better than other 
Braided Nylons
•  Stronger.
•  Greater in vivo tensile strength.
•  Better hand, thanks to silicone 
treatment
SURGILON
silicone-treated braided nylon suture 
from DAVIS+GECK
® Registered Trademark
D A V IS + G E C K
where progress is born 
Cyanamid Canada Inc ..Mont real
V O L U M E  23, NO. 6, N O V E M B E R  1980 /  THE CANADIAN JOURNAL OF SURGERY
CANADIAN SOCIETY FOR VASCULAR SURGERY
Concomitant Revascularization of Intestines 
during Aortoiliac Reconstruction:
Deterrent to Catastrophic Bowel Infarction
Jack H.M. K waan, md, facs, John E. Connolly, md, facs and T heodore Coutsoftides, md, frcs[c]
This report points out the necessity 
for revascularization of the intestines 
in patients with asymptomatic 
mesenteric occlusive disease at the 
time of aortoiliac reconstruction. 
Emphasis is placed upon the well­
being of 15 patients followed up for 2 
to 5 years, who underwent concomitant 
bypass grafting of asymptomatic 
stenosis or occlusion of the mesen­
teric arteries, in contrast to the fatal 
or near fatal outcome of 3 patients 
who did not receive such corrective 
measures. Aortomesenteric bypass 
grafting in conjunction with aortobi- 
femoral bypass grafting or endarterec­
tomy does not involve additional 
operative exposure or add greatly to 
the operating time, but may prevent 
catastrophic bowel infarction resulting 
from progressive occlusion of the 
mesenteric arteries.
Ce rapport fait etat de la necessity 
de revasculariser I'intestin chez les 
malades ayant une occlusion mesen- 
terique asymptomatique au moment 
de la reconstruction de I'aorte iliaque. 
On souligne le bien-etre de 15 malades 
suivis pendant 2 a 5 ans apres avoir 
subi la greffe d’une derivation pour 
une stenose ou une occlusion des 
arteres mesenteriques, en comparaison 
a I'issue fatale ou quasi fatale chez
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3 patients qui n'ont pas eu de telles 
mesures correctives. Une derivation 
de I'aorte mesenterique effectuee 
de concert avec une derivation de 
I'aorte femorale ou une endarteriec- 
tomie n'ajoute pas a I'exposition 
operatoire et ne prolonge pas beaucoup 
ie temps d’intervention, mais peut 
prevenir un infarctus catastrophique 
de I’intestin resultant de 1'evolution 
d’une occlusion des arteres mesen­
teriques.
Following the introduction of 
homologous grafting for abdominal 
atherosclerotic occlusion by Oudot1 
and for aneurysm by Dubost, Allary 
and Oeconomos2 only 29 years ago, 
reconstruction of the aorta has be­
come one of the most common vas­
cular operations. Successful correc­
tion of thrombotic, occlusive or 
aneurysmal lesions of the aorta has 
resulted in the preservation of life 
and limb. With refinements in sur­
gical technique, the operation has 
become safe and complication rates 
continue to decline. One of the more 
critical and yet preventable complica­
tions following aortic operation is 
gangrene resulting from intestinal 
ischemia. While immediate postoper­
ative bowel infarction may be readily 
recognized, delayed bowel necrosis 
from progressive constriction of a 
known mesenteric arteriosclerotic oc­
clusive lesion has rarely been docu­
mented.
Twenty patients who underwent 
aortobifemoral bypass grafting for 
arterial insufficiency and in whom 
asymptomatic mesenteric artery oc­
clusion was noted on the preopera­
tive arteriogram form the basis of 
this report. We emphasize the well­
being of 15 of 17 patients, followed 
up for 2 to 5 years, who underwent
concomitant correction of the occlu­
sive mesenteric disease in contrast to 
the fatal or near fatal outcome in 
the other 3 patients who did not re­
ceive these corrective measures at 
the time of the aortofemoral pro­
cedure.
Patients
We reviewed the records of 150 
patients who underwent aortoilio- 
femoral reconstruction. Of these, 20 
had significant occlusive disease in­
volving the celiac and mesenteric 
circulation, identified preoperatively 
by aortography. All 20 patients were 
men, aged 56 to 68 years (mean 62 
years). Two of the patients had had 
a previous myocardial infarction that 
required hospitalization. Four others 
had undergone carotid endarterec­
tomy. None were diabetics, but all 
were heavy cigarette smokers.
Intermittent claudication was the 
main complaint leading to operation. 
The claudication was brought on by 
walking distances from 3 to 9 m. 
No patient had a history of abdomi­
nal symptoms or weight loss.
The systolic blood pressure in 
these 20 patients ranged from 110 
to 180 mm Hg (mean 130 mm Hg). 
The diastolic range was 80 to 100 
mm Hg (mean 90 mm Hg). Femoral 
pulses were diminished in 12 and 
absent in 8 patients. Ankle and 
popliteal pulses were absent in all. 
A bruit was clearly audible over the 
mid-abdomen in 13 patients.
Aortography revealed aortoiliac 
stenosis in all patients, stenosis of 
the deep femoral artery in 6 and 
occlusion of the superficial femoral 
artery in 16 patients. Of particular 
importance was the lateral aorto- 
gram: stenosis of the superior mesen­
teric artery was noted in 6 and oc­
clusive disease of the superior and
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inferior mesenteric arteries was seen 
in the remaining 14 patients. The 
occlusive and stenotic mesenteric 
lesions were the classic type of proxi­
mal segmental arteriosclerosis.
Treatment and Results
Because of the differences in the 
operative procedure and the clinical 
outcome, the patients were arbitrarily 
divided into two groups.
In group 1 were three patients 
who underwent aortic reconstruc­
tion only. Because of the lack 
of intestinal symptoms, no attempt 
was made to revascularize the intes­
tinal circulation even though stenosis 
of the superior mesenteric artery and 
occlusion of the inferior mesenteric 
artery were evident on the lateral 
aortogram Two of these three pa­
tients were readmitted 1 and V/z 
years later because of abdominal 
pain. In both instances, the aorto­
gram showed progression of the su­
perior mesenteric artery lesion (Figs.
1 and 2). At operation, impending 
gangrene of the small bowel was 
noted. Fortunately, emergency re­
vascularization with an aortomesen- 
teric bypass graft was successful. The 
third patient, readmitted 2 years after 
the aortofemoral procedure, had ir­
reversible bowel changes that pre­
cluded mesenteric revascularization 
and died of massive intestinal infarc­
tion.
In the second group (group 2) of 
17 patients, concomitant revasculari-
FIG. 1—Preoperative lateral aorto­
gram showing stenosis of celiac and su­
perior mesenteric arteries (arrows).
zation was undertaken. Aortomesen- 
teric bypass grafting with saphe­
nous vein or reinforced polytetra- 
fluoroethylene was combined with 
the insertion of a button of the in­
ferior mesenteric artery. The addi­
tional procedure did not require in­
creased operative exposure and 
added no more than 1 hour to the 
operating time. Except for two pa­
tients who died of myocardial infarc­
tion at 1 and 2 years after operation, 
respectively, the remaining 15 pa­
tients are well at follow-up periods 
of 2 to 5 years. None have experi­
enced symptoms of malabsorption, 
abdominal pain or weight loss refer­
able to intestinal ischemia following 
the concomitant revascularization 
procedures. Subsequent follow-up 
aortography has confirmed patency 
of the aortomesenteric graft in five 
of these patients.
Discussion
Advances in vascular surgery have 
made it possible to correct occlusive 
disease of almost all major vessels 
and great strides have been made in 
saving limbs from the ravages of 
atherosclerosis. In certain critical 
vessels, such as the carotid arteries, 
revascularization is accepted even as 
a prophylactic measure.3 Equally 
important is the operative correction 
of the occluded celiac and mesenteric 
circulations. Although the surgical 
treatment of symptomatic mesenteric 
occlusive disease was first accom-
FIG. 2—Lateral aortogram, lV i years 
after aortobifemoral bypass showing 
progression of disease with complete oc­
clusion of superior mesenteric artery 
(arrow).
plished more than 20 years ago,4 
operative revascularization of the in­
testines is still carried out relatively 
infrequently. Eklof, Hoevels and 
Ihse5 noted that, until 1977, only 
about 200 cases of vascular recon­
struction for chronic intestinal is­
chemia had been reported. Often 
the surgeon is confronted with an 
acute abdominal condition for which 
a frustrating and futile laparotomy 
for massive bowel gangrene is done.
Much of the emphasis in the cur­
rent literature is upon early recogni­
tion of the signs and symptoms such 
as postprandial abdominal pain and 
weight loss, which are frequently 
vague and elusive, or upon labora­
tory tests such as dye dilution or 
intestinal absorption studies which 
are often nonspecific and seldom 
pathognomonic in the early phases 
of this lethal condition. Aortography, 
especially in the lateral projection, 
will identify arteriosclerotic stenosis 
or occlusion of the splanchnic ves­
sels. However, in the absence of 
clinical confirmation of mesenteric 
ischemia, mesenteric revasculariza­
tion is seldom attempted, even 
though the operative procedure can 
be performed with ease and without 
complications.
Our attention was first drawn to 
the condition when angiographic evi­
dence of superior mesenteric artery 
stenosis was noted incidentally in a 
patient subjected to aneurysmec­
tomy.1’' Failure to heed this critical 
information almost resulted in dis­
aster, when the patient returned 1 
year later with impending bowel gan­
grene and a totally occluded superior 
mesenteric artery. The revasculariza­
tion should have been carried out 
at the time of aneurysmectomy. 
The experience in our group 1 pa­
tients was similar except for the one 
patient whose irreversible bowel 
changes precluded subsequent mesen­
teric revascularization. The clinical 
course of these patients demonstrates 
well the consequence of mesenteric 
arterial occlusive disease. In fact, the 
natural course of arteriosclerotic oc­
clusion of the mesenteric vessels does 
not differ appreciably from that of 
other peripheral arteries such as the 
femoral, deep femoral or popliteal 
arteries.
The concept of prevention in ar­
terial surgery is not new. As early 
as 1961, Rob7 stated that “the ad­
vances in arterial surgery have been 
such that in many patients with an 
arterial stenosis, a prophylactic pro­
cedure to prevent the development 
of an arterial thrombosis is now jus-
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tified, not only for occlusion of the 
extracranial cerebral arteries, but in 
other sites including other visceral 
arteries and the vessels to the limb”. 
Although their concern centred upon 
bowel ischemia immediately after op­
eration, Johnson and Nabseth8 out­
lined various conditions in which re­
construction of the splanchnic circu­
lation should be performed prophy- 
lactically at the time of aortic opera­
tion. Eidemiller, Nelson and Porter9 
reporting on the surgical treatment 
of chronic visceral ischemia in eight 
patients, mentioned that prophylactic 
revascularization was carried out 
during aortoiliac endarterectomy in 
two of their patients in the hope of 
avoiding bowel gangrene and death 
in these asymptomatic patients dur­
ing hypotensive episodes following 
operation.
On the basis of our experience, 
reconstitution of the mesenteric vas­
culature at the time of aortoilio- 
femoral reconstruction is essential if
important arteriosclerotic mesenteric 
disease is noted. An abdominal bruit 
may be an important clue. The ad­
vantages of obtaining a lateral aorto- 
gram are emphasized for identifying 
occlusive lesions of the mesenteric 
artery. The meandering mesenteric 
artery, when present, is also helpful 
in that it indicates the need to ob­
tain a lateral view of the abdominal 
aorta. Clearly, the addition of a 
simple concomitant aortomesenteric 
bypass graft does not complicate the 
standard aortic reconstructive proce­
dure, but may forestall future inte­
stinal ischemia or infarction associated 
with a poor prognosis and high mor­
tality.
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Carotid Endarterectomy:
Early and Late Results in 161 Patients
Charles R. Lye , m d , frcs[c ]* and A llan R. D ow ns, m d , frcs[c], FAesf
Over a 15-year period, 161 patients 
underwent 186 carotid endarterec­
tomies. Of these patients, 97% had 
symptoms preoperatively. The incidence 
of new neurologic deficits appearing 
immediately postoperatively was 7% 
(13 of 186), and 1.6% (3 of 186) 
were major permanent strokes. Nine­
teen patients were lost to follow-up. 
The cumulative patient survival was 
83% at 5 years and 59% at 10 years. 
The cause of death in the late 
postoperative period was ascertained 
in 22. of 24 patients; it was related 
to ischemic cardiac disease in 16. 
There were no late deaths from 
neurologic complications. New or
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recurrent neurologic symptoms 
developed in the late postoperative 
period in 22 patients. There were 
no disabling strokes in this group. 
The cumulative rate of freedom from 
new neurologic symptoms was 82% 
at 5 years and 71% at 10 years. 
Repeat angiography was carried out in 
12 patients who had new or recurrent 
neurologic symptoms in the late 
postoperative period. The repaired 
artery was found to be widely 
patent in nine, stenosed in one 
and occluded in two. Reoperation 
of the same carotid was 
not performed in this series. Routine 
intraoperative angiography aided the 
detection and correction of potential 
technical problems.
Au cours d'une periode de 5 ans,
161 patients ont subi 186 endarteriec- 
tomies carotidiennes. De ces malades, 
87% presentaient des symptomes 
avant I’operation. L'incidence des 
nouveaux deficits neurologiques 
apparaissant immediatement apres 
I’intervention fut de 7% (13 sur 186), 
et 1.6% (3 sur 186) etaient des 
accidents cerebro-vasculaires majeurs 
permanents. Dix-neuf malades ne se 
presentment pas aux examens de
controle. Le taux cumulatif de survie 
a 5 ans fut de 83%, et de 59% apres 
10 ans. La cause du deces dans la 
periode post-operatoire tardive a pu 
etre precisee pour 22 patients sur 24; 
celle-ci etait rattachee a la maladie 
coronarienne dans 16 cas. II n'y eut 
aucune mort tardive resultant de 
complications neurologiques. Durant 
la periode post-operative tardive il y 
a eu apparition ou recidive des 
symptomes neurologiques chez 
22 patients. On n’a enregistre aucun 
accident cerebro-vasculaire invalidant 
dans ce groupe. Le taux cumulatif 
des cas exempts de symtomes 
neurologiques fut de 82% apres 5 ans 
et de 71% apres 10 ans. Des angio­
graphies de rappel ont ete pratiquee 
chez 12 malades presentant une 
recidive des symptomes neurologiques 
durant la periode post-operatoire 
tardive. La reparation s'est averee 
amplement fonctionnelle dans neuf cas, 
stenosee dans un et obliteree dans 
deux cas. Aucune re-operation de la 
meme carotide n'a ete effectuee dans 
cette serie. L'angiographie pratiquee 
systematiquement durant I’operation 
a aide a detecter, puis a corriger les 
problemes techniques possibles.
536 VOLUME 23, NO. 6, NOVEMBER 1980 /  THE CANADIAN JOURNAL OF SURGERY
►►
►
¥■
¥
*
f
►
Carotid endarterectomy is now estab­
lished treatment for transient ischemic 
attacks and for preventing stroke in 
patients with extracranial carotid oc­
clusive disease. While the reported 
operative morbidity and mortality 
vary widely, it is generally believed 
that mortality should be less than 
1 % and permanent neurologic se­
quelae less than 4% .' This paper will 
review early and late results in a 
series of patients who underwent 
carotid endarterectomy at the Health 
Sciences Centre in Winnipeg.
Patients and Methods
Between Jan. 1, 1965 and Dec. 
31, 1979, 161 patients (108 men, 53 
women) underwent 186 endarterec­
tomies. Their ages ranged from 42 
to 81 years (median 64 years). Of the 
25 patients with bilateral operations, 
the second side was operated on with­
in 3 months in 22 and in 1 to 4 years 
because of recurrent symptoms 
in the other 3. Five patients (3%) 
were asymptomatic. In 87 (54%) 
the symptoms were limited to tran­
sient ischemic attacks. A further 63 
(39%) had sustained strokes but had 
recovered relatively well; the strokes 
had occurred at least 3 weeks before 
operation. Six patients (4%) had sus­
tained an acute stroke and underwent 
operation within a few hours to a 
few days.
Of our patients 146 (91%) pre­
sented with complaints referable to 
one carotid system; 98 (61%) had 
paresis, 52 (32%) had paresthesia, 
52 had amaurosis fugax and 39 
(24%) had dysphasia. Carotid bruits 
were present unilaterally in 42%,
bilaterally in 36% and were absent 
in 22%. Eleven patients (7%) had 
vertebrobasilar symptoms and 13 
(8%) had global symptoms preoper- 
atively.
Preoperative angiograms were re­
viewed and each carotid stenosis was 
classified by maximal reduction of 
diameter (Table I). Eighty-five per­
cent of the lesions repaired were 
hemodynamicaily important; 28 pa­
tients (16%) had contralateral occlu­
sion.
All endarterectomies were per­
formed under general anesthesia. 
Blood pressure was maintained at or 
near ward levels with pharmacologic 
agents when necessary. Arterial pres­
sure of carbon dioxide was main­
tained at normal or slightly hypo- 
carbic levels. A Javid shunt was 
used in 97 patients (36%). Endar­
terectomy was completed with simple 
running closure in all but four pa­
tients in whom saphenous vein 
patches were used to widen the out­
flow. Angiography was done at the 
end of the operation in 113 patients 
(70%) and in two instances prompted 
immediate revision of a seemingly 
adequate repair.
Results
Early Results
One death occurred within 24 
hours of operation. The patient sus­
tained a stroke intraoperatively and 
this was complicated by myocardial 
infarction. Stroke occurred perioper- 
atively in 10 patients, 6 of whom 
made rapid and relatively complete 
recoveries. Four patients, including
the patient who died, had relatively 
severe neurologic deficits. Three pa­
tients suffered a transient ischemic 
attack during the operation. The re­
lation of preoperative clinical status 
to immediate postoperative status 
is shown in Table II.
Late Results
Nineteen patients have been lost 
to follow-up. Twenty-four patients 
have died, 16 of cardiac disease. 
New or recurrent neurologic symp­
toms developed in 22 patients— 
strokes in 6 and transient ischemic at­
tacks in 16. Symptoms were ipsilateral 
to the original repair in 12, contra­
lateral in 6 and nonspecific in 4. 
There have been no late deaths due 
to stroke. Cumulative patient survival 
calculated by the life-table method 
was 83% at 5 years and 59% at 10 
years (Fig. 1). The cumulative rates 
for freedom from new neurologic 
events were 82% and 71% at 5 and 
10 years, respectively (Fig. 2). In 
five of the six patients who had a 
new stroke, the deficit was mild. The 
only patient to have a severe late 
stroke did so during an operation to 
clip a giant intracranial aneurysm 1 
year following his endarterectomy. 
Cumulative rates for freedom from 
stroke, including operative stroke, 
were 93% at 1 month, 90% at 5 
years and 82% at 10 years.
Twelve patients underwent repeat
FIG. 1— Cumulative survival of 161 
patients following carotid endarterec­
tomy.
FIG. 2— Cumulative rates of freedom 
from new neurologic symptoms follow­
ing carotid endarterectomy in 161 pa­
tients.
Table I— Degree of Stenosis of Internal Carotid Artery Expressed as Reduction of Vessel
Diameter
Reduction of diameter, %  of patients
100%
Status (occluded) > 6 0 %  <60%
Repaired carotid 0.5 84 15
Opposite carotid 16 18 66
Table II— Relation of Preoperative Clinical Status to Immediate Postoperative Morbidity
New postoperative deficit, %
Preoperative status 
(no. of patients) None
Transient
ischemic
attack
Cerebrovascular
accident
Major
cerebrovascular
accident
Asymptomatic (5) 89 0 11 11
Transient ischemic attack (87) 90 3 7 1
Stable cerebrovascular accident (63) 97 0 3 3
Acute cerebrovascular accident (6) 84 0 16 16
Mean 92 2 6 3
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angiography following the onset of 
new neurologic symptoms. The origi­
nal repair was widely patent in nine, 
stenosed in one and occluded in two. 
Endarterectomy of the contralateral 
carotid artery alleviated symptoms 
in three cases. There were no reoper­
ations for recurrent stenosis or occlu­
sion in this series.
D iscussion
Carotid endarterectomy has been 
shown to reduce the incidence of 
subsequent stroke in patients with 
transient ischemic attacks and to re­
duce the incidence and severity of 
recurrent stroke.1 To influence fav­
ourably the natural history of carotid 
occlusive disease, operative morbidity 
and mortality must be held to a mini­
mum. This in turn demands adequate 
preoperative assessment and selec­
tion of patients as well as meticulous 
technique.
Ninety-three percent of our pa­
tients underwent endarterectomy fol­
lowing either a transient ischemic at­
tack or a stroke followed by good 
recovery. This is the group for whom 
the benefits of endarterectomy have 
been best established. In contradis­
tinction to earlier reports,2-3 the over­
all incidence of cerebral deficits in 
the present study was greater in the 
group with transient ischemic attacks. 
However, we found no substantial 
difference in permanent major neu­
rologic morbidity between the groups 
with a transient ischemic attack and 
with stable stroke.
The management of the patient 
who presents with an asymptomatic 
carotid bruit remains controversial.4,5 
Although some surgeons take a more 
aggressive approach we limit investi­
gation and treatment to those pa­
tients about to undergo major intra­
abdominal or intrathoracic vascular 
procedures. One such patient in our 
series sustained a permanent hemi­
plegia which was probably related to 
intraoperative hypotension occurring 
during the endarterectomy procedure 
in the absence of a temporary shunt.
Six patients in this series under­
went endarterectomy within 72 hours 
of the onset of an acute stroke. 
Although there were no deaths, no 
patient was immediately improved 
and one was appreciably worse 
postoperatively. Most surgeons no 
longer consider the acute pro­
found stroke a surgical lesion because 
of the associated high operative mor­
tality and relatively small benefit de­
rived. There is, however, consider­
ably more support for operative in­
tervention in the patient with fluctu­
ating mild stroke and stroke in the 
immediate postoperative or postan- 
giographic periods.6 We currently 
limit our indications for operation 
to the patient with a mild, acute, 
fixed deficit, in whom superimposed 
severe or crescendo transient ischemic 
attacks develop. We have not in-
Fig. 3b
FIG. 3— Bilateral percutaneous caro­
tid punctures in patient with recent 
stroke: (a) right carotid occlusion (ar­
row). (b) Critical stenosis of left carotid 
artery (arrow).
vestigated or reoperated upon pa­
tients with acute strokes postopera­
tively.
Complete preoperative arch and 
selective biplane carotid angiography 
of high quality are absolutely essen­
tial both for the adequate assessment 
of occlusive lesions and for the ex­
clusion of intracranial lesions. Such 
angiography should be performed 
using a remote catheter technique 
since direct percutaneous carotid 
puncture is hazardous in patients 
with suspected extracranial occlusive 
disease (Fig. 3). The carotid bifur­
cation must be clearly visualized as 
small lesions can be hidden by adja­
cent overlying vessels (Fig. 4).
Angiography at the end of the 
operation has been nearly routine for 
the last 7 years of the study, al­
though some authors have suggested
Fig. 4b
FIG. 4— (a) Selective innominate and 
(b) right carotid angiograms in patient 
with recently formed embolus in right 
middle cerebral artery. Crossing vertebral 
artery completely obscures localized 
stenosis of carotid artery (arrow).
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a low benefit to risk ratio with this 
technique.7 Seventy percent of our 
patients had “completion angiogra­
phy" and the overall incidence of 
neurologic deficits postoperatively 
was 4%. The rate of severe perma­
nent strokes in this group was 2%. 
In contrast, patients who did not 
undergo completion angiography had 
overall and severe neurologic com­
plication rates of 15% and 4% re­
spectively. In two patients notable 
technical defects were identified 
(Figs. 5 and 6). One was repaired 
with a distal vein patch, the other by 
proximal extension of the endarterec­
Fig. 5a
tomy. Both patients did well. It is 
entirely possible that similar unde­
tected lesions were responsible for 
part of the increased morbidity in 
the second group. There was no 
evidence of increased risk associated 
with the angiography itself and we 
continue to advocate its use.
Stable anesthesia, with blood pres­
sure maintained at ward levels, and 
meticulous operative technique are 
probably the most important factors 
in reducing operative morbidity. 
Ideally all patients should have ar­
terial lines in place before anesthesia 
is induced since it is at this time
Fig. 5b
that hypotension is most likely to 
occur. Marked fluctuations in blood 
pressure are not infrequent perioper- 
atively and must be controlled 
promptly.8,9 Particularly hazardous 
are hypotension before and during 
endarterectomy and extreme hyper­
tension in the immediate postopera­
tive period. These two complications 
were associated with at least two of 
the severe permanent strokes in our 
study. Hypotension is managed by the 
use of pressor agents such as Neo- 
Synephrine or aramine and hyperten­
sion with nitroprusside. Induction 
doses of intravenous barbiturates have
Fig. 5c
FIG. 5—(a) Preoperative and (b) intraoperative angiograms of patient with severe stenosis of right carotid artery 
(arrow). Although repair appeared adequate externally, completion angiogram (b) demonstrated distal end-point stenosis (ar­
row). This was corrected by application of vein patch (c).
Fig. 6a Fig. 6b Fig. 6c
FIG. 6—(a) Preoperative and (b and c) intraoperative angiograms of patient with severe stenosis of left carotid artery. 
Repair was performed with temporary shunt and residual proximal atheromatous plaque was not recognized until completion 
angiogram was obtained. Endarterectomy was subsequently extended.
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been used occasionally when the 
cerebral collateral circulation ap­
peared marginal and the use of a 
shunt was undesirable. This tech­
nique may, however, result in pro­
longed and profound hypotension.
The use of temporary shunts re­
mains controversial.*0 A shunt was 
used in 36%  of the patients in this 
series and the decision to shunt was 
based on a number of factors includ­
ing recent stroke, severe contralateral 
disease, absence of hemispheric 
cross-fill, poor back-bleeding at the 
time of operation and a carotid 
stump pressure of less than 50 mm 
Hg. The last two indices can be 
unreliable since back-bleeding is of­
ten hard to quantify and accurate 
stump pressures are dependent upon 
reliable equipment and a knowl­
edgeable anesthetist. Moreover, the 
systemic blood pressure must not be 
allowed to drop below that measured 
at the time the stump pressure is 
assessed. At least one operative 
stroke in our series was probably re­
lated to placing inappropriate trust 
in an erroneously high stump pres­
sure. In contrast to earlier re­
ports,11'12 we were not able, in this 
study, to define any consistent gen­
eral relationship between operative 
morbidity and either shunt use or 
stump pressure. There was, however, 
increased morbidity in the presence 
of severe contralateral disease; 4  of 
28 patients with contralateral occlu­
sions sustained strokes intraopera- 
tively. This has been observed by 
others.13 Conversely, results were 
best when the repaired carotid was 
critically stenosed. Among 59 pa­
tients with stenosis of more than 
9 0%  who underwent endarterectomy 
without a shunt there was only one 
operative stroke. We continue to use 
shunts on a selective basis following 
our earlier guidelines, but particu­
larly in patients with less severe 
stenosis.
The absence of late death due to 
stroke in our series supports the 
prophylactic value of endarterec­
tomy. Late recurrence of cerebral 
symptoms was uniform throughout 
the initial 10 postoperative years with 
an average attrition rate of 3%  to 5%  
annually. Symptoms were seldom 
severe and usually were not related 
to recurrent stenosis of the repair. 
No secondary repairs were per­
formed in this series but we advocate 
angiography for patients with new 
or recurrent complaints.
Summary and Conclusions
In this series 161 patients under­
went 186 endarterectomies with an
operative mortality of 0 .5%  and 
permanent major neurologic m or­
bidity of 2 % . The 5- and 10-year 
cumulative mortality rates were 83%  
and 5 9% , respectively, and 5- and 10- 
year rates of cumulative freedom 
from all neurologic symptoms were 
82%  and 71%  respectively. Late 
neurologic symptoms were not se­
vere. Intraoperative angiography was 
found to be valuable and safe. We 
shall continue to use intraoperative 
shunting in selected patients.
References
1. T hompson JE, Talkington CM: 
Carotid endarterectomy. Ann Surg 
184: 1, 1976
2. Stanford JR, Lubow M, Vasko 
JS: Prevention of stroke by carotid 
endarterectomy. Surgery 83: 259, 
1978
3. T hompson JE, Austin DJ, P at­
man RD: Carotid endarterectomy 
for cerebrovascular insufficiency: 
long-term results in 592 patients fol­
lowed up to thirteen years. Ann 
Surg 172: 663, 1970
4. Moore WS, Boren C, M alone JM, 
et al: Asymptomatic carotid steno­
sis. Immediate and long-term re­
sults after prophylactic endarterec­
tomy. Am J Surg 138: 228, 1979
5. T hompson JE, Patman RD, T alk­
ington CM: Asymptomatic carotid 
bruit: long-term outcome of pa­
tients having endarterectomy com­
pared with unoperated controls. 
Ann Surg 188: 308, 1978
6. G oldstone J, Moore WS: A new 
look at emergency carotid artery 
operations for the treatment of 
cerebrovascular insufficiency. Stroke 
9: 599, 1978
7. Anderson CA, Collins GJ j r . 
Rich N M : Routine operative arteri­
ography during carotid endarterec­
tomy: a reassessment. Surgery 83: 
67, 1978
8. Bove EL, F ry WJ, G ross WS, et 
al: Hypotension and hypertension 
as consequences of baroreceptor 
dysfunction following carotid en­
darterectomy. Surgery 85: 633, 1979
9. C aplan LR, Skillman J, Ojem a n n  
R. et al: Intracerebral hemorrhage 
following carotid endarterectomy: 
a hypertensive complication? Stroke 
9: 457, 1978
10. Baker WH, D orner DB, Barnes 
RW: Carotid endarterectomy: is an 
indwelling shunt necessary? Surgery 
82: 321, 1977
11. H ertzer NR, Beven EG, G reen-
street RL, et al: Internal carotid 
back pressure, intraoperative shunt­
ing, ulcerated atheromata, and the 
incidence of stroke during carotid 
endarterectomy. Surgery 83: 306,
1978
12. H ays RJ, L evinson SA, W ylie EJ: 
Intraoperative measurement of caro­
tid back pressure as a guide to 
operative management for carotid 
endarterectomy. Surgery 72: 953, 
1972
13. Collins GJ j r , R ich NM, Ander­
sen CA, et ai: Stroke associated 
with carotid endarterectomy. Am 
J Surg 135: 221. 1978
proven in burns
Flamazine
now indicated for leg ulcers 
A b rid g e d  P ro d u c t In fo rm a tio n
Chemical Name
Silver 2- (4-aminobenzenesulfonamide) -pyrimidine.
Description
Silver sulfadiazine is a light-stable white powder, very slightly soluble in 
water and most organic solvents, but readily dissolved in nitric acid and 
concentrated ammonia solutions.
Composition
Silver sulfadiazine 1% in a cream base.
Action
The action of silver 2-(4-ammobenzenesulfonamide)-pyrimidine is 
bactericidal. Little of the active ingredient is absorbed; the silver 
sulfadiazine acts as a drug depot which reacts slowly with cellular debris 
and microorganisms on the burn wound to release that amount of 
sulfadiazine which is absorbed. The silver remains largely at the wound 
surface.
There is little delay in the bactericidal activity of silver sulfadiazine, and 
the experimental evidence suggests that its site of action is the bacterial 
cell membrane. Silver sulfadiazine inhibits DNA, RNA, and protein 
synthesis which may explain its bactericidal activity.
Silver sulfadiazine has been shown to be effective in vitro against various 
strains of the following pathogens isolated from infected burn wounds: 
Pseudomonas aeruginosa, Aerobacter aerogenes, E. coli, Proteus mirabilis, 
Candida albicans, Proteus vulgaris. Staphylococcus aureus, Klebsiella 
spp.. Aspergillus mger.
Indications and Clinical Uses
Flamazine is indicated for the adjunctive treatment and prevention of 
infection in severe burns and leg ulcers. Flamazine is particularly effective 
against Gram negative organisms, such as Pseudomonas aeruginosa. 
Flamazine has not caused electrolyte disturbance, acidosis or subsequent 
hyperventilation. It causes very little skin sensitization and there is no 
pain on application. Flamazine does not cause argyria and does not cause 
staining of the skin or bedclothes. The development of bacterial resistance 
to Flamazine would seem to be slight.
A disadvantage that has been noted, in burn therapy, is a delay in the 
separation of slough from the burn wound, due to the absence of bacteria 
which contribute to slough separation by producing proteolytic enzymes 
and by stimulating leucocytosis.
Contraindications
Flamazine is contraindicated in women of child-bearing age, unless the 
burnt area is more than 20% of the total body surface, or in the 
investigator's judgment benefit outweighs risk. Further, because 
sulfonamide therapy is known to increase the possibility of kermcterus, 
Flamazine should not be used in pregnant females at term, in premature 
infants, or in newborn infants in the first month of life.
Warnings
Flamazine should not be used in patients with a known, or suspected, 
sensitivity to sulfonamides.
Precautions
Flamazine should be used with caution if hepatic or renal function is im­
paired. The cream should be applied with a sterile gloved hand or spatula. 
Each jar and tube of Flamazine cream should be reserved for the exclusive 
use of a single patient, and any remaining cream should be discarded on 
completion of treatment. Flamazine should be stored in a cool place. 
Adverse Reactions
Sensitivity has been observed, but the incidence is lower than with other 
sulfonamides. A fall in white blood count has been demonstrated occa­
sionally, but this is not thought to be associated with the treatment per se 
and more likely reflects the condition of the burned patient.
Symptoms and Treatment of Overdosage
As a topical preparation. Flamazine does not lend itself to overdosage by a 
systemic route; topically applied it has shown little evidence of toxicity in 
experimental animals, and the clinical situations in which it has been 
studied are such that evidence of systemic toxicity, if any, is unlikely to be 
revealed.
The absorption studies which indicate that only a small percentage of 
sulfadiazine and virtually no silver are absorbed suggest that overdosage 
following topical administration, even on burned skin, is unlikely to be a 
problem.
Dosage and Administration
Flamazine should be applied topically in a layer approximately 3-5 mm 
thick with a sterile gloved hand or spatula, daily, or more often as 
required. The wound may be dressed or left open.
Duration of administration can be from a few days to several months, 
depending upon the nature and severity of the wound. Treatment should 
be continued until satisfactory healing has occurred or until the burn site 
is ready for grafting. The drug should not be withdrawn from the 
therapeutic regimen while there remains the possibility of infection 
except if a significant adverse reaction occurs.
Dosage Forms
Flamazine is presented as a cream containing 1% w/w silver sulfadiazine 
in containers of 500 g and tubes of 50 g.
Complete product monograph available on request.
Smith & Nephew Inc.
I 'C rU ' ,  2100 , 52 A ven u e  
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body defences
They should share the 
same treatment.mazine
Flamazine
has met one of the toughest challenges of 
topical antibacterial therapy. Major burns 
And the reasons that have made it the 
number one antibacterial in burn 
therapy make it the logical anti­
bacterial for the treatment of 
leg ulcers.
And the dual bactericidal action of silver and sulfadiazine prevents the 
emergence of resistant strains.
1. Data on File. Smith & Nephew Inc.
The antibacterial of choice 
for burns is also the logical 
choice for leg ulcers.
Unsurpassed effectiveness.
Flamazine is bactericidal and 
fungicidal. Its exceptionally 
broad spectrum covers most 
major pathogens, including 
Staph, aureus, Pseudomonas 
aeruginosa and Candida 
albicans.
Unsurpassed safety. Flamazine has been used extensively on full­
thickness burns, yet the incidence of systemic effects and sensitization 
was reported to be less than 'U  of 1%!' Sensitization to topical anti­
biotics or antiseptics often disrupts the 
treatment of leg ulcers. This problem 
is unlikely to occur with Flamazine.
Smith & Nephew Inc.
2100, 52 Avenue 
Lachine, Que., Canada 
H8T 2Y5
Soothing pain relief.
Flamazine actually relieves 
the pain and itching of leg 
ulcers. And its water-miscible 
base allows it to be removed 
easily and painlessly.
S.N
Hemodynamic Assessment of the Aortoiliac Segment:
a Prospective Study
G.G. Barber , m d , frcs[c], H. F ong , m d , N.V. M cP hail, md , frcs[c] and T.K. Scobie , m d , frcs[c]
A test for assessing stenosis in the 
aortoiliac segment is described in 
which femoral pressure is measured 
directly by continuous monitoring 
and an intra-arterial injection of 
papaverine is used to augment blood 
flow. This test has been described 
previously but is not widely used.
A prospective study of this test 
was carried out on 64 patients and 
the results were compared with those 
obtained by aortography. The test 
helped to determine whether an 
operation on the aortoiliac segment 
was indicated. Clinical results were 
assessed. Thirty-two of the 64 patients 
were found to have significant inflow 
disease (more than 50% stenosis).
They underwent aortic reconstruction 
with total relief or improvement of 
symptoms in all cases. Aortography 
demonstrated an essentially normal 
aortoiliac segment in 3 of the 32 
patients and 16 had only irregular 
segments with no definite stenosis.
The authors conclude that any 
patient presenting with sufficient 
indication to warrant reconstructive 
surgery who has a normal or equivocal 
angiogram should undergo the 
papaverine pressure test.
On decrit une epreuve permettant 
d'evaluer une stenose de I'aorte iliaque, 
alors que la pression femorale est 
mesuree directement sous controle 
continue et oil de la papaverine est 
injectee par voie intra-arterielle 
afin d’augmenter le debit sanguin. 
Cette epreuve a ete decrite prece- 
demment mais elle est peu utilisee.
Une etude prospective de cette 
epreuve a ete realisee chez 64 
malades et les resultats ont ete 
compares a ceux qui ont ete obtenus 
par aortographie. Ce test a contribue 
a determiner si une operation de 
I’aorte iliaque etait indiquee. Les 
resultats cliniques ont ete evalues.
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of medicine, University of Ottawa, 
Ottawa, Ont.
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Trente-deux patients sur 64 ont 
presente une atteinte de I'apport 
sanguin (avec une stenose superieure 
a 50%). Ms ont subi une reconstruction 
de I'aorte donnant un soulagement 
complet ou une amelioration des 
symptomes dans tous les cas. 
L'aortographie a demontre une aorte 
iliaque essentiellement normale chez 
3 patients sur 32 et 16 ne montraient 
que des segments irreguliers sans 
stenose evidente.
Les auteurs concluent que tout 
patients presentant les conditions 
suffisantes pour indiquer une 
restauration chirurgicale mais qui 
montre un angiogramme normal ou 
equivoque devrait passer le test 
de tension a la papaverine.
A decision must often be made on the 
basis of knowledge, sufficient for action 
but insufficient to satisfy the intellect.
Immanuel Kant 
We wish to reintroduce a method of 
hemodynamic assessment of the aor­
toiliac segment in order to add intel­
ligence to our actions in performing 
reconstructive surgery. The success 
of reconstructive arterial surgery in 
relieving the symptoms of ischemia 
depends on an accurate assessment of 
the level at which arterial diseases 
cause functional impairment and then 
on bypass of the diseased segment. 
It is well recognized that clinical 
assessment and single-plane angio­
graphy may not detect significant 
(more than 50% stenosis) aortoiliac 
occlusive disease.1,2 This may con­
tribute to early failure of a femoro- 
popliteal bypass graft if reconstruc­
tion is performed when occult inflow 
disease (aortoiliac segment) is pres­
ent.'1 Gosling, King and Woodcock,4 
Johnston5 and Harris and associates6 
assessed aortoiliac flow before opera­
tion using the Doppler principle. Al­
though they confirmed the value of 
this method it is expensive in terms 
of equipment used.
To obtain a more accurate estimate 
of the extent of aortoiliac im­
pairment, blood flow and pressure 
characteristics must be measured 
during exercise or at least during in­
creased flow. Moore and Hall7 meas­
ured directly arterial pressure and 
responses to increased flow during 
exercise. Quin, Evans and Bell8 car­
ried out a similar test but used papa­
verine to simulate the increased flow 
of exercise. The relative drop in 
pressure that confirmed the presence 
of significant aortoiliac disease was 
18%. In our prospective study, which 
was carried out to confirm the ac­
curacy of this method, 20 mg of 
papaverine was used to increase 
blood flow.
Patients and Method
Sixty-four patients were studied at 
the Ottawa Civic Hospital between 
July 1, 1977 and Mar. 31, 1980; 63 
had intermittent claudication and 1 
had gangrene. All patients were 
suspected clinically to have arterial 
occlusive disease of sufficient severity 
to warrant arterial reconstruction 
and were considered to be acceptable 
operative risks, if an appropriate 
anatomic lesion was detected. Aorto­
graphy was carried out on all pa­
tients by the translumbar or the Sel- 
dinger transfemoral approach. Aorto­
iliac segments were then graded as 
follows: grade 1—normal (17 pa­
tients), grade 2—irregular but with no 
notable stenosis (31 patients), grade 
3—stenosis greater than 50% (13 
patients) and grade 4—occluded (3 
patients). On the basis of clinical 
assessment and aortography, the 
papaverine pressure test was applied 
to two groups of patients. In one 
group clinical examination and aorto­
graphy demonstrated that the patients 
had significant (more than 50% ste­
nosis) aortoiliac disease; the pressure 
test was done to assess its ac­
curacy. In the second group were 
patients with essentially normal aor- 
tograms who were thought, on clin­
ical grounds, to have occult aortoiliac 
disease. In them the papaverine pres­
sure test was done as a diagnostic 
procedure.
The common femoral artery was 
cannulated with an 18-gauge plastic 
needle (Becton, Dickinson and Com­
pany, Rutherford, NJ) and with a 
pressure transducer (Statham Instru­
ments, Oxnard, Calif.) the pressure 
tracings for each artery were re­
corded on photographic paper with a 
VR6 Simultrace Recorder (Electronics 
for Medicine, White Plains, NY). 
Papaverine (20 mg) was introduced
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into a manometer line through a three- 
way tap, care being taken to avoid 
introducing air bubbles. The pres­
sure changes induced by the papaver­
ine were recorded on the multichannel 
recorder (Electronics for Medicine) 
with the opposite leg being used as a 
control. Relative percentage falls in 
the systolic pressure were noted. After 
allowing 10 minutes for dissipation of 
the drug we studied the pressure re­
sponse to papaverine in the other 
leg. Most of the tests were performed 
under local anesthesia without seda­
tion; all patients experienced a burn­
ing sensation.
Several patients with unilateral iliac 
artery thrombosis were studied at 
operation after exposure of the com­
mon femoral artery. The other side 
was thought to have normal inflow. 
The test was done to measure the flow 
increase with papaverine, using the 
electromagnetic Gould-Strattan flow­
meter (model SP2204; Statham Instru­
ments), and to compare the response 
on the two sides.
Patients were divided into three 
groups according to the results of the 
pressure test: (a) patients with a re­
lative pressure drop more than 18%, 
(b) those with a pressure drop be­
tween 8% and 18% and (c) those 
with a pressure drop of less than 8%. 
Arteriograms were compared with the 
results of hemodynamic assessment 
and the treatment and results of treat­
ment were studied. No complications 
were attributed to the procedure.
Results and Discussion
Twenty-five patients had a pres­
sure drop greater than 18% (Table I). 
On the aortogram 4 of these patients 
had no apparent aortoiliac disease, 11 
patients had grade 2 disease, 7 patients 
had grade 3 disease and 3 patients 
had grade 4 disease. In other words, 
15 of these 25 patients had insufficient 
angiographic evidence of disease of 
the aortoiliac segment to indicate the 
need for an aortic graft. Twenty-two 
of these 25 patients underwent an in­
flow operative procedure (aortoiliac
T a b le  1 - C o rre la t io n  o f A o r to g ra p h ic  Grade
w ith  P re s s u re  D ro p  a f te r  A d m in is tra tio n
o f  P a p a v e r in e
P re s s u re  d ro p , %
G rade > 1 8  8 -1 8  < 8
1 4 11 2
2 11 13 7
3 7 6 0
4 3 0 0
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bypass grafting) and all had either 
complete relief of symptoms or appre­
ciable improvement of symptoms by 
clinical assessment at follow-up from 
2 to 34 months later. Eleven of the 
22 patients had serious femoropopli- 
teal occlusive disease; of these 11, 4 
might have undergone only femoro- 
popliteal grafting (with possible graft 
failure) if the pressure test had 
not been carried out. Of the three pa­
tients who did not undergo an inflow 
operative procedure, two were consi­
dered unacceptable candidates for an 
aortic graft and one underwent a dis­
tal procedure alone for limb salvage.
Thirty patients had a pressure drop 
between 8% and 18%. Of these, 11 
had grade 1 disease as shown by aor­
tography, 13 had grade 2 disease and 
6 had grade 3 disease. Our decision to 
operate on these patients was influ­
enced by clinical and radiologic cri­
teria as well as by the results of the 
papaverine pressure test. Of the pa­
tients in this group 10 had an aortic 
graft and all had clinical improve­
ment, 5 underwent femoropopliteal 
bypass grafting, 1 had a sympathec­
tomy and 14 had no treatment.
Nine patients had a pressure drop 
of less than 8%; two patients had 
grade 1 disease and seven had grade 2 
disease as shown by aortography. One 
patient underwent a femoropopliteal 
bypass graft, one had a sympathec­
tomy and seven were not operated 
upon. The two operative cases in this 
group had a good short-term result.
In two of the three patients who 
had complete occlusion on one side, 
the opposite side showed no evidence 
of disease on angiography and the 
femoral pulses were normal. On pres­
sure testing, the pressure dropped 
33% and 28% on the occluded side 
and 16% and 15% on the other side.
Of the 32 patients who received an 
aortic graft, 18 had a standard exer­
cise response test in which the ankle 
pressures were measured using the 
Doppler principle. Of the 18 patients 
tested preoperatively and postoper- 
atively, 16 showed a notable improve­
ment after the aortic graft was placed.
The papaverine pressure test is ac­
curate if an 18% drop in pressure is 
used as the level of significance.
Twenty-two patients with this pressure 
drop underwent aortic grafting as did 
10 patients with a pressure drop be­
tween 8% and 18%. Our follow-up is 
short, but each patient selected for 
operation with the aid of the pressure 
test was either improved or completely 
relieved of symptoms. Three patients 
had normal aortoiliac segments and 
16 patients had only irregular seg­
ments. Therefore, 19 patients would 
not have been considered candidates 
for an inflow operative procedure 
without the benefit of the pressure 
test, yet they were all improved 
by aortic grafting (Table II). Two 
patients had previously undergone 
femoropopliteal grafting with no im­
provement and were helped only after 
the aortic graft was inserted. One of 
these patients had functioning grafts 
and the other occluded grafts at the 
time of aortic operation.
Our conclusions are very similar to 
those of Brener and associates9 who 
used reactive hyperemia to increase 
blood flow and Moore and Hall7 who 
used exercise to increase flow. Any 
patient presenting with indications for 
arterial surgery whose aortogram de­
monstrates a normal or an equivocal 
aortoiliac segment should undergo the 
papaverine pressure test. The test is 
diagnostic of aortoiliac disease if there 
is a pressure drop greater than 18% 
(100% good results even if the aor­
togram is not impressive). If the pres­
sure drop is between 8% and 18% 
the test may be used in conjunction 
with clinical and angiographic assess­
ment to determine the level at which 
vascular reconstruction should be 
done. The papaverine pressure test has 
helped us to avoid performing femoro­
popliteal reconstructions alone on pa­
tients with occult aortoiliac disease.
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Enhancement of Thrombus Formation by 
Vascular Prostheses
P e t e r  N . M a d r a s , m d , f r c s [c ] , *  W e b s t e r  R .  Jo h n s o n , p h  D f a n d  C h a r l e s  A .  W a r d , p h  d $
The stagnation point flow experiment 
has been used to identify the micro­
scopic events that occur in thrombus 
formation on foreign surfaces. In this 
investigation it was used to study 
the role of vascular grafts in pre­
activating blood, as well as the role 
of pretreatment of these grafts to 
remove the gas nuclei. The experiment 
was carried out under two conditions:
(a) in which whole blood was 
led from the carotid artery of a dog 
to the undersurface of a microscope 
coverslip (control experiment) and
(b) in which blood flowed from 
the left carotid artery of the dog 
through a 10-cm vascular graft to the 
right carotid artery and finally to 
the flow chamber for visualization.
The thrombus morphology, time to 
thrombus formation and thrombus
From the departments of surgery 
and mechanical engineering,
University of Toronto, Toronto, Ont. 
Presented at the 2nd annual meeting 
of the Canadian Society for 
Vascular Surgery, Ottawa, Ont.,
June 5, 1980
* Assistant professor, department of 
surgery, University of Toronto
t Research associate, departments of 
surgery and mechanical engineering, 
University of Toronto
tProfessor, department of mechanical 
engineering, University of Toronto
Supported in part by the Ontario 
Heart Foundation, The Medical 
Research Council of Canada and the 
Wellesley Hospital, Toronto
Accepted for publication June 26, 1980 
Reprint requests to: Dr. Peter N. Madras, 
Department of surgery, New England 
Deaconess Hospital, 185 Pilgrim Rd., 
Boston, MA 02215, USA
adhesiveness to the foreign surfaces 
were compared using knitted Dacron, 
woven Dacron, expanded polytetra- 
fluoroethylene (PTFE) and saphenous 
vein grafts. Blood led through the 
vascular grafts showed a marked 
predisposition to thrombus formation, 
with no change in clotting times. Knitted 
Dacron most highly preactivated the 
blood, while PTFE showed a lesser 
degree of preactivation.
Treating expanded PTFE so that it 
may be completely wetted eliminated 
any activation of blood and caused 
blood to behave as if it had not 
contacted a foreign surface. It was 
the only graft material, including 
autogenous vein to demonstrate this 
property. Therefore, of the materials 
tested, hydrophobic Teflon with no 
entrapped gas appears blood 
compatible.
[.'experience du debit au point de 
stagnation a ete employee afin 
d'identifier les evenements qui 
surviennent a I'echelle microscopique 
pendant la formation du thrombus sur 
des surfaces etrangeres. Dans ce 
travail de recherche, il a ete utilise 
dans le but d'etudier le role des 
greffons vasculaires sur la pre­
activation du sang, de meme que le 
role d'un pre-traitement de ces 
greffons visant a eliminer les noyaux 
gazeux. L'essai a ete realisee sous 
deux conditions experimentales: a) une 
ou le sang entier a ete transports 
de la carotide d'un chien sous la 
lamelle d'un microscope (controle) et 
b) I'autre oil le sang a circule de la 
carotide gauche du chien a travers un 
greffon vasculaire de 10 cm vers
la carotide droite et, finalement, 
jusqu’a une chambre a circulation 
pour etre visualise.
La morphologie du thrombus, le 
temps de formation du thrombus et 
I'adhesivite du thrombus sur des 
surfaces etrangeres ont ete compares 
pour les mailles de Dacron, le tissage 
de Dacron, le polytetrafluoroethylene 
(PTFE) dilate et les greffons de 
veines saphenes. Le sang qui avait 
circule a travers les greffons vascu­
laires a manifesto une nette predis­
position a la formation de thrombi 
sans alteration du temps de coagula­
tion. Les mailles de Dacron ont 
preactive le sang le plus fortement 
alors que le PTFE a demontre le plus 
faible degre de pre-activation.
Lorsque le PTFE dilate a ete traite 
de facon a ce qu'il puisse se mouiller 
completement, I'activation du sang 
a ete eliminee et celui-ci s'est 
comporte comme s'il n'etait pas venu 
en contact avec une surface etrangere. 
C'est le seul material! utilise pour les 
greffes, y compris les veines autogenes, 
qui a demontre cette propriety, En 
consequence, de tous les materiaux 
testes, le Teflon hydrophobe purge 
des gaz qui y adherent semble le 
plus compatible avec le sang.
The interaction o f blood with foreign 
surfaces may lead to thrombosis, 
hemolysis or protein denaturation.1 
N ew er vascular prostheses have 
achieved sufficient biocompatibility 
that these problems are less evident 
on an immediate or short-term basis. 
Nevertheless when b lood is in contact 
with large areas o f  foreign  surface as 
in hemodialysis and cardiopulmonary
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bypass, the more subtle effects of 
foreign surfaces on blood become in­
creasingly important.
Means for gauging these blood- 
surface interactions are not well de­
fined. The standard Lee-White clotting 
time has two disadvantages: it is a 
static test that measures clotting time 
rather than thrombogenesis and the 
blood is in contact with several foreign 
surfaces (air, the needle and syringe 
used to draw the blood) other than 
the surface of interest.
The stagnation point flow experi- 
ment2,3 offers an opportunity to ob­
serve blood in its native state as it 
contacts a foreign surface (Fig. 1). It 
also allows the experimenter to have
FIG . 1— Stagnation point flow experi­
ment. Carotid artery is rigidly mounted. 
Blood emerges from artery at 2 ml/m in 
and central stream enters region of ob­
servation. Blood diverges from stagnation 
point in radially symmetric manner to 
collecting gulley around coverslip.
FIG . 3— Blood flow within stagnation 
point flow chamber. Blood accelerates 
away from stagnation point at rate pro­
portional to its distance from stagnation 
point.
the blood contact any amount of for­
eign surface before observation.4 In 
this study, the rate at which thrombi 
form upon initial contact with a glass 
surface is compared under two sets of 
conditions: (a) control conditions in 
which blood has contacted no foreign 
surface before the surface of observa­
tion (b) test conditions in which blood 
is led through a vascular prosthesis 
before entering the region of observa­
tion.
M ethods
Control Experiment
The stagnation point flow experi­
ment was used in its original form to 
serve as a control. The left carotid ar-
FTG. 2— Left: stagnation point flow 
experiment in usual configuration. C a­
rotid artery is divided low in neck so that 
blood passes through circle of Willis 
before entering flow chamber. This 
diminishes tendency for pulsatile flow 
within observation chamber. Right: sys­
tem for evaluating vascular grafts. G raft 
is placed from  right to left carotid artery 
so that blood flowing into chamber has 
previously passed through graft.
tery of a dog weighing 20 kg was 
divided low in the neck to allow the 
mobilized distal segment to enter the 
flow chamber freely (Fig. 2). Within 
the chamber blood flowed to the 
undersurface of a glass coverslip (Fig. 
3). The blood diverged at the stagna­
tion point in an axisymmetric fashion 
and collected in a circumferential gut­
ter around the field of observation 
Blood was withdrawn from the cham­
ber (and the animal) at a rate of 2 
ml/min. Before each run the chamber 
was primed with saline. A typical run, 
measured from the time of blood with­
drawal until the field of observation 
was 80% to 100% covered with 
thrombus, lasted approximately 15 
minutes. Eight runs were performed 
in each experiment, leading to a 
gradual blood loss in the dog of 250 
to 300 ml. No blood was returned to 
the animal.
Observation of the glass coverslip 
was by dark field reflected light micro­
scopy. Events were recorded perma­
nently by means of Polaroid photo­
micrography at x40 magnification. 
The estimated surface coverage by 
thrombus (expressed in percent) was 
obtained from these photographs (Fig. 
4). In any run, surface coverage was 
estimated at four separate times and 
the best-fit linear approximation to 
these points was drawn. This line was 
used to obtain an estimate of the time 
to 50% surface coverage which was 
the point used for comparison of all 
runs.
F'lG. 4__Photograph of throm bus covering approximately 50%  of surface
taken at 8 minutes into run. N um ber of wedge-shaped throm bi point tow ards stag­
nation point (S). Discrete white dots are individual leukocytes and areas of am or­
phous cloudy material (arrows) are fibrin and platelet aggregate (reduced by 28%  
from  X40).
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Test Experim ent
To test the activation of the blood 
by vascular prostheses, an 8 X 8-cm 
segment of prosthesis was inserted 
joining the right and left carotid arte­
ries and held in place with two T 
tubes (Fig. 2). Since the pressure is 
higher in the right carotid artery than 
in the distal segment of the left, the 
blood flowed through the graft, down 
the left carotid artery, into the cham­
ber and the field of observation.
Knitted Dacron, woven Dacron, 
microporous polytetrafluoroethylene 
(PTFE) and autogenous vein were 
used. The time for 50% thrombus for­
mation to take place was measured. 
Heparin was not administered. Hema­
tocrit and leukocyte counts were meas­
ured in all experiments and a run 
was discounted if these were abnor­
mal. Leukocyte counts typically 
reached levels of 15 to 20 X 109/1 
during the course of the experiment.
The results with PTFE that was 
treated so as to assure complete wet­
ting of the hydrophobic material are 
presented. (Details of this form of 
pretreatment and the rationale for its 
application are presented elsewhere.4)
Results
Typical results for any one run are 
presented in Fig. 5, which also shows 
how the time to 50% coverage was 
estimated.
Control data were obtained from 13 
runs.
Fig. 6 shows the average time to 
50% coverage in all cases. All the 
vascular grafts used with the exception 
of the thoroughly wetted PTFE led to 
marked enhancement of thrombus for­
mation, the time to surface coverage 
being approximately one fifth of the 
control time.
When expanded PTFE is treated to 
remove all entrapped air within this 
hydrophobic material, the blood-gas 
interface is removed so that blood will 
contact no surface other than the 
PTFE. This inert material shows no 
activation of blood by our criteria and 
was the only material to give this re­
sult.
Discussion
The stagnation point flow experi­
ment was originally conceived to study 
thrombus formation on foreign sur­
faces.2 As such it revealed the micro­
scopic events that occur around the 
time of thrombus inception and 
growth. A variety of surfaces have 
been studied3 in which blood touching 
the foreign surface under study has 
contacted no surface other than
natural vascular endothelium prior to 
its observation.
The stagnation point flow experi­
ment is readily modified to interpose 
vascular graft material before the point 
of observation. By timing the rate at 
which thrombi form within the cham­
ber, the blood-activating properties of 
different vascular prostheses may be 
compared. It is instructive to note 
that the morphology of thrombi form­
ing from blood that contacts a 
vascular prothesis differs from blood 
that does not. In the control case,3 
thrombi grow downstream from dis­
crete initiation points on the foreign 
surface, thus developing a wedge- 
shaped mass pointing towards the 
stagnation point. However, when a vas­
cular graft is interposed, the blood is 
activated, leading to thrombus growth 
in concentric rings around the stagna­
tion point. Thrombus typically starts 
near the periphery of a field and 
grows towards the stagnation point. 
This is consistent with the fact that
FIG. 5—Time taken for 50% surface 
coverage by thrombus. In each run, 
four points are taken presenting ap­
proximate rate of thrombus growth on 
surface. Straight line is best fitted to these 
points and time to 50% coverage is inter­
polated from this line.
age using vascular grafts. Data from all 
runs. Control data were obtained from 
13 runs while figures for any vascular 
prosthesis were obtained from 7 runs 
each. Bars represent one standard devia­
tion.
the peripheral blood is more highly 
activated, since it would have been the 
blood in contact with the vascular 
graft.
In other work4 we have shown that 
the surface contacted by blood flow­
ing through expanded PTFE, inserted 
in the standard surgical manner, is 
approximately 80% gas and 20% 
PTFE. The detrimental effects of a 
blood-gas interface have been known 
since the days when the bubble oxy­
genator was in use, but the potential 
detrimental effects of submicroscopic 
amounts of gas have never been de­
monstrated. Trudell, Boudreau and 
Van de Water,5 using ethanol as a 
priming solution, were able to obtain 
better contact of blood with PTFE 
than would occur with standard sur­
gical techniques and they showed 
improved tissue ingrowth into the 
pores of the PTFE. It is known clinic­
ally that PTFE grafts frequently are 
encapsulated rather than incorporated 
into the surrounding tissue. Trudell, 
Boudreau and Van de Water stated 
that the ethanol seemed to improve the 
porosity of the PTFE, a result con­
sistent with simple wetting of this hy­
drophobic material.
Dacron is known to be a highly 
active material in contact with blood 
and indeed relies upon blood clotting 
for integrity of the knitted graft. The 
thrombus-initiating effect of Dacron 
is well illustrated in these experiments. 
Similarly, autogenous vein in the dog 
served to activate blood. This is not 
surprising, since dissection of the vein 
is traumatic. Whether this finding is 
applicable to the model of human 
saphenous vein is uncertain. No vein 
in a dog is subjected to the pressures 
of the saphenous vein in the human. 
Nevertheless, damage to human sa­
phenous vein also occurs during its 
removal, so that it would be expected 
to activate blood as well, at least 
until the vein is well healed.
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Transluminal Dilatation in the Treatment of Peripheral
Arterial Occlusive Disease
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The authors review their experience 
over a 2-year period with transluminal 
arterial dilatation using the Griintzig 
catheter. In 96 patients 136 aortoiliac 
or femoropopiiteal arterial segments 
were dilated. The success rates at 
1 year were 76% and 70%, respectively, 
for aortoiliac and femoropopiiteal 
dilatations. The early and late 
results indicate that this procedure 
is useful in managing peripheral 
arterial occlusive disease in certain 
patients and that there are few 
complications when the procedure is 
carried out by a skilled angiographer.
Les auteurs passent en revue une 
experience de 2 ans de la dilatation 
de la lumiere arterielle a I'aide du 
catheter de Griintzig. Une dilatation 
a ete pratiquee sur 136 segments 
arteriels aorto-iliaques ou femoro- 
poplites, chez 96 malades. Les taux 
de reussite apres un an ont ete 
de 76% et 70% respectivement pour 
les dilatations aortoiliaques et 
femoro-poplitees. Les resultats a court 
et a long terme indiquent que cette 
intervention est utile au traitement 
des maladies obliterantes des arteres 
peripheriques chez certains patients, 
et que les complications sont rares 
quand I’intervention est pratiquee 
par un specialiste en angiographie 
experiments.
Transluminal dilatation of stenosed or occluded arteries is popular in Europe 
but until recently there has been 
relatively little interest in the technique in North America. Dotter and 
Judkins1 first described percutaneous recanalization of arteries in 1964, but 
their method was similar to bouginage 
and was associated with a high rate
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of thrombotic and embolic complica­tions. Thus it never became popular.
An important advance was made in 
1974 by Griintzig and Hopff2 who developed a dilating catheter similar 
in design to a Fogarty embolectomy catheter hut having a cylindrical rather 
than a spherical balloon. It consists 
of an inner base catheter, through 
which dye can be injected for angio­
graphy and pressures measured, and 
an outer catheter with a balloon 
dilating segment.
The purpose of this paper is to de­
scribe our experience with translu­
minal dilatation using the Griintzig catheter and to discuss the role of this 
technique in managing patients with 
peripheral arterial occlusive disease.
Patients and Method
The details of the technique have 
been described previously.3’4 We do 
not perform percutaneous transluminal dilatation at the time of diagnostic ar­teriography but rather as a planned 
second procedure. This approach provides time for the radiologist and 
vascular surgeon to determine the best method for managing the vascular dis­
ease and to discuss the therapeutic alternatives with the patient. Anti­
platelet drugs are administered for 2 
or 3 days before the procedure and for 2 to 3 weeks after. Heparin (5000
MONTHS
0 1 2 3 9 5 6 7
AORTA  O
CF + Cl •
CF + El ----------------- O
CF  O
CF --------•
CF + SF --------------------- •
DF •
DF •
SAPHENOUS ------------------------------O
GRAFT
FIG. 1—Results of miscellaneous dila­tations. Success is denoted by open circle, failure by closed circle. Cl = common iliac, El = external iliac, CF = common femoral, SF — superficial femoral, DF = deep femoral.
units) is administered during the dila­tation procedure but anticoagulants 
are not used on a long-term basis.Under local anesthesia the femoral artery is punctured. The angiographic 
catheter is introduced percutaneously 
and passed through the stenosis or oc­clusion. Once beyond the obstruction 
the catheter is withdrawn over a 
guidewire and replaced by a Griintzig 
dilating catheter with a balloon of 
appropriate length and diameter. The 
balloon is inflated and after the dila­tation, arteriography is repeated. The 
success of the procedure is evaluated 
hy measuring the pressure gradient 
across the stenosis and comparing 
it with the predilatation value.In the last 2 years at the Toronto 
General Hospital, 96 patients have 
undergone transluminal dilatation of 
136 aortoiliac or femoropopiiteal ar­terial segments. The procedure was 
considered an early success if all of the following improved: angiographic appearance, systolic pressure gradient 
and ankle systolic pressure. Subse­quently, dilatation was considered suc­cessful if the symptoms, the ankle systolic pressure and Doppler ultra­
sonographic recordings were im­
proved.
Results
Of the 136 arterial segments dilated, 
evaluation of the early or late results, 
or both, was impossible in nine cases 
because the results were equivocal, 
because no pressure gradient was present across the stenosis or because 
the patient could not be re-evaluated 
owing to associated medical problems.The results of nine miscellaneous 
dilatations are shown in Fig. 1. Of 38 dilatations for femoropopiiteal ste­
nosis or occlusion, 1 (2.6%) was a technical failure because the catheter could not be advanced through the 
stenosis. The success rate at 1 year was 76% (Fig. 2). Of 79 aortoiliac dilatations, 3 (3.8%) were technical 
failures. At 1 year the cumulative suc­cess rate was 70% (Fig. 3).The results of aortoiliac dilatation differ depending on the site and ex­tent of the disease. The cumulative 
success rate at 1 year was much greater for dilatations of isolated com-
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mon iliac lesions and of external iliac 
lesions alone than for dilatation per­
formed for combined common and 
external iliac lesions (Fig. 4).
Complications in our series were 
few. Small hematomas of the groin 
were common. One patient had a 
large groin and scrotal hematoma 
which delayed his discharge from hos­
pital but the hematoma resolved spon­
taneously. Ischemia due to thrombosis 
occurred in two patients, in one fol­
lowing common iliac dilatation of a 
diffusely diseased aortoiliac segment 
and in the other following dilatation 
of a segment of the deep femoral ar­
tery. Both patients were given heparin 
immediately and were improved with­
in 2 to 3 hours. Ischemia due to em­
bolic complications was not a serious 
problem clinically, although small em­
boli were frequently seen on the post­
dilatation angiogram. Other complica­
tions, such as rupture of the vessel or 
of the balloon, did not occur.
Discussion
No patient should undergo trans­
luminal dilatation without first being 
assessed by a physician or surgeon 
who is fully aware of the alternatives 
for treating peripheral arterial occlu­
sive disease. The patient is best man­
aged on an individual basis, which 
requires close cooperation between 
the angiographer and the vascular 
surgeon.
Transluminal dilatation should be 
performed only by skilled, well trained 
angiographers. Before attempting the 
procedure, the physician should have 
extensive general experience in angio­
graphy and should take the op­
portunity to observe the technique in 
a centre where it is performed often.
The role of transluminal dilatation 
is not yet clearly defined. It may be
FIG. 2—Results of femoropopliteal 
dilatation expressed by life-table method. 
Vertical bars indicate standard error and 
number at each point denotes num­
ber of patients at each follow-up interval.
a useful adjunct to operation, in treat­
ing surgical complications or an al­
ternative to operation in certain pa­
tients. When a patient has multilevel 
disease, but the principle lesion is in 
the femoropopliteal segment, we have 
found that transluminal dilatation is 
a useful adjunct to distal vascular re­
construction since it can be used to 
correct a minor localized iliac lesion 
which might jeopardize the patency of 
the distal repair. Although our ex­
perience is limited, the technique may 
also be useful for correcting minor 
lesions at the time of vascular recon­
struction.
Transluminal dilatation may play 
a role in treating certain complications 
of saphenous vein bypass grafting, 
such as valve bicuspid hyperplasia, 
intimal hyperplasia or atherosclerosis. 
Anastomotic defects are unlikely to be 
corrected by dilatation.
Transluminal dilatation works in 
some patients and is clearly an altern­
ative to operation, but the selection of 
patients is difficult. The majority of 
those with notable ischemic symptoms 
of the lower extremity have diffuse 
disease involving the aortoiliac, femo­
ropopliteal or tibial artery segments,
FIG. 3—Results of aortoiliac dila­
tations.
mon iliac (square), external iliac (circle) 
and combined common and external iliac 
(triangle) segments.
or all three. Thus, it is not surprising 
that only a small percentage of patients 
with vascular problems are candidates 
for transluminal dilatation. The clinic­
al and hemodynamic improvements 
observed following this procedure are 
less impressive than those following 
operation, but this is offset by the 
lower mortality and morbidity, short­
ened hospital stay and reduced cost.
For patients with mild claudication 
who do not accept their mild disabil­
ity, transluminal dilatation is a good 
alternative. For them, the procedure is 
not really an alternative to operation 
since we do not operate on patients 
with mild claudication. For patients 
with severe, disabling claudication, 
transluminal dilatation appears to be 
a good alternative to operation if the 
aortoiliac or femoropopliteal lesion is 
localized, less than 10 cm long and 
not calcified, if the symptoms are of 
recent onset and if the patient is a 
poor surgical risk. Patients with severe 
manifestations of peripheral vascular 
disease including ischemic pain, ul­
ceration or gangrene usually do not 
have localized disease which is 
amenable to dilatation and, in general, 
require operation.
Summary
We have presented our experience 
at the Toronto General Hospital with 
transluminal dilatation. In the last 2 
years, 136 peripheral arterial segments 
have been dilated. The early and late 
results indicate that the procedure is 
useful in managing certain patients 
with peripheral arterial occlusive dis­
ease and that there are few complica­
tions when the procedure is carried 
out by a skilled angiographer.
We thank Mrs. C. Mori for her sec­
retarial assistance and Mrs. B. Hanson 
and Mrs. S. Ungaro for performing the 
vascular laboratory studies and assisting 
in the patient follow-up.
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1980 GALLIE MEMORIAL LECTURE
Lung Cancer in Historical Perspective: Lessons 
from the Past, Implications of Present Experience,
Challenges for the Future
Norman C. D elarue, md, m s(tor), facs, fccp, frcs[c]*
Initial experience with a review of 
the 5882 patients with lung cancer 
admitted to the Toronto General 
Hospital since 1933 was encouraging 
as the salvage rate seemed to improve. 
By 1966, the overall salvage rate had 
increased from 3% to 13%. At that 
time, a 16% salvage rate was predicted, 
based on a resectability rate of 40% 
and a 5-year survival for resected 
cases of 40%. It seemed reasonable 
to anticipate continuing improvement 
as the value of treating early cases 
became more apparent.
A recent review of 450 consecutive, 
unselected patients seen in primary 
referral showed that significant 
changes have not occurred in the past 
decade despite therapeutic innovations. 
These innovations have included radical 
combination therapy (preoperative 
radiotherapy) for biologically favour­
able, locally advanced disease (e.g., 
a 5-year survival of 31% in squamous 
carcinoma), limited resection in the 
compromised host (e.g., 5-year survival 
rate of 18% following sleeve resection), 
and combination chemotherapy with 
irradiation for small cell anaplastic 
carcinoma (e.g., approximately 20% 
free of active symptomatic disease 
for longer than 2 years). Unfortunately, 
the relatively small number of patients 
affected by these special maneuvers 
does not appreciably alter the 
overall survival rate.
Presented at the 49th annual meeting 
of the Royal College of Physicians 
and Surgeons o f Canada, Ottawa, Ont., 
June 4, 1980
*Professor of surgery, faculty of 
medicine, University o f Toronto,
Toronto, Ont.
Accepted for publication July 29, 1980
Reprint requests to: Dr. Norman 
C. Delarue, 25 Donlea Dr.,
Toronto, Ont. M4G 2M1
VOLUME 23, NO. 6, NOVEMBER 1980
In the 450 patients, the resectability 
rate has been 43.5% with a 5-year 
survival of 42.0% in resected cases, 
producing a salvage rate of 18.3%. 
There was a 5-year survival of 2.4% 
in inoperable disease treated by other 
means (primarily radiotherapy). Sal­
vage has, therefore, been achieved, 
in only one of five patients— scarcely 
an acceptable figure.
The profession must encourage 
greater use of screening programs 
and offer the stimulus for increased 
interest in withdrawal programs. The 
potential dividends of these programs 
are outlined. Short of these measures, 
modifications of management are 
unlikely to be reflected in 
acceptable improvements in patient 
salvage. The professional challenge 
is clear-cut and exciting.
La premiere impression qui s'est 
degagee de I’etude des 5882 malades 
atteints d'un cancer du poumon, 
accueillis au Toronto General Hospital 
depuis 1933, a ete encourageante 
puisque le taux des patients suscep- 
tibles d'etre sauves a semble s'etre 
ameliore. En 1966, le pourcentage 
global des sujets possiblement sauves 
etait passe de 3 a 13%. A ce moment, 
etant donne un pourcentage de cas 
operables de 40% et une survie a 
5 ans pour les cas operables de 40%, 
on prevoyait un pourcentage de 
sujets possiblement sauves de 16%.
II semblait raisonnable d’anticiper 
une amelioration constante puisque 
I’interet de traiter les cas des le debut 
etait devenue plus evidente.
Une etude recente de 450 malades 
non choisis, vus consecutivement en 
premiere consultation, a revele qu’aucun 
changement significatif n’est survenu 
au cours de la derniere decennie en
depit des innovations therapeutiques. 
Ces innovations englobent le traitement 
radical dissociation (la radiotherapie 
preoperatoire) pour les tumeurs locales 
avancees mais biologiquement 
favorables (p. ex. une survie a 5 ans 
de 31% dans I’epithelioma malpighien), 
la resection partielle chez le malade 
hypotheque (p. ex. une survie a 5 ans 
de 18% a la suite d'une resection 
en manchon), et I'association de 
chimiotherapie et de radiotherapie 
dans les cas de cancer anaplasique 
a petites cellules (p. ex. environ 
20% de patients exempts de maladie 
symptomatique active pendant plus 
de 2 ans). Malheureusement, le nombre 
relativement petit de malades touches 
par ces interventions speciales ne 
modifie pas de fapon appreciable 
le taux de survie d’ensemble.
Chez les 450 patients, le pourcentage 
de cas operables a ete de 43.5% 
et le taux de survie a 5 ans, de 42.0% 
pour les cas operes, donnant un 
pourcentage de malades possiblement 
sauves de 18.3%. On a enregistre 
un taux de survie a 5 ans de 2.4% 
chez les malades inoperables traites 
par d'autres moyens (par radiotherapie 
surtout). La recuperation des malades 
n'a pu etre obtenue que chez un patient 
sur cinq, une statistique difficilement 
acceptable.
La profession doit donner son appui 
a une plus grande utilisation des 
programmes de depistage et offrir 
le stimulus necessaire pour accroitre 
I'interet dans les programmes de 
sevrage. Les benefices escomptes 
de ces programmes sont soulignes. 
Ces mesures mises-a-part, les 
modifications de traitement sont peu 
susceptibles de se traduire par une 
amelioration acceptable du nombre 
de malades aptes a etre sauves.
Le defit pour la profession est net et 
stimulant.
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Mr. President, honoured guests, fel­
lows of the College and assembled 
“Gallie slaves”.
Today we gather to honour the 
memory of Dr. Gallie. I have very 
special personal memories of that 
great man which must inevitably 
colour my expression of respect for 
the enormous contributions he made 
in the professional arena even though 
they seemed to emanate from him 
in an unending stream of unique 
images.
From the purely persona] standpoint 
it would be no exaggeration to state 
that any of us who were fortunate 
enough to have been put through our 
paces as “Gallie slaves”, and most 
particularly as his chief residents, 
would consider the opportunity to 
deliver the Gallie memorial address 
the climax of our own careers—such 
was the affection, loyalty and admira­
tion with which we viewed Dr. Gallie 
and his deep concern for our educa­
tion and welfare. Seldom does anyone 
in a position of authority earn such 
love and respect from those for whom 
he has assumed responsibility. Dr. 
Gallie assumed that responsibility with 
such enormous zeal and enthusiasm 
that he became personally involved 
in all our careers. A warm and com­
fortable feeling of camaraderie de­
veloped amongst us as a bond which, 
once forged, could never be broken. 
Consequently we owe him a debt of 
gratitude that can never be fully 
repaid.
At no time was this more apparent 
than during World War II when he 
kept in touch with all of us no matter 
where we were. How important it was 
for us to be reassured in those sad 
times by his protective and proprietary 
influence.
It is always Dr. Gallie's personal 
warmth and concern which those who 
were close to him recall so fondly. 
The stories that are told and retold 
relate not to his pioneer use of fascia 
lata as a forerunner of the transplan­
tation of living tissue nor to his far­
sighted training scheme for young 
surgeons, but rather to his joy of life 
and the enthusiastic manner in which 
he participated in every activity 
whether it be fishing, enjoying the 
beauty of nature in which he felt so 
comfortable or the social interplay 
amongst his associates that he 
cherished so highly, particularly when 
his willing “slaves” were involved.
His spontaneity was perhaps best 
illustrated by his legendary reputa­
tion as a raconteur nonpareil. Never 
did he fail to hold his audience en­
thralled. To say that he always left 
them buzzing with excitement or roar­
ing with laughter after some under­
stated anecdote—usually offered at 
his own expense—would be a master­
piece of understatement. Dr. Banting 
perhaps expressed our admiration 
most succintly in a letter to Mrs. 
Gallie following the 1938 meeting of 
the Royal College of Physicians and 
Surgeons of Canada. This note, pen­
ned on the stationary of this same 
grand old hotel [Chateau Laurier in 
Ottawa] is as follows:
October 30. 1938
Dear Mrs. Gallie:
Your husband filled us with pride last 
night when he replied to His Excellency’s 
speech. I congratulated him. His reply 
was “Please tell my wife”.
Hence this note.
Sincerely,
Fred Banting
It was in 1940 that Dr. Gallie gave 
the first annual lecture in surgery to 
this College. In the same year, he was 
elected president of the American Col­
lege of Surgeons, a position he was 
to hold for an unprecedented 6-year 
term.
It is small wonder that his circle of 
friends, as distinct from mere acquain­
tances, did in truth encircle the globe.
Challenges from the Past
I would like, therefore, to begin 
today with some observations by two 
close friends and contemporaries of 
Dr. Gallie, both of whom rank as 
North American pioneers in the man­
agement of lung cancer. I was for­
tunate enough to have had the 
privilege of working closely with both 
of them.
Dr. Norman Shenstone, who was 
my own sponsor at the Toronto Gen­
eral Hospital, undertook the first re­
section for lung cancer at that hos­
pital within a year of Dr. Evarts 
Graham’s initial pneumonectomy. He 
demonstrated remarkable insight 
when, in 1941,' worried about the 
large number of explorations per­
formed for nonresectable disease in 
the attempt to find lesions that were 
suitable for excision, he expressed the 
opinion in the form of a challenge 
that it should be possible to define 
more clearly the boundary between 
operable and inoperable cases.
Subsequently, in 1957, Dr. Graham 
exhibited his own brand of foresight 
when he commented on the signif­
icance of the relation between smoking
and lung cancer. These comments 
were made shortly before his own 
death from that disease. He posed 
two more challenges2 to the profes­
sion:
1. “The more important part is to 
do away with the carcinogenic agent 
which is responsible for the disease 
in the first place.”
2. “The other part is to try and get 
those patients earlier who permit their 
cancers to develop in spite of the very 
strong evidence already at hand that 
heavy cigarette smoking is an im­
portant etiologic factor.”
To digress for a moment: It was 
while I was working on Dr. Graham’s 
service after the war that, frustrated 
by his inability to affect the disease 
by treating it as a sex-linked pheno­
menon, he asked me to find out what 
was causing the epidemic. It was 
in 1947 that the evidence was 
eventually collected which indicated 
that cigarette smoking played a role 
in the pathogenesis of lung cancer. 
Dr. Graham, a chain smoker, scorned 
the purely statistical evidence but, 
several years later, supported a fur­
ther study and did then accept the 
relation as factual. He promptly 
stopped smoking completely but with­
in a year succumbed to inoperable lung 
cancer—surely a quirk of fate that 
resulted in the loss of one of the truly 
great surgeons of our time.
Let us then initiate this discourse 
from the three challenges presented to 
us by these two pioneers at the time 
when thoracic surgical practice was 
passing from the pioneer era into the 
modern era of technical capability.
The importance of these challenges 
can scarcely be overstated, because we 
had, for so long, failed miserably to 
solve the last two challenges effect­
ively, despite steadily increasing atten­
tion to the problem. None the less 
there have been accomplishments 
which I should like to review with you 
before discussing those that remain 
for future attention.
The need to view the current situa­
tion with concern is clearly apparent 
when one considers the steady increase 
in the prevalence of lung cancer and 
the alarming increase in deaths from 
lung cancer so clearly indicated in the 
national data for 1980 in the United 
States3 and in the Ontario statistics.
Our experience at the Toronto Gen­
eral Hospital reflects these observa­
tions. It has been my privilege to 
review this experience and report on 
the findings since Dr. Shenstone ini­
tially asked me to do so in 1939. The 
data now cover more than 40 years
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(Table I). That 370 patients—more 
than 1 new patient every day—-are 
seen currently at this one hospital each 
year must cause not only concern but 
frank alarm. Thoracic surgeons are 
acutely aware of the increasing rate 
of new cases of lung cancer since two 
of every three patients are referred to 
them for definitive therapeutic pro­
posals (Table I).
The Accomplishments
What then are some of the accom­
plishments?
Dr. Shenstone’s Challenge
There has been a steady improve­
ment in operability and resectability 
rates. The gap between operability and 
resectability has narrowed to an ac­
ceptable figure of 3% to 4% (Table 
II). We have, therefore, met success­
fully the challenge presented by Dr. 
Shenstone.
This improvement has been due to 
recognition of the biologic factors that 
determine curability and adherence to 
the principle of individualizing treat­
ment according to the tumour-host 
“equation” in effect at the time of 
treatment. The manner in which the 
therapeutic decision can be finalized 
has been described4 as a four-stage 
process:
1. Assessment of curability—the 
biologic aspect.
2. Determination of resectability— 
the technical aspect.
3. Evaluation of the tumour-host 
equation-—is the disease curable (i.e., 
is it biologically favourable)? and can 
the local (and regional) disease be 
excised completely (i.e., is it techni­
cally favourable)?
4. Therapeutic individualization—a 
little operation for “little" disease, 
since one is dealing with a vital organ 
and a big operation for “big” disease, 
provided it is biologically favourable. 
Technical advances permit radical pro­
cedures if the disease allows salvage.
To date, we have found no better 
method.
Dr. Graham ’s Challenges
Unfortunately, the challenges posed 
by Dr. Graham have not been met 
successfully. They were designed to 
lower the toll taken by the disease. 
This we have not affected signif­
icantly, although slow improvement is 
being made.
I. Current Experience
It is obvious that, despite rapidly 
accumulating experience with an in­
creasing number of patients, the im­
provement has not met the necessary 
goals. To illustrate this I have re­
viewed 450 cases (Table III). These 
patients represent a series of un­
selected consecutive admissions to my 
own service over a 10-year period up 
to 1976. They provide an opportunity 
to assess present results.
This was a representative group 
pathologically (Table IV) reflecting 
the spectrum of diseases currently seen 
in North America. Although 64% had 
squamous or undifferentiated lesions, 
surprisingly 16% were described as 
having small cell anaplastic cancers 
(oat cell type).
The results were not impressive. 
The resectability rate was still only 
43.5% (Table III). Although a 5-year 
survival rate of 42% for patients who 
had resection (Fig. 1) sounds en­
couraging the overall salvage rate of 
only 18.3% (Fig. 2) cannot be ac-
T a b le  111— C h a r a c t e r i s t ic s  o f  P r im a r y  
R e f e r r a l  P a t ie n t s  w ith  B r o n c h o g e n ic  
C a rc in o m a  (450  C o n s e c u t i v e  U n se le c te d  
P a t ie n t s )
C h a r a c t e r is t ic N u m b e r  ( % )
C o m p le te  f o l lo w -u p 440 (9 8 )
E x c lu d e d  ( in v e s t ig a t io n
in c o m p le te ) 8
In o p e ra b le 226 (5 2 .3 )
N o n re se c t a b le 18 (4 .2 )
R e se c ta b le 188 (4 3 .5 )
P o s t o p e r a t iv e  m o r ta l it y 6  (3 )
S u r v iv a l  > 1  y r 136 (7 2 )
FIG. 1—Five-year survival of 295 
patients with bronchogenic carcinoma.
FIG. 2—Overall salvage rate, over 
four decades, of patients with broncho­
genic carcinoma admitted to Toronto 
General Hospital.
T a b le  1 - A d m is s io n s  fo r  L u n g  C a n c e r  to T o ro n to  G e n e ra l 
H o sp ita l from  1934 to 1976
A d m is s io n s
P e r io d T o ta l no. A n n u a l no. S u r g ic a l  re fe rra l,  %
1934 -  1945 508 42
1946 -  1948 161 54
1949 -  1952 349 87
1953 -  1956 655 164
1957 1964 952 119
1965 160 160
1966 and  1968* 364 182 56  -  59)
1969 -  1972 1252 313 72 -  79 67
1973 -  1976 1481 370 6 1 - 6 3
*1967 re c o rd s  u n a v a ila b le .
T a b le  I I —  R e s u l t s  o f T re a tm e n t  in  P a t ie n t s  w ith  L u n g  C a n c e r  A d m it te d  
to T o ro n to  G e n e ra l H o sp ita l
P e r io d
N o. o f 
p a t ie n ts O p e ra b il ity ,  % R e se c ta b il it y ,  %
5 - y r  s u r v iv a l ,  %
R e se c ta b le  O v e ra ll 
c a s e s  s a lv a g e
1934 -  1952 1018 34 14 27.7 3
1954 -  1957 408 37 24.7 34.6 9
1965 160 40.6 37.5 39 15
1966 -  1976 450 47.7 43.5 42 18.3
• C o n se cu t iv e  u n se le c te d  p e r so n a l re fe rra ls.
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cepted when death is primarily due to 
tumour—either local recurrence or 
distant dissemination (Table V). If, 
in the 80% who die, most deaths re­
sult from the disease itself, other 
methods of management are obviously 
mandatory. Thus the unresolved chal­
lenges remain current indeed. What 
has been done to improve the re­
cord?
2. Impact of Therapeutic 
Innovations
Although the steady improvement 
in overall salvage is encouraging (Fig. 
2) the pace of change is unacceptable 
despite innovative improvements in 
patient management. The impact of 
these therapeutic innovations can be 
summarized as follows:
Significance of superior mediastinal 
adenopathy.—My interest in the su­
perior mediastinal nodes was stimul­
ated by a wave of enthusiasm during 
the 1950s for a procedure called a 
radical pneumonectomy—a procedure 
in which an extended resection was 
performed including a block dissec­
tion of the ipsilateral superior media­
stinum in continuity with an intra- 
pericardial resection of the root of the 
lung. Admittedly, the technical ele­
ments were simplified and the opera­
tion therefore appeared attractive. 
However, when the procedure was 
used in 23 patients with palpable—and 
therefore gross—superior mediastinal 
adenopathy not a single patient sur­
vived 2 years (Table VI).
These results had to be compared 
with isolated reports of long-term sur­
vival following the same radical proce­
dure and it seemed obvious that a 
more detailed study of the nature of 
superior mediastinal adenopathy was 
necessary to clarify the issue.
Quite fortuitously, at this time Dr. 
F.G. Pearson returned from post­
graduate training in Europe with 
knowledge of Carlen’s maneuver of 
mediastinoscopy which allowed pre­
operative staging of mediastinal dis­
ease and differentiation between gross 
extranodal involvement and micro­
scopic intranodal spread and also be­
tween ipsilateral and contralateral dis­
ease. It seemed logical to assume that 
the long-term survivors would come 
from the group with the least disease 
(e.g., ipsilateral microscopic intranodal 
dissemination) in keeping with similar 
observations of the significance of 
axillary adenopathy in mammary car­
cinoma. For example, in that disease, 
patients harbouring microscopic intra­
nodal metastases affecting only nodes 
in the lower third of the axilla have
been found to have survival and local 
recurrence rates as good as those of 
patients with true stage I disease.
A study of radical combination 
treatment with preoperative irradia­
tion was therefore undertaken in this 
more favourable group of patients 
with superior mediastinal adenopathy 
that was ipsilateral, microscopic and 
intranodal. Indeed a 5-year salvage 
rate of 31 % was achieved although 
long-term survivors were found only in 
the group with squamous cell carcino­
ma (Table VI). The fact that only 16 
patients have been found to harbour 
disease suitable for completion of this 
type of treatment unfortunately means 
that this form of therapy can have 
little effect on the overall salvage.
The “little” operation for “little” 
disease.—Since cigarette smoking
plays an important role in the patho­
genesis of chronic obstructive lung 
disease and coronary artery disease, 
many patients with lung cancer will 
have a degree of cardiorespiratory
functional impairment that would 
make consideration of pneumonectomy 
unwise although they might well toler­
ate a lesser procedure.
Examination of the role of limited 
resection in these compromised pa­
tients was obviously warranted. A sub­
stantial 5-year salvage rate was ob­
tained: if a potentially curative resec­
tion was possible, 18% of these pa­
tients were alive and free of disease 
5 years after resection.5
This result led us to explore the 
value of sleeve resection in the re­
latively uncompromised host. In these 
more favourable cases a 5-year sur­
vival rate of 36% was obtained when 
the resection was of a potentially cura­
tive type. This must be compared with 
an overall 5-year survival rate of 64% 
after pneumonectomy and a potentially 
curative resection. However, the ac­
tuarial survival rates were similar for 
both procedures reflecting the fact that 
more patients with the limited resec­
tion suffered from associated life-en-
Table IV - Pathological Classification of Bronchogenic Carcinoma
Toronto General Cumulative
Type Hospital, % (North America), %
Squamous
Undifferentiated
48 42
(large ce ll) 16 22
Oat cell 16 18
Adenocarcinoma 11 10
Bronchioloalveolar 4 4
Mixed 2
Other 3 4
Table V—Significance of Cell Type in Death from Bronchogenic Carcinoma 
(Figures Are Percentages)
Squamous Undifferentiated
Cause of death carcinoma (large cell) Oat cell Adenocarcinoma Bronchioloalveolar
Other diseases 25* 2 2 12 10
Tumour 72 98 98 88 90
Recurrence 36 43 16 30 40
Dissemination 36 55 82 58 50
*Not specified in 3% .
Table V I— Treatm ent and Results in Patients with Lung Cancer 
Who Had Mediastinal Adenopathy
Treatment Number 5-yr survival
Radical pneumonectomy
(prior to mediastinoscopy) 23 0 (2 yr)
Preoperative radiotherapy* 32 (26 squamous carcinoma)
Resection 22
(mediastinoscopic staging) 16 squamous carcinoma 5 (31%)
3 adenocarcinoma 0 (2 yr)
3 small cell carcinoma 0 (2 yr)
*10 patients had radiotherapy only; 1 died.
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dangering diseases although they were 
not compromised to the point where 
pneumonectomy was contraindicated.5
Although these results appear en­
couraging, only 70 patients were sub­
jected to the limited resection over a 
12-year period.5 This means that the 
procedure was used on only six pa­
tients a year, so the results would 
again have little impact on the salvage 
of the 370 patients now admitted an­
nually.
Adjuvant therapy.—From the ex­
perience with the most recent series 
it is apparent that the patient 
with lung cancer who dies, re­
gardless of the operability or resect­
ability of the disease, succumbs 
primarily to the tumour: there is only 
a moderate preponderance of dissemi­
nation as the major cause of death 
but local recurrence plays an impor­
tant role in the outcome as well. Ob­
viously, although local treatment 
remains the focus for controlling local 
disease, supplementary measures are 
required to manage the metastatic 
phenomenon more effectively.
In the very first study of adjuvant 
chemotherapy in solid tumours (one in 
which we were fortunate enough to 
participate) the use of a single drug 
(nitrogen mustard intrapleurally and 
systemically) did indeed increase 
longevity for a minor subgroup 
of patients having small tumours 
and regional adenopathy. It is now 
considered illogical to use a single 
drug in a short course of chemother­
apy.
More logical protocols for adjuvant 
chemotherapy using a combination of 
drugs and prolonged therapy4 as well 
as other protocols involving radio­
therapy or immunotherapy have un­
fortunately not yet produced the anti­
cipated improvement in recurrence 
or death rates. None the less further 
investigation of these adjuvant meas­
ures is clearly in order. There is al­
ready a suggestion that adjuvant ther­
apy of this type may be beneficial 
in more advanced although resectable
adenocarcinoma or large cell undif­
ferentiated cancers.
Of more immediate importance is 
the evidence that combination ad­
juvant therapy has a significant im­
pact on patients suffering from oat 
cell carcinoma.
Small cell anaplastic carcinoma (oat 
cell).—Special attention has been di­
rected to the oat cell component of 
malignant lung disease because of the 
increasing frequency with which it is 
being recognized and because of the 
extent of the disease when it produces 
symptoms as indicated by the very 
high inoperability (92%) (Table VII) 
and death rates (98% ) (Table V).
It is encouraging to note the high 
response rate (Table VIII) and excel­
lent performance status (Table IX) 
achieved by combination chemother­
apy in 147 patients treated at the 
Toronto General Hospital.6 The rates 
of local and intracranial recurrence 
provide the rationale for the use of 
radiotherapy at these sites (Table X). 
The intracranial disease is sequestered 
from systemic therapy, the rapidity 
of response to the treatment program 
is striking and the appearance of 
long-term survivors encouraging and 
reassuring. Currently, approximately 
20% of such patients can be expected 
to survive longer than 2 years.
Current Challenges for the
Medical Profession
Although these innovations may be 
of great importance to individual pa­
tients, the numbers affected and the 
survival achieved will unfortunately
Table V III Response to Chemotherapy
and Radiotherapy of 147 Patients w ith
Small Cell Anaplastic Lung Carcinoma
Limited Extensive
Response disease disease
Complete 16 \  83% (60% after
4s } 65%Partial 39 /  radiotherapy)
No response 11 28
Total 66 81
have little or no impact on the overall 
salvage rate. If we are to affect the 
increasing prevalence and mortality 
other approaches to management are 
required.
Many problems and failures con­
tinue to plague us (Table XI). We 
have not succeeded in eradicating the 
disease. We have not found ways to 
recognize lung cancer at an earlier and 
more favourable stage. We now have 
no recourse but to concentrate on (a) 
early diagnosis by screening and (b) 
prevention of disease.
Table IX — Perform ance Status 
of 147 Patients w ith Small 
Cell Anaplastic Lung 
Carcinoma afte r Chemotherapy and 
Radiotherapy
Performance
status*
Limited
disease
Extensive
disease
0 15 11
1 47 57
2 4 10
3 0 3
Total 66 81
‘ Standard scale used by Eastern Cooperati­
ve Oncology Group; 0 =  normal ac tiv ity , 1 =  
symptomatic but am bulatory, 2 =  < 5 0 %  
bedridden, 3 =  > 5 0 %  bedridden.
Table X — Incidence and Site of Tumour
Recurrence in 55 Patients w ith Lim ited
Disease Who Responded to Chemotherapy
and Radiotherapy
Site Incidence, %
Local 22
Brain 25
Bone 10
Table X I— Lung Cancer: the “ Problems” 
and the "F a ilu re s”
Preventable disease —  smoking remains 
acceptable social custom 
Prevalence increasing 
M orta lity  increasing 
Early recognition not common 
Results of treatm ent unacceptable
Table V I I— Significance of Cell Type in Bronchogenic Carcinoma (Figures Are Percentages)
Squamous
carcinoma
Undifferentiated  
(large cell) Oat cell Adenocarcinoma Bronchioloalveolar
S ex -m a le 92 84 81 74 72
Inoperable 39 60 92 52 28
Extrathoracic disease 27 37 24 42 40
Mediastinoscopy positive 42 44 68 60 80
(superior mediastinal 
adenopathy present) 
Resectable 58 31 7 39 61
Curative resection 45 19 4 30 44
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Obviously the challenges posed by 
Dr. Graham almost 25 years ago have 
not been resolved.
The Hope for Earlier Diagnosis
by Screening
How can we accept such a poor 
record when the clinical spectrum of 
the disease (Table XII) indicates the 
potential salvage with earlier recog­
nition and prompt treatment? Al­
though this possibility was demon­
strated as early as the 1950s when 
the presence of a clinical spectrum 
was recognized, little progress has been 
made. Several facts underscore the 
difficulty of obtaining enthusiastic sup­
port for screening programs even 
though the disease lends itself well to 
screening techniques:7 (a) it sloughs 
malignant cells from its earliest ap­
pearance (carcinoma in situ), (b) it 
produces warning symptoms (e.g., he­
moptysis, obstructive pneumonitis), 
(c) obstructive phenomena can be re­
cognized radiologically before the ap­
pearance of a radiologically detectable 
shadow and (d) asymptomatic peri­
pheral lesions can be detected radiolo­
gically.
Unfortunately earlier assessments 
of survey roentgenograms or sputum 
cytology were discouraging. However, 
recent re-evaluations have been much 
more encouraging.
1. Radiologic Screening
It is the frequency of screening that 
determines the value of this method. 
The experience of Saito, Sakuma 
and Kakita in Tokyo® can be com­
pared with the findings of Boucot and 
Weiss from the Philadelphia mass 
survey” to put this factor in clear 
perspective (Table XIII).
2. Combined Radiologic and 
Cytologic Screening
The Mayo lung project10 in which 
high-risk smokers were screened 
radiologically and by cytologic exami­
nation of pooled sputum samplings at 
intervals of 4 months and compared 
with a control group subjected to an 
annual clinical examination alone 
clearly indicates the value of frequent 
screening and the primary importance 
of the radiologic studies. The tumour 
is recognized at an earlier stage and 
there is a definite increase in the 
number of curative resections (Table 
XIV). One would therefore expect the 
number of survivors to be greater. 
However, the high number of deaths 
(over 50%) from cardiovascular dis­
ease minimizes the long-term impact
of these improvements. Consequently, 
the disease must he detected early 
enough to overcome the competing 
mortality risk of other cigarette-related 
diseases, particularly coronary artery 
disease. This means we must look for 
still earlier stages of lung cancer as 
exemplified by radiologically occult 
disease. For recovery of these patients 
greater emphasis will have to be 
placed on cytologic screening.
3. Cytologic Screening
Recent evaluations have helped to 
dispel the sense of frustration that 
coloured earlier reports. At a time 
when only bronchography and the 
rigid bronchoscope were available for 
examination of the bronchial tree it 
was difficult to locate the occult 
lesions identified cytologically.
With the introduction of the flexible 
bronchoscope it became possible to 
study the individual segments of the 
lungs in the search for radiologically 
occult lesions. It is now rare for 
these lesions not to be located
Table X II—Clinical Spectrum of
Bronchogenic Carcinoma
Clinical syndrome 5-yr survival, %
Symptomatic disease 5-8
Coin lesion 40
Curative resection 40
Asymptomatic 52
Semioccult disease 70
Occult disease 100
within 3 months of the initial cytologic 
report of the presence of malignant 
cells.
What dividends have been declared?
Definition of carcinoma in situ and 
microinvasive cancer.—The skilled 
cytologist, who has become an integral 
part of the health care team, can now 
identify the presence of carcinoma in 
situ or microinvasive cancer and not 
only frankly invasive disease. This dif­
ferentiation has enormous clinical 
significance for the practising phy­
sician and surgeon.
Patients who have malignant cells 
of the noninvasive type and who suc­
ceed in giving up cigarette smoking 
may slough away the carcinoma in 
situ once the stimulus for malignant 
change is withdrawn, thereby in effect 
curing themselves of their disease 
(Table XV). This was noted in seven 
patients in our original series. They 
represented a group of patients in 
whom localization of the malignant
Table X II I—Value of Radiologic Screening 
in Bronchogenic Carcinoma*
Resectability, 5-yr survival,
Interval % y0
Semiannual 100 54.5 (12f)
Annual 54 22 (4 t)
> 1  yr 39 0
‘ Data obtained from reports of Health Con­
trol Centre, Tokyo Metropolitan Govern­
ment 1976.
(Comparative figures from Philadelphia 
mass survey 1972.
Table X IV—Dividends of Repetitive Screening in Bronchogenic Carcinoma*
Technique
No. of
patients (% )
Screening
interval Number
Curative
resection
3-yr
survival, %
Radiology 112 (80) 1 2 out of 3 50Cytology \ 4 mo 84 (85% stage 1)(alone) 21 (15) ]
Clinical
(alone) 7 (5) annual 56
(symptoms 2 out of 3) <1  out of 3 <20
‘ Data from Mayo lung project (9223 men), 140 “ new” cases.
Table XV—Sputum Cytology Changes in Continuing Smokers 
with Moderate or Marked Dyskaryosis*
Dyskaryosis
Cytologic changes
No. of 
patients Marked dyskaryosis
Malignant
cells
Moderate 44 7 __ y 3
Marked 43 --------- y 3
Total 87 6 (7%)
*Exsmokers: 7 with malignant cells had no further "positive” samplings.
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lesion proved impossible on the in­
itial investigation (before the advent 
of the fiberoptic bronchoscope). If the 
lesion can be located excision is of 
course warranted because of the pos­
sibility that invasive carcinoma may 
coexist with the noninvasive form. To 
determine whether this might be true 
for microinvasive cancers requires fur­
ther study. The observation probably 
explains—in a much larger group of 
patients—why the appearance of a 
second primary cancer is so infrequent 
in cigarette smokers who give up their 
habit following excision of an initially 
invasive cancer. Presumably the other 
areas of multicentric disease, which 
might logically be anticipated in the 
bronchial mucosa of these smokers, 
have not reached the stage of frank 
invasion before the nourishing insult 
is withdrawn.
Definition of hazardous reactive 
epithelial change.—Those who show 
an earlier stage of reactive epithelial 
change (moderate or marked dyskary- 
osis) may evade the steady progres­
sion to malignant disease if they stop 
smoking. In contradistinction, those 
who continue smoking may stimulate 
steadily increasing change to malig­
nant epithelium. There was a 7% (6 
of 87) yield of samplings positive for 
malignant cells when continuing 
smokers who showed significant
dyskaryosis were followed up to 4 
years and the incidence was steadily 
rising at that time (Table XV). In ex­
smokers the dyskaryotic changes sub­
sided. The implications for preventive 
therapy are obvious.
Radiologically occult disease.—Cy­
tologic screening, therefore, plays an 
important role in our attempts to de­
tect changes at the stage when cura­
tive therapy is possible. In the current 
Baltimore study11 the 3-year survival in 
patients with truly occult disease 
stands at 100% and remains at 70% 
in stage I (TtN0) cases even though 
invasive disease is found.
Similarly, our own experience with
radiologically occult disease has not 
shown a single death from the malig­
nant disease in 23 patients from a 
nonindustrial population (Table XVI).
Industrial screening.—A compari­
son with screening in industry shows 
some interesting differences. The re­
sults from our initial screening pro­
grams (Table XVII) had such an un­
rewarding yield (0.1%) of favourable 
cases that it was not thought econ­
omically practical to translate these 
studies into programs for the general 
public (Table XVIII). It was altern­
atively proposed in 1966 that “screen­
ing of asymptomatic cigarette smokers 
should be directed at that segment of 
this high risk population in which 
cigarette smoking acts in concert with 
some other significant form of at­
mospheric pollution, industrial or 
otherwise”.7
The nickel industry was chosen for 
further study and, by 1978, 268 miners 
had been screened with a yield of 12 
cancers (4.4%) including one case of 
paranasal sinus cancer and one of 
laryngeal cancer.12 These miners had 
all been exposed to smoking and to 
atmospheric pollution within the plant. 
Eight additional cases can now be 
added to this series although their 
follow-up information is too recent 
for inclusion in the overall data. Our 
experience with the nickel industry— 
the high number of oat cell cancers, 
the multiple tumours, the recurrences 
and the deaths from the disease— 
clearly differs from the nonindustrial 
experience (Table XVI).
Regional screening.—A continu­
ing search for more producive 
target groups is obviously warranted 
(Table XIX). Such groups will 
be found somewhere, between the 
two extremes. Our experience in 1978 
and 1979 raises again the hope for 
more worthwhile dividends in a com­
munity with continued screening pro­
grams. The practice of routine screen­
ing of employees working in a refinery 
has stimulated interest within the re­
gional community in combined radiol­
ogic and cytologic studies and has en­
couraged referral of smokers from the 
community for similar studies. Dur­
ing this short time five radiologically 
occult lesions have been detected, 
three from the plant workers and two 
from the community population. The 
lesions have all been of squamous 
origin and only one showed an intra- 
lobar adenopathy. All were located by 
fiberoptic bronchoscopy during the 
original investigation; further study 
necessitated a delay of therapy in 
one patient. All are currently free of 
disease. These cases reflect the entire 
gamut of radiologically occult disease 
and were managed as follows:
Case /.—A patient with occult dis­
ease was treated by sleeve resection of 
the upper lobe of the right lung be­
cause of chronic obstructive lung dis­
ease. A preoperative biopsy specimen 
of the right upper lobe showed malig­
nant cells. There was carcinoma in 
situ at the bronchial suture line. The 
patient stopped smoking and no fur­
ther treatment was required. Repeat 
bronchoscopic biopsy has shown no 
residual disease over 3 years.
TableXVIl— Features of Cytologic Screening 
for Lung Cancer in 2799 High-Risk Smokers
Feature Number ( % )
“ Negative” 2575 (92)
Significant dyskaryosis 
“ Positive”
205 (7.3)
19 (0.7)
Lesion located 7 (0.3)
Potentially curative resection 3 (0.1)
Table X V III — In itial Conclusions from  
Study of Cytologic Screening for Lung 
Cancer (1966)
Economically impractical because
(a) Adequate sampling unlikely
(b) Sequential examinations unaccept­
able
(c) Yield of “ positive” samplings unsa-
tis factory
(d) Localization frequently impossible
(e) Incidence of favourable cases disap­
pointing
Table X IX —Initial Recommendations from 
Study of Cytologic Screening for Lung 
Cancer (1966)
Choose target groups more specifically 
Smoking in conjunction with other car­
cinogenic exposure 
Industrial risks 
Atmospheric pollution 
Semioccult disease (radiologically occult) 
Hemoptysis
Obstructive (stasis) pneumonitis
Table XVI —Cytologically Detected Lung Cancer in Patients with 
Radiologically Occult Disease
Characteristic
Nonindustrial
population
Nickel industry 
screening program*
Resection 23 10
Pathology 96% squamous carcinoma >40%  small cell carcinoma
Multicentric cancer 0 1
Second primary cancer 0 2
Adenopathy 0 1
Recurrent cancer 0 2
Death from lung cancer 0 1
*268 miners screened: 12 (4.4%) had lung cancer. Sinus carcinoma and laryngeal carcinoma 
were also detected.
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Case 2.—Suspicious cells (i.e., not 
diagnostic of carcinoma) were found 
in the sputum of this patient with an 
occult lesion. The lesion was visualized 
bronchoscopically below the orifice of 
the middle lobe of the right lung. At 
thoracotomy a palpable lesion was 
found with one local node showing 
metastatic disease. Lobectomy of the 
right and middle lower lobes was car­
ried out. There was residual carci­
noma in situ at the bronchial stump. 
The patient stopped smoking. Repeat 
bronchoscopic biopsy showed no resi­
dual disease at 1 year.
Case 3.—This patient had a semi­
occult lesion with hemoptysis. A tiny 
lesion (anterior basic segment) of the 
right lung was visualized broncho­
scopically. A biopsy specimen showed 
malignant cells. Right lower lobe 
lobectomy was performed. The patient 
is well l'/i years after operation.
Case 4 .—A patient with a semi­
occult lesion had obstructive (stasis) 
pneumonitis. Microinvasive carcinoma 
was found at the bronchial stump of 
an initial left upper lobe lobectomy. 
Pneumonectomy was performed. The 
bronchial stump was free of disease, 
but there was extensive “carpet” tu­
mour within the upper lobe bronchus 
and its subdivisions. This patient re­
mains well at Vh years.
Case 5.—The patient had a chronic 
granulomatous lesion at the apex of 
the right lung, unrelated to bilateral 
occult disease (left upper lobe, right 
middle lobe). The patient continued to 
smoke cigarettes and the carcinoma in 
situ progressed to invasive cancer as 
follows: On May 16, 1979 the pa­
tient was asymptomatic but sputum 
cytology showed the presence of squa­
mous carcinoma. Fine needle biopsy 
of the right upper lobe lesion showed 
no evidence of malignant disease. On 
June 4. 1979, brushings from the left 
upper lobe (LB 1 and 2) showed squa­
mous carcinoma (invasive type). On 
Aug. 8, 1979 brushings LB 1 and 2 
again showed invasive squamous car­
cinoma and brushings from the right 
middle lobe (RB 4) showed in-situ 
squamous carcinoma. One week later 
similar brushings again showed squa­
mous carcinoma in situ. On Aug. 21,
1979 a left upper lobectomy was car­
ried out. Microinvasive squamous car­
cinoma, LB 1 and 2, was found. Cy­
tologic examination of the sputum on 
Dec. 11 showed in-situ squamous car­
cinoma. On Jan. 22, 1980 brushings 
from RB 4 showed microinvasive 
squamous carcinoma and on Jan. 28,
1980 right middle lobe lobectomy de­
monstrated the presence of microin­
vasive squamous carcinoma of RB 4 
(extensive in situ squamous carcinoma 
—'“carpet” tumour). Brushing, wash­
ing and biopsy findings of all other 
segments showed no carcinoma.
Reasonably good results can be ob­
tained so we must learn how to use
these screening techniques to maxi­
mum advantage. The Mayo Clinic lung 
project suggests that the cost is not 
prohibitive. With increasing use the 
dividends and the cost experience are 
bound to improve and once this point 
has been reached more enthusiastic 
support can be anticipated. The im­
portance of the challenge will permit 
nothing less.
Prevention of Disease
Although I hesitate to belabour this 
point we simply cannot ignore the fact 
that lung cancer is largely preventable. 
The toll taken in illness, disability and 
premature death is one of the major 
tragedies of our time.
If the medical profession can make 
a greater commitment to prevention 
the impact would assuredly be dra­
matic since the public continues to 
look to the profession for example, 
leadership and advice in all matters 
of health.
Doctors’ advice to abstain carries 
more influence than any other single 
factor in a smoker’s decision to give 
up his habit. This advice may be 
offered in two different settings: (a) 
office encouragement of smoking pa­
tients to stop and (b) by smoker par­
ticipation in group therapy. In the 
office the advice cannot be restricted 
to facts alone but must include an ex­
planation of the steps to be taken in 
ensuring success. The patient primarily 
wants to know how to stop. Certain 
fundamentals can be reiterated: identi­
fy the smoking pattern, isolate the 
smoking habit, develop alternatives to 
smoking and, the final step, confirm 
nonsmoking status. When group ther­
apy is carried out in properly con­
structed groups which are small and 
homogeneous and when repetitive 
courses are provided, successful total 
abstention at the end of a year can 
be anticipated in over 50% of the 
participants.13 The effort is therefore 
eminently worthwhile.
Admittedly the sentimental recol­
lection of the physician as the person 
who was “all things to all people” is a 
thing of the past. None the less, al­
though our professionalism now pos­
sesses a keener insight and a sharper 
edge, we can no longer evade the de­
manding responsibility of protecting 
the health of the public as well as that 
of treating the ill.
We, as physicians, may resent the 
additional load that this role implies 
since the traditional view still persists 
in many areas that provision of relief 
from symptomatic disease fulfils our 
responsibilities. Today medical re­
sponsibilities cannot end there. Health
promotion has become a major duty 
for the physician and failure to use a 
real opportunity to dissuade the 
smoker from continuing his habit can 
no longer be accepted.
Implications for the Future
These observations imply a subtle 
change in the philosophy of practice 
in the years to come.
In the recent past the changing 
nature of the physician-patient rela­
tionship led to a reappraisal of the 
profession by the public— a reap­
praisal currently not entirely to our 
credit. Quite obviously most of the 
blemishes which are considered to sul­
ly our reputation are related to mat­
ters beyond our control. Too little 
has been made—at least in the public 
mind—of the enormously important 
advances that have been made as the 
direct result of professional interest 
in marshalling new information and 
applying it to the welfare of the pa­
tient. Public questioning of profes­
sional competence and judgement 
should no longer go unchallenged.
Nevertheless, the public continues 
to look to the profession for leader­
ship in all matters of health. This 
poses an undeniable challenge to 
provide “care” at all stages of disease. 
The public has a right to this care 
from the profession. We, in turn, must 
keep reminding ourselves that we treat 
patients and not diseases. Frequently 
we seem to forget this in the face of 
the overwhelming deluge of new 
discoveries and treatment resources 
with which we have to keep abreast.
In attending to the needs of pa­
tients with malignant disease, this 
“care” must encompass the entire dis­
ease spectrum from carcinogenesis to 
terminal care. The local lesion is in­
deed but an incident in the natural 
history of the disease. In accomplish­
ing this purpose, a team approach is 
mandatory. Physicians of all disci­
plines must be involved since they 
must deal with all stages of the natural 
history of the disease. Actually, if 
maximum benefits are to be achieved, 
the team approach will involve the 
public sector as well as the profes­
sional disciplines. Development of this 
team concept may in fact anticipate 
the real golden age of surgery.
If our social system is to work ef­
fectively in this type of interplay, the 
advantaged or the endowed must play 
a major role in ensuring the welfare 
of the disadvantaged or the unen­
dowed. This means that the medical 
profession must assume responsibilities 
that are supplementary to the tradi-
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tional role of the physician in dealing 
with established symptomatic disease.
Let us then briefly review the 
natural history of lung cancer and the 
manner in which professional respon­
sibilities are designed to fit the needs 
of the sequential changes in the dis­
ease spectrum.
•  At the stage of carcinogenesis, 
prevention, because it is feasible, re­
presents the most exciting future pro­
spect.
•  Once the primary lesion is estab­
lished it must be recognized early 
(while it is biologically favourable for 
treatment) and treated promptly, (a) 
Practical screening measures for high 
risk groups must be implemented and 
(b) treatment must be individualized, 
based on the tumour-host equation 
that is defined by the biologic and 
technical staging of the disease.
•  The situations in which the tu­
mour-host interplay makes dissemina­
tion probable have to be recognized 
and systemic therapy for the occult 
systemic disease should be used.
•  When the terminal stage is 
reached the patient must not be de­
serted. Medical “care” becomes even 
more important. The patient in this 
situation deserves active quality care 
by a team of dedicated practitioners 
of the art provided with the equip­
ment and facilities with which to pro­
duce this service.
How can we fail but respond to
these exciting challenges when current 
knowledge shows us the prospect of 
meeting the challenges effectively? By 
demonstrating our real concern for the 
welfare of the public, we can correct 
the misconceptions that colour the 
manner in which we are all too fre­
quently viewed by them. Once our 
motives are no longer suspect a true 
partnership between the public and 
the profession can again flourish, as 
trust replaces suspicion, confidence 
replaces doubt and the patient-doctor 
relationship regains its humanitarian 
basis.
Dr. Gallie would applaud such a 
happy turn of events. He frequently 
referred to his belief that the profes­
sion should primarily be concerned 
with the health of the public,14 im­
plying this to be preferable to the 
treatment of symptomatic disease. He 
would be excited and enthusiastic 
about these prospects and without hesi­
tation would wish us well—with the 
unfailing and always sincere toast to 
our success!
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Items 539-542
(A) Medullary carcinoma of thyroid gland
(B) Pheochromocytoma
(C) Malignant sacrococcygeal teratoma
(D) Metastatic carcinoid tumor
(E) Carcinoma of sigmoid colon
539. Elevated a-fetoprotein
540. Elevated serum calcitonin
541. Elevated urinary catecholamines
542. Elevated urinary 5-hydroxyindoleacetic acid (5-HIAA)
For each numbered phrase above, select the one lettered heading that is 
most closely associated with it. Each lettered heading may be selected once, 
more than once, or not at all.
For the critique of Items 539-542 see page 595 of this issue.
(Reproduced by permission from SESAP 111 Syllabus: Surgical Education 
and Self-assessment Program No. 3. For enrolment in the Surgical Educa­
tion and Self-assessment Program No. 3, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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CANADIAN ONCOLOGY SOCIETY
Suppressive Therapy for Postirradiation Thyroid Nodules
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From the thyroid screening program 
at the Roswell Park Memorial Institute 
in Buffalo, New York, 85 patients 
with thyroid nodules who had received 
previous irradiation to the head and 
neck were identified. The diagnosis 
was confirmed microscopically by 
needle aspiration cytology and the 
patients were treated with thyroid 
replacement therapy. In 24 patients, 
the nodules disappeared completely; 
a partial response (more than 50% 
reduction in size) was seen in 26;
11 patients were improved (20% to 
50% reduction in size); 14 had stable 
disease (less than 20% reduction in 
nodule size) and in 10 the condition 
progressed (an increase of more than 
20% in nodule size). Six of 21 
patients who underwent operation 
had well differentiated tumours. The 
number of cases of Hashimoto’s 
thyroiditis (14) was high.
Suppressive therapy will separate 
those patients whose nodules will 
disappear completely and who will 
thus be spared operation. Continued 
follow-up of such patients is essential. 
All other patients should be offered 
operation since thyroid nodules are 
malignant in 30% of cases.
A partir du programme de depistage 
des maladies thyroi'diennes du Roswell 
Park Memorial Institute de Buffalo,
From the departments of *medical oncology, t developmental therapeutics, Xhead and neck surgery, Eradiation medicine and f pathology, Roswell Park Memorial Institute, Buffalo, NY
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etat de New York, on a identifie 
85 porteurs de nodules thyroidiens qui 
avaient prealablement recu une 
irradiation de la region de la tete et 
du cou. Le diagnostic fut confirme 
au microscope par cytologie a 
I aiguille et les malades regurent une 
thyrotherapie suppletive. Chez 24 
patients, les nodules disparurent 
completement; 26 autres patients 
montrerent une reponse partielle 
(avec une reduction de plus de 50% 
de la taille des nodules); 11 malades 
furent ameliores (reduction de taille 
de 20 a 50%); 14 presentment 
une maladie stable (moins de 20% 
de reduction de la taille des nodules) 
et la pathologie evolua chez 10 
(augmentation de plus de 20% de la 
taille des nodules). Six des 21 patients 
qui subirent une operation montrerent 
des tumeurs bien differenciees. On 
observa un nombre eleve de 
thyroidites chroniques de Hashimoto.
Un traitement suppressif permettra 
de separer les malades dont les 
nodules disparaitront completement 
et qui pourront done eviter I'operation. 
Une surveillance continue de ces 
patients est essentielle. Tous les autres 
patients devraient se voir offrir 
I'operation puisque les nodules 
thyroidiens sont malins dans 30% 
des cas.
The treatment of thymic enlargement 
in infancy by external irradiation was 
first reported in 1907' and was enthu­
siastically received because the mor­
tality for thymectomy was over 50%. 
For the next 50 years, external irra­
diation to the head, neck and upper 
thorax was common for a variety of 
other benign conditions including ton­
sillitis, cervical lymphadenitis, acne 
vulgaris, tinea capitis and vascular 
malformations. In 1950, Duffy and 
Fitzgerald2 drew attention to the
association of thyroid carcinoma with 
previous thymic irradiation. Since then 
numerous studies have confirmed the 
increased prevalence of benign and 
malignant thyroid disease occurring 
many years after irradiation. It is 
estimated that for every rad of radia­
tion there will be two to five more 
cases of thyroid cancer per million 
people annually.3 Many screening pro­
grams have been initiated and our own 
results with such a program have been 
reported.4
Many authorities believe all patients 
at high risk for goitre should receive 
suppressive therapy with thyroactive 
agents. Our preliminary data have 
indicated that the response of nodular 
goitre to suppressive therapy is sim­
ilar in irradiated and nonirradiated 
glands.5 The present study was under­
taken to evaluate this question further 
and to compare the effectiveness of 
liothyronine (T3) with desiccated thy­
roid in shrinking nodular goitre.
Patients and Methods
During its first year, 735 patients 
were studied as part of the Roswell 
Park Memorial Institute (RPMI) 
screening program. Physical examina­
tion of the head and neck was per­
formed together with a complete 
blood count and SMA 12 biochem­
ical analysis. The erythrocyte sedi­
mentation rate was measured and the 
serum thyroxine (T4) level was estim­
ated by radioimmunoassay.
For patients with palpable thyroid 
abnormalities, 6-hour uptake and thy­
roid imaging were performed using 
iodine-123 and a scintillation camera 
with a pinhole collimator. Additional 
laboratory tests included radioimmu­
noassay for serum triiodothyronine 
(T3), thyroid-stimulating hormone 
(TSH), circulating thyroglobulin and 
thyroxin-binding globulin (TBG) and
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measurement of antithyroglobulin and 
antimicrosomal antibodies. All patients 
underwent indirect laryngoscopy. With 
informed consent, needle aspiration 
was performed in most patients as 
previously described.6 Single or mul­
tiple nodules and diffuse enlargements 
were aspirated at the first visit and 
aspiration was repeated if cells were 
not obtained or were suggestive of 
malignancy. Patients participating in 
the study were stratified according to 
the site irradiated (for conditions of 
the thymus, tonsils and adenoids, for 
acne and for miscellaneous condi­
tions), and were randomized to re­
ceive either liothyronine (T3) (50 u.g/ 
d) or desiccated thyroid (120 m g/d). 
Increased dosage was permitted after 
2 months of treatment if the TSH level 
failed to decrease to less than 0.3 uU/ 
ml (normal less than 4.6 txU/ml). 
Decreased dosage of 50% was also 
permitted when signs of thyrotoxicity 
were present. Patients were seen by 
the same investigator at monthly in­
tervals for 6 months. All nodules were 
measured in two dimensions and the 
product of the measurements was 
calculated for comparison with the 
baseline value. Complete response was 
defined as complete and sustained 
disappearance of the nodule and par­
tial response as a decrease of more 
than 50% in the calculated nodule 
area. Improvement was considered to 
be a 20% to 50% decrease in area 
and stable disease any reduction less 
than 20%. The nodule was considered 
to have progressed if there was an in­
crease of more than 20% of the base­
line size.
Patients whose nodules had disap­
peared were maintained bn suppressive
therapy. All others were offered 
operation.
Of the 735 patients examined, 159 
(21.6%) had palpable nodules. Of 
these, 90 patients agreed to participate 
in this study. Eighty-five of the 90 
patients were available for re-evalua­
tion at the end of the first year. There 
were 29 men and 56 women. The 
mean age was 39 years (range 16 to 
72 years).
Results
As shown in Table I, there was no 
difference in response between liothy­
ronine and desiccated thyroid. Twen­
ty-four patients (28.2%) achieved a 
complete response and 26 (30.2%) 
achieved a partial response. Operation 
was recommended for all 61 patients 
who did not have a complete response. 
Twenty-one patients consented. One 
patient with a partial response was 
found at operation to have a follicular 
carcinoma and three with stable dis­
ease had papillary carcinomas; two 
patients with progression were also 
found to have papillary carcinomas 
(Table II). One of these patients had 
had an initial transient complete re­
sponse. Histologically many glands 
showed more than one abnormality. 
Eight (38%) of the 21 patients had 
histologic changes typical of Hashi- 
moto’s thyroiditis and 7 (33%) had 
nonspecific thyroiditis. Of the 24 pa­
tients who achieved a complete re­
sponse 6 had significantly elevated 
antimicrosomal and antithyroglobulin 
titres.
Discussion
Shimaoka and Sokal,7 in a double­
blind study of suppressive therapy for 
nontoxic goitre, found a significantly 
better response to T3 than to T4. 
We did not find any difference 
between liothyronine (T3) and de­
siccated thyroid in this study (Table 
I). When these studies are considered 
together, 28 (70%) of 40 irradiated 
patients and 40 (73%) of 55 non- 
irradiated patients treated with T3 
showed a decrease in nodule size of 
more than 20%. Complete remission 
in patients treated with T3 is not sig­
nificantly higher in the irradiated 
group (11 of 40) than the nonir- 
radiated group (6 of 55) (P =  0.075, 
X2 analysis). However, when the two 
groups of patients are compared re­
gardless of the type of suppressive 
therapy, a complete response in the 
irradiated group (24 of 85) was sig­
nificantly (P <  0.005) more frequent 
than in the nonirradiated group (13 of 
114). Patients in the nonirradiated 
group were a mean of 9 years older 
than those of the irradiated group; 
part of the difference may be due to 
this, as it is possible that they had a 
greater bulk of disease.
It is postulated that, following irra­
diation, chromosomal and other 
damage occurs within thyroid cells 
and, with hypofunction of the gland, 
continued stimulation by TSH pro­
motes hyperplasia, adenomatous 
change and ultimately carcinoma.8'9 
These thyroid tumours, therefore, ap­
pear to be endocrine dependent and 
for more than 40 years thyroid car­
cinoma has been known to regress in 
patients given desiccated thyroid.10 In 
a review of 19 patients with metastatic 
papillary carcinoma, 12 responded for 
5 to 16 years (mean 11 years).11 Re­
sponse was best in patients under 40 
years of age who had received radia­
tion therapy to the neck for benign 
disease. Similar results were noted 
by DePapp, Pincus and Hempel- 
mann,12 who observed responses of 
both benign and malignant nodules. 
Most malignant nodules, however, re­
main unchanged or increase in size.13-14
All of our patients who achieved 
a complete response were maintained 
on thyroid hormone and are being 
followed up at 3- to 6-month intervals. 
One patient who achieved a complete 
response initially but whose disease 
then progressed was found to have 
carcinoma, reaffirming the impor­
tance of close follow-up in this group 
of patients. Operation was performed 
in 21 patients and in 6 (28.6%) a 
malignant lesion was found. All tu­
mours were well differentiated.
Of the 24 patients who achieved
Table I—Suppressive Therapy: Liothyronine (T 3) versus Desiccated Thyroid (DT)
No. of patients
Result T3 DT
Total no. 
of patients
Complete response (100% regression) 11 13 24
Partial response (> 50%  regression) 11 15 26
Improvement ( >  20% regression) 6 5 11
Stable disease ( ^ 20% regression) 7 7 14
Progression (> 20% ) 5 5 10
Total 40 45 85
Table II--Histologic Findings in Thyroid Nodules
Suppressive
agent Carcinoma Thyroiditis Fibrosis
Other
benign
conditions
Total no. 
of patients
t 3 4 7 6 6 11
DT 2 8 9 7 10
Total 6 15 15 13 21
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a complete response, 6 (25%) had 
laboratory and cytologic findings com­
patible with Hashimoto’s thyroiditis. 
Of the 21 who underwent operation, 8 
(38.1%) had histologic changes ty­
pical of Hashimoto’s thyroiditis and 
7 (33.3%) showed nonspecific lym­
phocytic thyroiditis, but did not have 
typical findings of Hashimoto’s dis­
ease. This condition appears to be a 
late sequel to irradiation and may 
coexist with carcinoma.
We conclude that patients in whom 
thyroid nodules develop following 
irradiation exposure to the head and 
neck are sensitive to thyroid suppres­
sion therapy. All patients who do not 
have a complete remission should be 
offered operation, as the incidence of 
malignant change in a screened popu­
lation such as ours approximates 30%. 
Many patients who may harbour min­
imal carcinoma (less than 1 cm in dia­
meter) in their thyroid gland decline 
operation; they should be treated with 
suppressive agents and followed up 
closely. There is a high rate of 
Hashimoto’s thyroiditis and some 
patients with this condition also re­
pond to thyroid suppression. Patients 
in whom a benign lesion has been 
found at operation and who have 
residual thyroid tissue should remain 
on suppressive therapy indefinitely in 
an attempt to prevent new lesions de­
veloping in the thyroid remnant.
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Does Vascular Steal Occur following Femorofemoral
Bypass Grafting?
R.W. Landymore, md, C.E. K inley, md, frcs[c] and A.E. Marble, m eng, p eng
r
Vascular steal has been reported 
following aortoiliac and crossover 
femoral vascular reconstruction. 
Although the steal phenomenon has 
been described in clinical situations 
some have denied its existence. The 
authors attempted to determine 
whether or not vascular steal occurs 
after femorofemoral bypass operation.
Fifteen adult mongrel dogs under­
went femorofemoral bypass grafting. 
Stenosis of the iliac artery was 
simulated with a specially designed 
device. Blood flow was measured with 
the femoral graft open and closed in 
combination with superficial femoral 
and deep femoral artery obstruction 
in the donor and recipient circulations. 
There was no statistically significant 
decrease in flow to the donor leg in 
any situation. Thus the authors 
conclude that vascular steal does not 
occur following femorofemoral bypass 
operation.
Un detournement de I'apport circula- 
toire a ete signale a la suite de la 
reconstruction vasculaire de I’aorte 
iliaque avec entrecroisement de la 
femorale. Bien que le phenomene de 
detournement ait ete decrit dans 
des situations cliniques, certains en 
ont nie I'existence. Les auteurs ont 
tente de determiner si oui ou non 
un detournement de I'apport circula- 
toire survient apres une operation 
de pontage femoro-femoral.
Quinze chiens batards adultes 
subirent un pontage femoro-femoral.
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Une stenose de I'artere iliaque fut 
simulee a I’aide d'un appareil 
specialement concu a cette fin. Le 
debit sanguin fut mesure dans la 
circulation des vaisseaux donneur et 
recepteur alors que la greffe femorale 
etait ouverte ou fermee, en association 
avec une obstruction superficielle ou 
profonde de I’artere femorale. On n'a 
enregistre aucune diminution statis- 
tiquement significative du debit vers 
la patte donneuse dans aucune 
situation. Les auteurs concluent done 
qu'il n'y a pas de detournement de 
I'apport circulatoire a la suite 
d’un pontage femoro-femoral.
Vascular steal is a concept that has 
been used to account for the onset of 
ischemic symptoms resulting from re­
distribution of blood flow in two ad­
jacent vascular beds. Following 
femorofemoral bypass grafting blood 
flow is diverted to the ischemic limb 
at the expense of the donor circula­tion.
Although the steal phenomenon 
has been reported following cross­
over femoral bypass,12 some3,4 have 
denied its existence.
The purpose of this study was to 
determine whether or not vascular 
steal occurs following femorofemoral 
bypass grafting.
M aterials and Methods
Anesthesia was induced in 15 adult 
mongrel dogs (weight 24 to 33 kg) with a combination of fentanyl citrate and droperidol. Anesthesia was main­
tained with the aid of endotracheal 
intubation and a model 607 Harvard 
volume respirator (Harvard Appa­ratus Co., Millis, Mass.) with room air.
The surgical preparation is illus­
trated diagrammatically in Fig. 1. 
Blood pressure was monitored with a no. 6 French arterial catheter in­
serted through the left carotid artery 
and positioned in the distal abdomi­
nal aorta. Venous pressure was moni­
tored with a second no. 6 French 
catheter inserted through the left 
external jugular vein and positioned 
in the proximal inferior vena cava. 
These catheters were connected to a 
P23dB Statham transducer and a 
Statham SP1400 pressure monitoring unit (Statham Instruments, Oxnard, 
Calif.). Blood flows were measured 
by means of the Statham SP2201 
electromagnetic flowmeter and asso­
ciated flow probes (Statham Instru­
ments). The instruments were cali­
brated using the procedure outlined by Marble and Paasche.5 Blood pres­
sure was maintained with intravenous 
infusions of Ringer’s lactate solution.
FIG. 1—Dog preparation. A =  aorta, Cl =  common iliac artery, CF =  com­mon femoral artery, PF =  deep femoral artery, II -  internal iliac artery and SD =  stenosing device.
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The animals also received heparin (1 
mg/kg body weight) intravenously.
The iliac and femoral arterial sys­
tems were exposed through bilateral 
extraperitoneal inguinal incisions. 
Crossover grafts were created utiliz­
ing a 5-mm double velour-knitted 
Dacron prosthesis. An end-to-side 
anastomosis was carried out between 
both common femoral arteries using 
continuous 5-0 Prolene suture. The 
graft was brought out externally to 
avoid any possibility of kinking that 
might occur in a subcutaneous tun­
nel. Iliac stenosis was simulated with 
a specially constructed plastic occlud­
ing device (Fig. 2), designed to pro­
duce 75% reduction of luminal area 
and constructed in accordance with 
the mathematical relation between 
critical stenosis and reduction in dis­
tal flow described by Young, Cholvin 
and Roth.6 Obstruction of the super­
ficial femoral artery, deep femoral 
artery and graft was simulated with 
bulldog clamps. Blood flows were 
measured before and upon comple­
tion of the crossover femoral graft 
to ensure that blood flow was not 
obstructed because of poor surgical 
technique. The occluding device was 
then inserted into the left common 
iliac artery to simulate unilateral iliac 
stenosis. Blood flow was recorded 
with combinations of superficial fe­
moral and deep femoral artery ob­
struction with the crossover graft 
open and closed.
The paired Student’s f-test was 
used to determine statistical signifi­
cance and results were reported as 
mean values with their associated 
standard errors.
Results
The initial flow measurements are 
illustrated in Table I. Before the 
crossover femoral graft was con­
structed there was no significant dif­
ference in flow to the two extremities. 
This was also true after grafting.
FIG. 2— Iliac stenosing device.
indicating that the operative proce­
dure had not jeopardized the flow 
distal to the graft. Flow in the left 
common femoral artery was signifi­
cantly reduced (P <  0.01) following 
construction of left iliac stenosis.
Table II sets forth mean flow 
measurements obtained following 
crossover femoral grafting with com­
binations of superficial femoral and 
deep femoral artery obstruction. In 
each case flow was measured with 
the graft open and closed to deter­
mine if vascular steal occurred in the 
donor leg. No statistically significant 
reduction in flow to the donor leg 
occurred following crossover femoral 
grafting with any of the combinations 
of superficial femoral and deep 
femoral artery obstruction, indicating 
that vascular steal was not present.
Femorofemoral bypass for unila­
teral iliac stenosis resulted in in­
creased flow to the recipient leg in 
each case. The increase in perfusion 
was statistically significant when 
crossover grafting was associated with 
obstruction of the superficial femoral 
artery (P <  0.01) and obstruction 
of the combined superficial and deep 
femoral arteries (P <  0.05) in the 
donor leg.
Discussion
Crossover grafting was first de­
scribed by McCaughan and Kahn7 
in 1960 to treat poor-risk patients 
with unilateral iliofemoral occlusive 
disease. Since their original descrip­
tion the procedure has been widely 
used.1-3-8-9
Traditionally, aortoiliac occlusive 
disease has been managed surgically
T a b le  1— P ro f ile  o f Dog P re p a ra t io n
T im e  o f m e a s u re m e n t
C om m on fe m o ra l F lo w , m l/m in
a r te ry (m e a n  ±  S E M )
B e fo re  g r a f t in g R ig h t 177 ±  13
L e ft 176 ±  15
A f te r  g r a f t in g -
g r a f t  c losed R ig h t 181 ±  17
L e ft 187 ±  20
A f te r  g r a f t in g -  
g r a f t  c lo s e d  and  le f t
il ia c  a r te r y  s tenosed R ig h t 204 d= 18
L e ft 100 ±  13
*W e ig h t, ra n g e  24 to  33 kg (m e a n  28.6 k g ); h em o g lo b in  v a lu e , ra n g e  11 to  47 m g /d l (m e a n  13.1
m g /d l) ;  p a c k e d -c e ll v o lu m e , ran g e  3 4 %  to  4 4 %  (m e a n  3 9 .5 % ).
T a b le  I I - F lo w  M ea s u re m e n ts  fo llo w in g  C ro s s o v e r G ra ft in g
F lo w , m l/m in  (m e a n  d= S E M )
H e m o d yn am ic  s ta tu s
R ig h t com m on fe m o ra l a r te ry  
G ra ft c losed G ra ft  open
L e ft  com m on fe m o ra l a r te ry  
G ra ft  c losed  G ra ft  open
S u p e rf ic ia l fe m o ra l  
a r te ry  o b s tru c tio n , 
d o n o r leg 40 ±  6 40 =fc 7 132 d= 26 170 ±  23
S u p e rf ic ia l fe m o ra l  
a r te r y  o b s tru c tio n ,  
re c ip ie n t  le g 160 ±  19 158 ±  19 34 ±  7 44 ±  6
S u p e rf ic ia l fe m o ra l  
a r te ry  o b s tru c tio n ,  
b o th  legs 43 ±  7 44 ±  7 40 ±  8 56 ±  7
S u p e rf ic ia l fe m o ra l  
a r te ry  o b s tru c tio n ,  
d o n o r leg  a n d  deep  
fe m o ra l a r t e r y  s te n o s is , 
d o n o r leg 28 ±  8 28 ±  6 105 ±  18 116 ±  18
S u p e rf ic ia l fe m o ra l  
a r te r y  o b s tru c tio n ,  
re c ip ie n t  le g  and  
d e e p  fe m o ra l a r te ry  
s te n o s is , d o n o r  leg 110 ±  22 100 ±  18 25 ±  9 38 ±  12
B ila te ra l  s u p e r f ic ia l  
fe m o ra l a r te ry  
o b s tru c tio n  a n d  deep  
fe m o ra l a r te r y  s te n o s is , 
d o n o r leg 22 ±  8 25 d= 7 29 ±  8 42 =fc 16
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by replacing the obstructed seg­
ment with a unilateral or bilateral 
Dacron prosthesis with good relief of 
symptoms and with average long­
term patency rates of 80% .1014 How­
ever, these operations result in a 
higher morbidity and operative mor­
tality3 compared with low-risk cross­
over femora] bypass operations.
Originally, the use of crossover 
grafts was restricted to high-risk pa­
tients who were considered unable to 
withstand a major surgical proce­
d u re .'" '5 Recently the indications for 
this operation have been expanded 
and some3,8 are now suggesting that 
crossover grafting should be used as 
the initial procedure of choice.
With the widespread use of recon­
structive vascular procedures in the 
management of peripheral vascular 
insufficiency there have been nu­
merous reports alluding to the pres­
ence of vascular steal.1’*'15'1" The 
phenomenon was first described in 
patients following aortoiliac recon­
struction"'15'7'"1 to explain the sudden 
onset of mesenteric ischemia in the 
early postoperative period. Vascular 
steal was attributed to a sudden redis­
tribution of flow to the extremities at 
the expense of the mesenteric circula­
tion.
Although vascular steal has been 
reported following femorofemoral by­
pass,20'22 some authors3’4 have ques­
tioned its existence. Ehrenfeld. Harris 
and Wylie4 failed to demonstrate it 
in dogs with unilateral iliac stenosis 
following crossover grafting. No at­
tempt was made in this study to de­
termine the effect of significant out­
flow tract obstruction on the redistri­
bution of blood flow. If a steal phe­
nomenon does exist, it would be more 
likely to occur in a situation in which 
the vascular resistance is higher in the 
donor than in the recipient circula­
tion. Femorofemoral bypass in this 
situation conceivably results in in­
creased flow to the recipient circula­
tion at the expense of the donor cir­
culation because blood flow is always 
distributed to the vascular bed with 
the lowest resistance.
Our study was designed to deter­
mine the effect of serious peripheral 
vascular occlusive disease in the 
donor circulation on blood flow fol­
lowing crossover vascular reconstruc­
tion. From combinations of outflow 
tract obstruction in the donor and 
recipient circulations with associated 
unilateral iliac artery stenosis we 
found no statistically significant re­
duction in blood flow to the donor 
leg after crossover grafting. Acute 
ischemia in the donor limb after by­
pass surgery that has been reported 
by others1,17 might be explained by 
the fact that the donor circulation 
was jeopardized at the time of opera­
tion. Our results suggest that the 
acute ischemia observed in the donor 
limb following femorofemoral bypass 
is not truly representative of vascu­
lar steal.
We conclude that vascular steal 
does not occur as a result of femoro­
femoral bypass operation.
We thank J.A. Love and A. Fenton 
for their technical assistance and Mrs. 
Sandra Martin for preparing the manu­
script.
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Complications of Ventriculoatrial and 
Ventriculoperitoneal Shunts in a New Children’s Hospital
L.P. Ivan, md, frcs[c], facs,* S.H. Choo, md|  and E.C.G. Ventureyra, md, frcs[c]J
At a new children's hospital between 
1974 and 1978, 125 patients underwent 
243 shunt procedures performed by 
six neurosurgeons. In spite of diverse 
techniques used, the overall results 
were acceptable. Seventy-seven 
patients required 118 shunt revisions. 
The mortality related to the shunt 
procedures of 7.2% and the infection 
rate of 14.4% were comparable to 
those of other series reported during 
the same period. Ventriculoatrial 
shunts, although fewer in number, 
required fewer revisions (20 revisions 
of 18 shunts) than ventriculoperitoneal 
shunts (97 revisions of 58 shunts) 
for which the variation in technique 
was larger. A sharp decline in the 
complication rate was noted during 
the last year of the study.
Entre 1974 et 1978, dans un nouvel 
hopital pour enfants, 125 malades 
ont subi 243 operations de derivation 
pratiquees par six neurochirurgiens.
En depit du fait que des techniques 
diverses ont ete utilisees, les 
resultats d’ensemble sont acceptables. 
Soixante-dix-sept patients ont 
necessite 118 revisions. La mortalite 
reliee a I'operation de derivation 
a ete de 7.2% et le taux d’infection 
de 14.4%: ceci est comparable aux 
taux signales dans d'autres series 
au cours de la meme periode. Les 
derivations ventriculo-auriculaires, 
bien que moins nombreuses, ont 
necessite moins de revisions (20 
revisions pour 18 derivations) que les 
derivations ventriculo-peritoneales 
(97 revisions pour 58 derivations) pour 
lesquelles les variations de techniques
From the division of neurosurgery, Children’s Hospital of Eastern Ontario and the faculty of medicine,University o f Ottawa, Ottawa, Ont.
:,Head, division of neurosurgery, Children’s Hospital of Eastern Ontario, Ottawa
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ont ete plus nombreuses. Une baisse 
nette du taux d’infections a ete 
observee au cours de la derniere 
annee de I’etude.
Infection and blockage are the major 
problems of cerebrospinal fluid shunt­
ing procedures. This report studies 
the use of both ventriculoatrial and 
ventriculoperitoneal shunts in 125 con­
secutive patients with hydrocephalus 
admitted to a new children's hospital 
during the first 4 years of its opera­
tion. A standardized antibiotic regi­
men and operative protocol allowed 
some reduction in the rate of infec­
tious complications during the last 
year of the study.
Patients
Between Aug. 1, 1974 and July 31, 
1978, 125 patients with hydrocephalus 
(68 boys, 57 girls) were treated by six 
neurosurgeons at the Children’s Hos­
pital of Eastern Ontario in Ottawa. 
Their ages ranged from newborn to 
16 years. The follow-up was for a 
minimum of 10 months. One third of
the patients were newborn infants with 
associated myelomeningocele.
One hundred primary ventriculo­
peritoneal shunts were placed (group 
1) and 24 primary ventriculoatrial 
shunts were placed (group 2). One 
patient with a lumboperitoneal shunt 
done in another centre was later ad­
mitted to the Children’s Hospital of 
Eastern Ontario for shunt revision.
Causes
Aqueduct stenosis was the cause of 
hydrocephalus in 16 cases (13%) 
while brain tumour accounted for 13 
cases (10%) (Table I). In 36 cases 
(29%) there was a communicating 
hydrocephalus of undetermined cause. 
Associated myelomeningocele was 
present in 44 children (35%).
The need for a shunting procedure 
was determined by the patient’s his­
tory and clinical evidence of hydro­
cephalus. The diagnosis was confirmed 
by ventriculography or pneumoence­
phalography, or both. These tests have 
since been replaced by computerized 
tomography.
The types of valve mechanism used
Tab le  1 - -Causes o f H ydrocepha lus (125 P a tie n ts )
Cause
V e n tr ic u lo p e rito n e a l
shun t
V e n tr ic u lo a tr ia l
sh u n t
Lum bo­
pe ritonea l
shu n t T o ta l
H ydrocepha lus w ith
m ye lom en ingoce le 33 11 — 44
C om m un ica ting  hydrocepha lus  
cause un de te rm ine d 28 7 1 36
A queduct s ten os is 12 4 — 16
B ra in  tu m o u r 12 1 — 13
M e n in g itis 4 — — 4
Traum a 4 1 — 5
N onn eop las tic  cyst 5 — — 5
V ascu la r m a lfo rm a tio n  in 
p inea l re g ion 2 — — 2
T o ta l 100 24 1 125
Tab le  11—Types o f V a lve  M echanism  Used
S hun t
A ppara tus V e n tr ic u lo p e rito n e a l V e n tr ic u lo a tr ia l Lum boperitonea l
H o lte r 49 23 —
Raim ondi 38 — —
Pudenz 8 1 —
N ot spec ified 5 1
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for shunting are shown in Table II. 
The figures indicate only the neurosur­
geons’ preference. No “Unishunts”
were used, although the Raimondi
peritoneal catheter with a flushing
i device attached to a ventricular cathe-
T  # ter was next in popularity to the
0  ^ Holter valve.
Table I I I—Causes of Failure of Ventriculo-
peritoneal Shunts (58 Patients)
No. of
r  K Cause of fa ilu re* revisions
Obstruction of ventricular
catheter with choroid plexus, 
brain tissue, detritus 36
Retraction of peritoneal
catheter from peritoneal 
cavity 11
Disconnection of catheter
► ^ from flushing device 
Obstruction of peritoneal
9
catheter with omentum, fibrin 9
Shunt infection
Revision of medium pressure
6
to low pressure valve 5
* Leakage of shunt tubing 3
Skin erosion 2
Kinked tubing 2
r1 * Valve malfunction 
Distal catheter encysted in
3
A peritoneal cavity 
Shunt malfunction, undefined
1
Y
cause 10
Total 97
*1 revision of lumboperitoneal to ventri-
Y culoperitonea! shunt.
Table IV—Causes of Failure of Ventriculo-
atrial Shunts (18 Patients)
No. of
Cause of failure revisions
Proximal migration of atrial
►- Y catheter from atrium 6
A trial end blocked 2
Y v A trial catheter disconnected
from flushing device 
Malposition of ventricular
3
catheter in the subarachnoid
Y space 1
Shunt nephritis 2
Meningitis 1
r  y Overdrainage of cerebrospinal
fluid from low pressure valve 2
Shunt malfunction, undefined cause 3
Total 20
Table V - Frequency of Shunt Revisions
No. of No. of Total no.
revisions patients of revisions
0 48 0
1 51 51
2 18 36
3 3 9
4 4 16
6 1 6
Total 125 118
Results
During the 4-year study period 
there were 118 shunt revisions in 77 
patients. In 58 group 1 patients there 
were 97 failures requiring revision of 
the shunt. The reasons for failure are 
analysed in Table III. The most com­
mon reason (in 36 instances) was ob­
struction at the ventricular end of the 
shunt caused by choroid plexus, 
brain tissue or detritus. On the other 
hand, obstruction at the peritoneal end 
accounted for only nine failures re­
quiring revision; retraction and dis­
connection of the peritoneal catheter 
accounted for 20 failures in this 
group.
There were 20 failures in group 2 
necessitating revision in 18 patients 
(Table IV). In 13 of these revision 
procedures, the shunt was converted 
to a ventriculoperitoneal shunt. No 
ventricular obstruction was docu­
mented.
The revision rate for groups 1 and 
2 was 58% (58 of 100) and 75% 
(18 of 24), respectively, but the 18 
ventriculoatrial shunts needed only 20
Table V I— Infecting Organisms in
Group 1 Patients
No. of
Organism patients*
Staphylococcus epidermidis 5
Staphylococcus aureus 3
Mixed organisms 3
Escherichia coli 1
a-hem olytic streptococcus 1
’ In 1 patient no organism was cultured.
revisions while the 58 ventriculoperi­
toneal shunts required 97 revisions.
The only lumboperitoneal shunt was 
converted to a ventriculoperitoneal 
shunt.
The frequency of shunt revisions 
per patient is shown in Table V. The 
follow-up in these patients ranged 
from 10 to 48 months (average 24 
months). Forty-eight patients (38%) 
had no complications as a result of 
the shunt procedure.
There were 14 (14%) shunt infec­
tions among the group 1 patients and 
4 (16.7%) in group 2. The overall in­
fection rate was 14.4%. The organisms 
cultured from group 1 patients are 
listed in Table VI. Staphylococcus epi- 
dermidis was the predominant infect­
ing organism in both groups. In group 
2, three patients had chronic bactere­
mia; in two the infection was as­
sociated with shunt nephritis. There 
was one case of meningitis. In one 
patient the infecting organism was 
//-hemolytic streptococcus, Lancefield 
group A, and in three it was S. epider- 
midis. The nature of the infections in 
group 1 is shown in Table VII.
The culture and sensitivity results 
showed that the S. epidermidis and 
Staphylococcus aureus were sensitive 
to cephalosporin and /3-lactamase pe­
nicillin (Table VIII).
Routine antibiotic prophylaxis with 
either cloxacillin or cephalosporin was 
instituted in early 1977 and there was 
a notable decline in the number of 
shunt infections thereafter (Table IX).
Miscellaneous Complications
Inguinal hernia developed in three 
patients who subsequently underwent 
herniorrhaphy.
Table V II— 'Type of Infection in 
Group 1 Patients
Nature of infection
No. of 
patients
Ventriculitis 5
Abdominal wound 2
Meningitis 2
Cerebral abscess 2
Gut perforation with peritonitis 1
Septicemia 1
Shunt tubing 1
Table IX — Incidence of Shunt Infection
No. in fection s/
admissions
Period for surgery)
August 1 9 7 4 -July 1975 5/37
August 1975 -  July 1976 8/29
August 1976-J u ly  1977 4/59
August 1977-J u ly  1978 1/55
*14 ventriculoperitoneal shunts, 4 ve n tr i­
culoatrial shunts. 
f l8 0  admissions for 125 patients.
Table V III— Sensitiv ity of Organisms to Antibiotics
Organism Antibiotic Sensitive Resistant
S. epidermidis Cephalosporin 7 1
^-lactamase penicillin 8 0
S. aureus Cephalosporin 3 0
(1-lactamase penicillin 2 1
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The ventricular catheter was dis­
lodged and lost in the lateral ventricle 
in two patients; in one of these a 
craniotomy was necessary to remove 
the catheter because of persistent in­
fection.
One patient had a thalamic hemor­
rhage resulting from a revision proce­
dure.
Two patients had shunt nephritis 10 
and 12 years respectively after the in­
sertion of the initial ventriculoatrial 
shunt.
Fourteen patients died, 9 from 
complications directly related to the 
shunt procedure. The other five deaths 
were related to the condition for which 
the shunt was initially inserted. The 
mortality from shunt complications 
was, therefore, 7.2%, but the overall 
mortality was 11.2%. Of the nine 
deaths from shunt complications eight 
occurred in group 1 (Table X). Five 
deaths were directly related to shunt 
infections which accounted for 55% 
of the deaths from shunt complica­
tions.
Discussion
Despite the repeated labelling of 
shunting procedures as nonphysiologic 
by Scarff1,2 and despite new attempts 
to revive fenestration of the third 
ventricle,3,4 most neurosurgeons treat 
hydrocephalus by ventriculoatrial or 
ventriculoperitoneal shunting.5'8 Be­
cause of the simplicity of the ventri­
culoperitoneal shunt, the majority of 
neurosurgeons, including our own, 
prefer this method.8,9
In our patients ventricular catheters 
blocked more frequently with ventri­
culoperitoneal shunts than with ven­
triculoatrial shunts. This finding is in 
contrast to the observations of Little, 
Rhoton and Mellinger.8 On the other 
hand, we had fewer obstructions of 
the peritoneal catheter than did 
others.5,9 The development of in­
guinal hernia was also less frequent 
than in other series.5
Two cases of shunt nephritis, con­
firmed by renal biopsy, were clearly 
related to ventriculoatrial shunt infec­
tion with S. epidermidis. This compli­
cation, rare in all series,10 responded 
to treatment promptly.
Our overall infection rate of 14.4% 
is high and was probably related to 
the fact that neither the operative 
technique nor the use of prophylactic 
antibiotic therapy was uniform until 
1976 when the shunt operation was 
done by fewer surgeons, with a result­
ing decline of shunt infections. Al­
though some authors do not find anti­
biotics useful," we believe that stan­
dardized technique12 and routine use 
of antibiotic prophylaxis reduce in­
fection and mortality.7'13'15
Our overall mortality from shunt 
complications of 7.2% is comparable 
to that of other series.6 The majority 
of those who died had infectious com­
plications, confirming the findings of 
Raimondi, Robinson and Kuwamura.9
Overall the results of our series were 
good and compare favourably with 
some series,9 '8 but the relatively small 
number of procedures done by the in­
dividual neurosurgeons makes com­
parative evaluation of different tech­
niques impossible. The lower revision 
and mortality rates of ventriculoatrial 
shunting, however, are probably signif­
icant and confirm the findings of Ivan 
and associates,7 who reported their 
favourable impression of these shunts 
in 1968.
In 1976 we began a more stand­
ardized approach to primary shunts 
and to the management of complica­
tions. We believe that the sharp 
decline of infections is the result of 
these changes.
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Correction
On page 487 of the September 1980 
issue, in the article “Effect of Actino­
myces israelii on human peripheral lym­
phocytes”, the fourth sentence of the 
abstract reads: “Skin reactivity to various 
standard antigens was depressed in all 
seven patients.” This sentence should 
have read “Skin reactivity to various 
standard antigens was depressed in each 
of the patients.”
Table X M ortality Related to Shunt Complications
Shunt type Cause of death No. of deaths
Ventriculoperitoneal Septicemia 2*
Ventriculitis 1
Meningitis 1
Thalam ic hemorrhage 1
Sagittal sinus thrombosis 1
Blocked shunt 2
V entricu loatria l Meningitis 1
*Both patients had a myelomeningocele.
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Myocutaneous Flaps: the Saskatoon Experience
Brian J. M iller, mb, frcs[c]* and Wayne R. Perron, md, FRCs[c]f
The purpose of this study was to 
determine the results of myocutaneous 
flap procedures performed in three 
Saskatoon hospitals between 1977 
and 1979.
Twenty-two flap procedures were 
performed on 17 patients. Eleven 
patients were suffering from decubitus 
ulcers and 6 had other wounds. 
Myocutaneous flaps have a place 
in the early surgical management of 
decubitus ulcers. Fluorescein given 
intravenously in some patients during 
operation was used to assess flap 
viability; 4 out of 10 flaps required 
trimming as a result.
The myocutaneous flap technique 
provides rapid and durable closure for 
a wide variety of tissue defects 
which are otherwise difficult to cover.
Cette etude a pour but de determiner 
les resultats des greffes de lambeaux 
myo-cutanes pratiquees dans trois 
hopitaux de Saskatoon entre 
1977 et 1979.
Vingt-deux de ces greffes ont ete 
effectuees chez 17 patients. Onze 
patients souffraient d'ulceres de 
decubitus et 6 presentaient d'autres 
blessures. Les greffes myo-cutanees 
peuvent etre envisagees tot dans le 
traitement chirurgical des ulceres 
de decubitus. Chez quelques patients, 
I'administration intraveineuse de 
fluoresceine durant I'operation servit 
a evaluer la viabilite des greffons; 
en consequence, 4 greffons sur 10 
necessiterent des modifications.
La technique de greffe myo-cutanee 
assure la fermeture rapide et durable 
d’une grande variete d'imperfections 
de la peau qui sont autrement 
difficiles a couvrir.
From the department of surgery, University of Saskatchewan, Saskatoon, Sask.
Presented at the East African Association of Surgeons Conference, Dar-es-Salaam, Tanzania, Dec. 4-7, 1979
*Assistant professor, department of surgery, University of Saskatchewan, Saskatoon
'Staff surgeon and clinical instructor, department of surgery (plastic), University of Saskatchewan, Saskatoon
Accepted for publication Nov. 15, 1979
Reprint requests to: Dr. B.J. Miller, Department of surgery, University Hospital, Saskatoon, Sask. S7N 0X0
The purpose of our study was to re­view the results in patients who under­went myocutaneous flap procedures 
in three Saskatoon hospitals between November 1977 and July 1979 to de­termine how successful this technique 
is for wounds that are difficult to manage.The preservation of an island of skin by elevating it along with the 
underlying muscle was described by 
D’Este in 1912.' The concept did not become popular until McCraw defined 
more than 20 independent myocuta­
neous vascular territories2 and, in 1976, first coined the term myocuta­
neous flaps.3 Many applications have 
been found for these flaps in recon­structive surgery since then. They have 
certain advantages over other local 
flaps; safe length-to-base ratios of up to 5:1 may be achieved; excellent padding is provided by the carrier 
muscle over pressure areas; delaying procedures are unnecessary in most cases and the majority of operations 
may be performed in one stage.
Patients and Methods
Myocutaneous flaps have been used in reconstructive surgery at the three main Saskatoon hospitals since No­vember 1977. In the first 18 months of 
our experience 22 flap procedures were performed on 17 patients (15 
men, 2 women), whose ages ranged 
from 19 to 68 years (average 45 years).
A variety of conditions were treated. Sixteen decubitus ulcers (9 
ischial and 7 trochanteric) were treated 
in 11 patients who were paraplegic or 
quadriplegic. Two patients had chronic tibial osteomyelitis with sinus forma­
tion and ulceration. There was one 
case each of electrical burns of the knee, severe frostbite of the knee, pharyngeal fistula following pharyn- 
golaryngectomy for carcinoma and recurrent sarcoma of the left scapular area.The flap chosen to close each de­fect was the one whose arc would cover the wound in question. Eight rectus femoris flaps, six gracilis flaps and two biceps femoris flaps were per­formed for decubitus ulceration. Four gastrocnemius flaps were used for the wounds around the knee (Fig. 1). 
The patient with a pharyngeal fistula was treated with a sternomastoid flap. A latissimus dorsi flap was used for
the patient with the scapular sarcoma.Fluorescein (10 to 15 mg/kg) was injected intravenously at operation to
Fig. lb
FIG. 1—(a) Right knee of 24-year- old man who sustained electrical burn. Patella is necrotic, (b) After excision of patella, lateral gastrocnemius flap is elevated and laid over open knee joint.
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a different area in one patient, minor 
flap necrosis in four patients and 
wound infection in one. In no patient 
was there complete loss of a flap. 
Three out of four cases of minor 
necrosis of the flap postoperatively 
occurred in patients whose flap cir­
culation was not checked by fluor­
escein injection. One rectus femoris 
flap that was checked by fluorescein 
underwent partial necrosis. The viabil­
ity of this flap was probably com­
promised by edema of the pedicle 2
days after operation because the ische­
mic area was greatly diminished by 
prompt removal of some of the skin 
sutures (Fig. 3). In one patient who 
was quadriplegic, diabetic and very 
obese two of three myocutaneous flaps 
ulcerated in less than 4 months. The 
patient who underwent coverage of 
the pharyngeal fistula with a sterno- 
mastoid flap had necrosis of the tip of 
the flap 10 days after operation and 
the fistula recurred. Six months after 
operation the fistula had not healed.
Fig. 2a
Fig. 2b
FIG. 2— (a) Rectus femoris flap elevated to close excised trochanteric decubitus 
ulcer, (b) Luminescence under ultraviolet light after intravenous injection of 
fluoroscein reaches tip of flap indicating that its blood supply is adequate.
check the circulation in 10 of the 22 
flaps (Fig. 2). As a result 4 of the 10 
flaps required some trimming of skin 
and muscle.
Follow-up was from 6 months to 2 
years (average 9 months). Entry of 
patients to our series was terminated 
18 months after the first myocuta­
neous flap procedure had been done, 
to allow recognition of complications 
in the collected cases.
R esults
All 17 patients in the series are 
alive and have been available for fol­
low-up. The average time that elapsed 
before patients with decubitus ulcers 
could bear weight on their flaps was 
4 weeks.
Early complications included for­
mation of a hematoma in two patients, 
minor dehiscence of the suture line in 
three, further decubitus ulceration in
Fig. lc
FIG . 1—(c) Four weeks after opera­
tion patient is well mobilized with little 
functional disability resulting from flap.
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The other 15 patients have good re­
sults to date.
Split-skin grafting of donor sites 
was required in four out of eight rec­
tus femoris flaps, three out of four 
gastrocnemius flaps and in both the 
latissimus dorsi and the sternomastoid 
flaps. The need for grafting of the 
donor site depended on the patient's 
degree of obesity and the anatomic 
location of the flap. No gracilis flap 
required a donor site split-skin graft.
D iscussion
The use of myocutaneous flaps to 
close decubitus ulcers has not yet
Fig. 3a
been recommended as an initial proce­
dure despite their reported effect­
iveness. This is because elevation of 
the myocutaneous flap may interfere 
with the design of other simpler local 
flaps should the myocutaneous flap 
fail. The average time between onset 
of ulceration to closure by the m yo­
cutaneous flap procedure in our series 
was 2 '/x  years (range 1 month to 7 
years). O f the 11 patients with de­
cubitus ulcers, the 5 most recent have 
had m yocutaneous flaps as the initial 
procedure. The first six patients in 
our series had had an average of nine 
procedures before a m yocutaneous 
flap was used. Our experience with
Fig. 3b
Fig. 3c Fig. 3d
FIG. 3— (a) Trochanteric decubitus ulcer 10 cni in diameter in 37-year-old para­
plegic. (b) Island of skin is elevated on rectus fenioris muscle to  provide coverage. 
(C) Twenty-four hours after operation there is partial necrosis of flap. Pedicle 
was decompressed as soon as this was recognized, (d) No further necrosis took 
place after removal of sutures over pedicle. Result 3 weeks later after local debride­
m ent and split-sk inn g rafting  is satisfac to ry .
these flaps has been encouraging. W e 
tend now to use them earlier fo r decu­
bitus ulceration than previously. O ur 
success can be attributed to good re­
habilitation program s as well as to 
surgical technique.
The possibility that an innervated 
m yocutaneous flap may cause w ound 
dehiscence by muscle contraction  in 
the early postoperative period has been 
considered. We used six innervated 
flaps and this was recognized to  be a 
cause of suture line separation in the 
one patient with a latissimus dorsi 
flap. In our experience such a com ­
plication is rare. We would not nor­
mally risk jeopardizing the blood sup­
ply to a fresh flap by additional dis­
section in the region of the vascular 
pedicle to divide either the m otor 
nerve or the origin of the m uscle. 
M cCraw, Dibbell and C arraw ay4 have 
described the loss o f function to be 
expected with d ifferent innervated 
m yocutaneous flaps. This loss of 
function has not proved to be a m ajor 
problem with any of the flaps used 
in our series.
The intravenous injection o f fluor­
escein during the operation to check 
that flap circulation is adequate was 
helpful. This test was introduced in 
1931 by Lange and Boyd5 and has 
proved rem arkably safe; the occu r­
rence of allergic phenom ena is ex ­
trem ely low and no deaths have been 
reported. The intensity of skin lum i­
nescence under ultraviolet light is an 
expression of extracellu lar fluorescein 
accum ulation. The technique of the 
test as used in 285 flaps was described 
by M cCraw, Myers and S hanklin /' 
Solidly fluorescent skin will always 
survive. Spotty fluorescence often sig­
nifies viability, but skin and muscle 
that are blue under ultraviolet light are 
destined to necrose and should be 
trimm ed off in the operating  room. 
Only 1 of 10 fluorescent flaps exhi­
bited necrosis postoperatively. This 
partial necrosis was probably due to 
progressive edem a of the pedicle. F our 
flaps required some trim m ing in the 
operating room. The higher dose 
of fluorescein provided us with the 
best definition. T hree of 12 flaps in 
which fluorescein was not used under­
went partial necrosis.
M yocutaneous flap procedures have 
been employed in the treatm ent of a 
wide variety of indolent wounds. Their 
usefulness in the ischem ic ulcers of 
patients with sickle cell disease is 
well described by H eckler, D ibbell and 
M cCraw .7 G racilis m yocutaneous flaps 
have been successful in the m anage­
m ent of chronic perineal sinuses fol-
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lowing abdominoperineal resection for 
inflammatory bowel disease.8 Rectus 
abdominis flaps have been used for 
reconstruction in the patient with mas­
sive abdominal wall defects.”
Summary
The combined experience with myo- 
cutaneous flaps in Saskatoon in which 
22 flap procedures have been per­
formed on 17 patients resulted in no 
deaths and no total flap loss. The 
results have generally been satisfac­
tory. Only two patients had recur­
rent wounds. There is a growing ten­
dency, in view of our success, to use 
the myocutaneous flap as the initial 
procedure in patients with decubitus 
ulcers. Fluorescein injected intra­
venously at the time of operation in 
10 patients was helpful in delineating 
nonviable portions in 4.
We conclude that the myocutaneous 
flap technique is firmly established as 
a safe and effective means of dealing 
with many wounds that are difficult 
to cover.
We are grateful to Drs. L.R. Chasmar, 
D.J. Classen and J.H. Zondervan for 
their assistance in this study, and for 
permission to use their cases in this 
report.
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Arteriovenous Malformation of the Duodenum
G.R. Stallwood, b sc, m sc, md and T.A. R ichards, md, m sc, frcs[c], facs
In their report of a 55-year-old woman 
with an arteriovenous malformation 
of the duodenum, the authors illustrate 
some of the interesting clinical features 
of this uncommon cause of chronic 
gastrointestinal bleeding. The lesion 
was treated by surgical resection. 
Arteriovenous malformations have been 
classified according to location, age 
of the patient and family history. In 
this patient the malformation was 
considered to be a type 2 or congenital 
lesion. The authors review the 
literature on arteriovenous malfor­
mations and emphasize the use of 
selective visceral angiography for 
diagnosing arteriovenous malformations 
of the gastrointestinal tract.
Les auteurs signalent le cas d'une 
femme de 55 ans souffrant de
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malformation arterio-veineuse du 
duodenum et se servent de cette 
description pour illustrer quelques uns 
des aspects cliniques interessants de 
cette cause rare de saignement gastro­
intestinal chronique. Cette lesion a 
ete traitee par resection chirurgicale. 
Les malformations arterio-veineuses 
ont ete classifiees selon le siege 
anatomique, I'age du malade et les 
antecedents familiaux. La malformation, 
chez cette patiente, a ete consideree 
etre de type 2, ou congenitale. Les 
auteurs passent en revue la litterature 
sur les malformations arterio-veineuses 
et insistent sur I'angiographie selective 
des visceres pour diagnostiquer les 
malformations arterio-veineuses des 
voies digestives.
Arteriovenous malformation of the 
intestine is an uncommon cause of gas­
trointestinal hemorrhage but recently 
has been reported with increasing fre­
quency.'2 It is important not only that 
these lesions should be considered in 
the differential diagnosis of chronic 
gastrointestinal bleeding but also that 
the proper mode of investigation be
used to make the diagnosis. This re­
port describes a patient with arterio­
venous malformation of the duodenum 
causing chronic gastrointestinal he­
morrhage. The literature on this topic 
is also reviewed.
Case Report
A 55-year-old Caucasian woman who 
had a history of excessive ethanol con­
sumption was admitted to hospital in 
November 1976 because of fatigue and 
melena of 2 weeks’ duration. Her hemo­
globin value upon admission was 5.4 g/ 
dl. The patient had a family history of 
anemia. Her mother suffered from ane­
mia of “unknown cause” and her 
father had a folate deficiency anemia. 
One brother had recurrent gastrointes­
tinal bleeding attributed to congenital 
telangiectasia.
On physical examination no telangi­
ectasia was noted on her lips, palmar or 
plantar surfaces, buccal or nasal mucosa. 
A grade II/VI systolic ejection murmur 
was heard over the aortic and mitral 
areas radiating into both carotid arteries. 
The results of liver function tests and 
hematologic and coagulation studies were 
normal. Esophagogastroduodenoscopy
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revealed no ulceration. A presumptive 
diagnosis of hemorrhagic gastritis second­
ary to alcohol consumption was made 
and the patient was managed conserva­
tively on a bland nonfatty diet with an­
tacids. When she was discharged 3 weeks 
later her hemoglobin value was normal 
and she had no melena. She had re­
ceived 9 units of blood throughout the 
period of hospitalization.
During the spring and summer of 1977 
the patient was admitted to hospital on 
three occasions with melena, fatigue and 
anemia. Findings on repeat barium ro­
entgenography, endoscopy and colon­
oscopy were normal.
In August 1977 she returned to hos­
pital with the same complaints. Since 
barium roentgenographic and endo­
scopic examinations again gave normal 
results, selective celiac angiography was 
performed. This revealed the presence 
of a vascular tuft or group of dilated 
vascular channels indicating an arterio­
venous malformation which was located 
in a branch of the gastroduodenal artery 
in the anterior wall of the first part of 
the duodenum (Fig. 1). Early venous 
filling in this area was also present (Fig. 
2). Repeat duodenoscopic examination 
demonstrated bleeding from the anterior 
duodenal wall at this point.
At laparotomy close examination 
showed an increase in the number of 
small vessels on the serosal surface of 
the anterior wall of the duodenal cap. 
The duodenum was opened transversely, 
distal to these vessels; the anterior wall 
was bluish grey and thicker than normal. 
Since the malformation was close to the 
anterior pyloric sphincter, an anterior 
pylorectomy was done in continuity 
with removal of an adjacent 2.0- to 2.5- 
cm portion of the anterior duodenal wall 
which contained the malformation. The 
window produced was closed transver­
sely.
The resected specimen measured 
3 x 2  cm. A small irregular area of 
superficial mucosal ulceration over a
FIG . 1— A rterial phase o f selective 
gastroduodenal a rte riog ram  in left an ­
terio r oblique projection . V ascular tu ft 
(arrow ) appears to  he in an terio r duo­
denal wall. H em orrhage from  this site 
was confirm ed by duodenoscopy.
thickened wall could be seen. Histologic 
examination showed superficial mu­
cosal ulceration covered with fibrin clot. 
Anastomosing dilated vascular channels 
were not confined to the submucosa but 
extended through the submucosa into 
the serosa.
The patient's recovery was uncom­
plicated. She has had no melena for 3 
years and her hemoglobin concentration 
has been stable at approximately 14.0 
g/dl.
Discussion
This case exemplifies some inter­
esting clinical features of arterio­
venous malformation. The presenting 
complaints, which may include fatigue, 
hematemesis, melena or hematochezia, 
are caused by chronic gastrointestinal 
bleeding with resultant anemia.’ In 
most instances, the diagnosis of ar­
teriovenous malformation is delayed 
because conventional methods of 
examination (sigmoidoscopy, endo­
scopy and barium roentgenography of 
upper and lower gastrointestinal tracts) 
do not always identify the cause or 
site of bleeding. Conventional methods 
may fail to determine the cause of gas­
trointestinal hemorrhage in 8% to 
22% of cases.2"1
Exploratory laparotomy7,5 was once 
a popular diagnostic method for in­
vestigating chronic gastrointestinal 
hemorrhage. Retzlaff, Hagedorn and 
Bartholomew” reported that 70% of 
exploratory laparotomies resulted in 
negative findings (excluding patients 
with hematemesis). Since most arter­
iovenous malformations cannot be 
seen on gross inspection,7 exploratory 
laparotomy is not recommended.1,8S
In 1960, Margulis, Heinbecker and 
Bernard"1 first demonstrated the value 
of angiography for the diagnosis of 
arteriovenous malformation as a cause 
of gastrointestinal bleeding. After the
FIG . 2— Late a rte ria l phase o f se lec t­
ive hepatic a rte rio g ram  show ing early  
venous filling.
superior mesenteric artery was select­
ively catheterized, contrast medium 
was seen extravasating from a cecal 
arteriovenous malformation into the 
cecal lumen. Sheedy, Fulton and 
Atwell," in a series of 88 patients who 
underwent angiographic studies for 
chronic gastrointestinal hemorrhage 
because the cause could not be deter­
mined by conventional methods, found 
that 45 % of the lesions could be diag­
nosed by arteriography. Arteriovenous 
malformation made up 50% of these 
lesions, bowel tumours 12%, visceral 
artery aneuryms (mostly superior me­
senteric artery aneuryms) 10% and 
juvenile polyps 7% . Selective visceral 
arteriography is often necessary to 
diagnose arteriovenous malforma- 
tions1’2’5’7’8,12 and this method also 
proved valuable in our case.
Our angiographic findings demon­
strate the classic appearance of an 
arteriovenous malformation (Figs. 1 
and 2). There are large dilated vascular 
channels or tufts which arise from 
arteries and communicate with the 
venous system without an intervening 
capillary network. This results in ar­
teriovenous shunting and early venous 
filling.1’2’7’8’12 It is not necessary to de­
monstrate bleeding from an arterio­
venous malformation to prove it is the 
true source of hemorrhage. In the 
absence of other lesions, the malforma­
tion may be considered the cause of 
bleeding. Bleeding has not recurred 
after resection of a nonbleeding mal­
formation discovered arteriographical- 
ly.’2
Moore and associates7 derived a 
clinical classification of arteriovenous 
malformations based upon location, 
age and family history. They de­
signated a type 1 lesion as a single 
malformation occurring in older pa­
tients, most often localized to the ce­
cum and ascending colon and not visi­
ble grossly. Cavett and associates' re­
viewed 47 patients with malformations 
of this type and found 40% of lesions 
in the cecum and 80% in the distal 
ileum, cecum, ascending colon and 
hepatic flexure collectively. The aver­
age age of the patients at diagnosis 
was 56 years and 75% were between 
the ages of 50 and 80 years.
Type 2 arteriovenous malformations 
occur in younger age groups and most 
commonly are found in the small in­
testine. They are frequently visible at 
laparotomy; in 50%  of cases large 
abnormal mesenteric and subserosal 
veins can be seen. Moore and as­
sociates7 hypothesized that type 1 
lesions are acquired whereas type 2 
lesions are congenital in origin.
Lesions of hereditary hemorrhagic
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telangiectasia (Rendu-Osler-Weber 
syndrome) are classified by Moore 
and associates7 as type 3 arteriovenous 
malformations. Patients with these 
lesions have a family history of re­
current epistaxis and some family 
members have skin and mucosal telan­
giectasia. Small angiomas are often 
found on lips and buccal mucosa. 
Angiography reveals multiple punctate 
angiomas in the stomach and proximal 
small bowel of these patients. Patients 
are older and present with epistaxis 
and anemia. Gastrointestinal bleeding 
is usually not severe and may be con­
trolled in most cases with medical 
therapy (synthetic estrogens and trans­
fusions) in contrast to operative re­
section which is the treatment of 
choice for types 1 and 2 lesions.7
Boley and associates13'14 postulated 
that acquired malformations or “vas­
cular ectasia" of submucosal veins re­
sult from chronic intermittent obstruc­
tion of venous channels by circular 
and longitudinal muscle of the colonic 
wall. Later, mucosal veins, capillaries 
and arteries also dilate and eventually 
so do precapillary sphincters forming 
a true arteriovenous communication. 
This would explain why acquired le­
sions occur in the submucosa and 
mucosa of the bowel wall.
It is most likely that our patient 
had a type 2 (congenital) malforma­
tion. It was found in the duodenum 
as opposed to the cecum or ascending 
colon which are common sites for 
type 1 (acquired) lesions. The mal­
formation was visible on close inspec­
tion at operation and extended through 
the entire duodenal wall unlike ac­
quired type 1 lesions which are rarely 
identified at laparotomy and have 
been reported to occur in the sub­
mucosal and mucosal regions.7,1213
Review of the literature serves to 
emphasize the importance of an or­
ganized approach to a patient with 
chronic gastrointestinal bleeding in 
order to prevent chronic morbidity 
and needless delay in diagnosis. First, 
a complete history and physical 
examination are necessary. Hematol­
ogic tests, coagulation studies and en­
doscopic examination may yield im­
portant information. If no abnormality 
is found then selective celiac, superior 
or inferior mesenteric arteriography is 
indicated to determine the cause, site 
and extent of the lesion.5 Arterio­
graphy is necessary for the diagnosis 
of arteriovenous malformations and ra­
diographic magnification methods have 
been recommended to improve the 
diagnostic yield, especially when small 
lesions are present. Intraoperative ar­
teriography of the resected specimen 
can confirm removal of a lesion.7 If 
this technique is not used, a lesion may 
not be included in the resected portion 
of intestine and bleeding episodes may 
continue postoperatively as witnessed 
by Cavett and associates.1
We thank Drs. B.A. Richards and J. 
Smart for information and assistance in 
preparing this manuscript. Particular 
thanks go to Dr. D. Bell, chief of radio­
logy at the Joseph Brant Memorial Hos­
pital.
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Traditional treatments have all involved a significant risk of dose-related toxicities. The introduction of 
PYOPEN *(carbenicillin) was an important therapeutic advance, providing the safety of penicillin, combined with 
bactericidal effectiveness against Pseudomonas aeruginosa and other gram-negative organisms.
.. it would appear that carbenicillin is effective in modifying the course of a Pseudomonas 
surface culture in bum patients.” 1
In severe and overwhelming Pseudomonas infections so often found in burn patients, PYOPEN provides a logical choice 
of therapy—effectiveness without dose-related toxicities and the traditional margin of safety common to all penicillins. 
So, for the treatment of Pseudomonas infections in burns...consider PYOPEN
1. Copeland, Charles E., C arben ic illin  therapy in burn patients, Burn Unit, General Surgery, M ercy Hospital,
P ittsburgh, Pa. U.S.A. Proceedings o f the Symposium New York, N.Y. Ju ly  12, 1969,Excerpta M edica Foundation.
For brief p rescrib ing  in form ation  see page574.
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Rhabdomyosarcoma of the Brain
Kyu H. Sh in , md , fr c p[c]* and V.M. W hitehead , m d , FRCP[c]f
The authors present a case of 
primary intracranial rhabdomyosar­
coma. This is only the 10th reported 
case and is the only one in which 
the patient has survived longer 
than 2 years. A 9-month-old boy was 
found to have a large mass 
in the right posterior fossa.
Posterior fossa craniotomy revealed 
an unencapsulated tumour involving 
almost the entire right cerebellar 
hemisphere and extending to the right 
cerebellar pontine angle. Subtotal 
removal was done for internal 
decompression. On examination of the 
specimen by light microscopy there 
were definite sarcomatous features 
with occasional rhabdopoietic elements 
and many malignant giant cells.
The ultrastructural appearance con­
firmed the diagnosis of malignant 
rhabdomyosarcoma.
The child was treated with 
combination chemotherapy and cobalt- 
60 teletherapy. He is alive and well 
2 years after operation and has no 
clinical evidence of recurrent disease. 
His physical growth and mental 
development are satisfactory.
The response of our patient suggests 
that such tumours may be 
controlled by subtotal removal 
followed by radiotherapy and 
chemotherapy.
Les auteurs presentent un cas d'un 
rhabdomyosarcome intracranien 
primaire. II s’agit du lOe cas signale 
de rhabdomyosarcone cerebral pur 
et du seul qui a survecu plus 
de 2 ans. Un gros tumeur a ete 
trouve dans la fosse droite posterieure 
d’un garcon de 9 mois. Une cranioto- 
mie dans la fosse cerebrate posterieure 
a revele une importante tumeur 
acapsulee qui occupait presque tout 
I’hemisphere cerebelieux droit et qui 
s'eiendait jusqu'a t angle ponto- 
cerebelleux droit. Une ablation sub­
to ta l  a ete pratiquee afin de reduire 
la compression interne. L'examen de
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la piece de resection au microscope 
optique a montre des caracteristiques 
sarcomateuses definies avec des 
elements rhabdopoietiques occasion- 
nels et plusieurs cellules geantes 
malignes. L'aspect de I'ultrastructure 
cellulaire a confirme le diagnostic de 
rhabdomyosarcome malin.
L’enfant a recu une association de 
chimiotherapie et de telecobal- 
totherapie. Deux ans apres I'operation, 
il est vivant et en bonne sante, sans 
signe clinique de recidive. Son 
developpement physique et mental 
est satisfaisant.
La reponse de notre malade indique 
que ces tumeurs peuvent etre 
controlees par une ablation subtotale 
suivie de radiotherapie et de 
chimiotherapie.
Intracranial primary rhabdomyosar­
coma is a very rare tumour, and its 
histopathologic definition is controver­
sial. The tumour is composed of pure 
mesenchymal derivatives with both 
embryonal and striated muscle cells. It 
should be devoid of neuroblastic ele­
ments.1 Nine cases of pure rhabdo­
myosarcoma have been reported.2-10 
We report a 10th case.
Case Report
A 9-month-old boy was admitted to 
the Montreal Children’s Hospital on Jan. 
19, 1977 with a 14-day history of otitis 
media and upper respiratory tract infec­
tion. On admission the only abnormal 
finding was palsy of the right seventh 
cranial nerve. Skull roentgenograms 
showed widening of the coronal and 
lambdoid sutures, a fracture of the right
FIG . 1— Vertebral angiogram shows 
slip of right tonsillar hemispheric 
branch of posterior inferior cerebellar 
artery below foramen magnum and an­
terior displacement of proximal portion 
of basilar artery against clivus.
parietal bone and a 2.5-cm shift of the 
midline to the left. A vertebral angio­
gram (Fig. 1) and computerized tomo­
gram of the brain (Fig. 2) showed a 
large mass occupying most of the right 
side of the posterior fossa and extending 
medially to the right margin of the pons.
At posterior fossa craniotomy per­
formed 1 week after admission a large 
unencapsulated tumour was found in­
volving almost the entire right cerebellar 
hemisphere and extending to the right 
cerebellopontine angle. Subtotal removal 
of the tumour was carried out for in­
ternal decompression.
Examination of the tumour by light 
microscopy (Fig. 3a) showed marked 
pleomorphism and poorly differentiated 
tumour cells with definite sarcomatous 
features, occasional rhabdopoietic ele­
ments and many malignant giant cells. 
There were no neuronal or glial ele­
ments. The ultrastructural appearance of 
a malignant rhabdomyoblast is shown in 
Fig. 3b. Subsequent investigations in­
cluded bone, liver and spleen scanning 
and tomographic examination of the mid­
dle ear; the findings were normal. On 
Feb. 7, 12 days after operation, combina­
tion chemotherapy was begun. It con­
sisted of vincristine (0.6 mg intravenous­
ly), actinomycin (130 p.g intravenously), 
cyclophosphamide (140 mg intra­
venously) and methotrexate 12 mg/m2 
(intrathecally) every 6 weeks.
Using supervoltage cobalt-60 telether­
apy, the whole brain was irradiated with 
a total dose of 3000 rads over a period
FIG . 2— Computerized axial tomo­
gram of brain. Large mass occupies most 
of right side of posterior fossa, extend­
ing medially to right margin of pons.
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of 4 weeks, in 20 treatments. Then an 
additional tumour dose of 1500 rads 
was given over a period of 2 weeks in 
10 treatments to the posterior fossa. After 
radiotherapy was completed on Apr. 18. 
1978 he was maintained on combination 
chemotherapy with vincristine, actino- 
mycin, cyclophosphamide and intrathe- 
cally administered methotrexate in the 
same doses as before every 6 weeks. The 
chemotherapy was discontinued in Feb­
ruary 1979. Two years after the oper­
ation he is alive and well without clinic­
al evidence of recurrence. His physical 
growth and mental development are 
satisfactory.
Discussion
rhabdomyosarcoma of the brain ap­
pears to be the ectomesenchyme of 
the neural crests."
Tumours containing rhabdomyo- 
blasts may be classified into three gen­
eral types: teratomas, medullomyoblas- 
tomas and rhabdomyosarcomas. Rhab­
domyosarcoma is quite distinct from 
medulloblastoma and teratoma which 
are markedly argyrophilic and com­
posed of striated muscle cells and 
other mesenchymal tissue but without 
any neuroblastic or teratomatous ele­
ments.4
The reported cases of pure rhabdo­
myosarcoma of the brain, including 
the present case, are summarized in
Seven of the 10 reported rhabdo­
myosarcomas of the brain were in 
children, ranging in age from 9 
months to 18 years. There were six 
girls and four boys. Seven tumours 
were located in the posterior fossa: 
four in the cerebellum, one in 
the cerebellopontine angle, one in the 
brain stem and one in the fourth ven­
tricle. Three of seven demonstrated 
diffuse subarachnoid spread.
The use of combined treatment 
modalities has resulted in an im­
proved survival rate for children with 
rhabdomyosarcoma." Not until che­
motherapy was added to operation 
and radiotherapy did substantial im-
The histologic origin of primary Table I . provement occur. This is probably true
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Lopes de F a r ia , 1957" 52 F C e re b e llu m N o n e 5 mo D e a d
K oide and  Is h izo n e , 1957- 15 M C e re b ru m D e c o m p re s s iv e  o p e ra tio n 5 mo D e a d
w ith  ir ra d ia t io n
O z e k i, 1960M 29 M C e re b ru m N o n e H  mo D e a d
L e g ie r  and  W e lls  19674 
S h u a n g s h o ti, P iy a ra tn  an d
31 M C e re b e llu m E xcis ion  w ith  ir ra d ia t io n 2 y r D e a d
V ir iy a p a n ic h , 196 8 10 4 F C e re b e llu m N o n e 1 mo D ead
L eed h am , 1972* 
M a ts u k a d o , Y oko ta  and
45 F C e re b ru m E xc is io n 10 mo D e a d
M aru b a y a s h i, 1975r 31 F F o u rth  v e n tr ic le E xc is io n  w ith  ir ra d ia t io n 2 y r D ead
P a s q u ie r , C ouderc  an d  P a s q u ie r , 1975" 8 F B ra in  s tem N o n e 3 mo D ead
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c o m b in a tio n  c h e m o th e ra p y
Fig. 3a
FIG. 3—(a) Many malignant giant cells with hyper chromatic large nuclei and deeply eosinophilic cytoplasm 
(hematoxylin and eosin. reduced by 24% from X400). (b) Ultrastructural appearance of malignant rhabdomyoblast. Fila­
ments and abortive Z bands are seen in cytoplasm (reduced by 38% from X7000).
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of primary rhabdomyosarcoma of the 
brain. Among 10 reported patients, 
ours is the only one treated with com­
bined modalities (subtotal removal 
of tumour and adjuvant radiotherapy 
and chemotherapy) and the only one 
to survive with no clinical evidence of 
disease more than 2 years after treat­
ment.
The cause of death of the nine other 
patients was persisting primary 
tumour. There was no case of distant 
metastasis.
The response of our patient suggests 
that this rare tumour might be con­
trolled by subtotal removal followed 
by radiotherapy and chemotherapy.
We thank Dr. J.P. deChadravian, 
department of pathology, Montreal Chil­dren’s Hospital. Miss Nilo Moller for typing the manuscript and Dr. John Wu,
department of hematology, Montreal Children’s Hospital, for reviewing the manuscript.
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Glucagon Therapy in Acute Pancreatitis: 
Prospective Randomized Double-Blind Study
H .T. D eba s, m d , f r c s [c ], R.J. H ancock , md, f r c s [c ], P. So o n -Sh io n g , m b , b c h , H .A . Sm y t h e , p h m  b and
M.M. C a ssim , m d , fr c s[c ]
The known suppressive actions of 
glucagon on the secretion of pancreatic 
enzymes and of gastric acid, and 
the reported effectiveness of glucagon 
in treating acute pancreatitis, 
prompted the authors to carry out a 
prospective, randomized, double-blind, 
controlled trial of this hormone. Sixty- 
six patients with acute pancreatitis 
admitted to the surgical service of the 
Vancouver General Hospital were 
randomized into two groups of 33, 
receiving either glucagon or placebo 
in addition to their conventional 
therapy. The two groups were com­
parable with respect to the cause 
of the pancreatitis and the severity 
of the disease. Glucagon did not 
reduce the patients' analgesic 
requirements or the duration of
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abdominal signs, ileus, hyperamylase- 
mia or hospital stay. Of the 66 pa­
tients, 4 died. Three of these were in 
the group receiving glucagon. The 
authors conclude that, contrary to 
theoretical expectations and the results 
of past uncontrolled trials, glucagon 
has no beneficial effect on the clinical 
course or outcome of acute pancrea­
titis, irrespective of the etiology 
or severity of the disease.
L'activite suppressive bien connue du 
glucagon sur la secretion des enzymes 
pancreatiques et de I’acide gastrique, 
ainsi que I’efficacite signalee du 
glucagon dans le traitement de la 
pancreatite aigiie ont incite les 
auteurs a realiser une etude pros­
pective controlee, randomisee, et a 
double-insu de cette hormone. 
Soixante-six malades accueillis au 
service de chirurgie du Vancouver 
General Hospital pour pancreatite 
aigiie ont ete repartis au hasard en 
deux groupes de 33 sujets qui ont repu, 
en plus du traitement conventionnel, 
soit du glucagon, soit du placebo.
Les deux groupes etaient comparables 
pour ce qui est de la cause de la
pancreatite et de la gravite de la 
maladie. Le glucagon n'a reduit ni 
les besoins en analgesiques, ni la 
duree des signes abdominaux, de 
I’ileus, de I'hyperamylasemie ou du 
sejour a I 'hop i ta I. Quatre des 66 
patients sont decedes, dont 3 dans 
le groupe qui recevait du glucagon.
Les auteurs concluent que contrai- 
rement aux attentes theoriques et 
aux resultats d’etudes anterieures 
non controlees, le glucagon n'a aucun 
effet favorable sur 1'evolution clinique 
ou I'issue de la pancreatite aigiie, 
quelle qu'en soit I'etiologie ou la 
gravite.
Four physiologic actions of glucagon, 
the 29-amino-acid pancreatic poly­
peptide, suggest that it might have 
beneficial effects on the clinical 
course of pancreatitis: (a) it is a 
powerful inhibitor of pancreatic en­
zyme;1 (b) it inhibits gastric acid 
secretion,2 which is the main drive 
for secretin release from the intestine; 
(c) it increases pancreatic blood flow; 
and (d) its inotropic action is capa­
ble of improving cardiac output. In­
deed, in an uncontrolled clinical study
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in 1973, Condon, Knight and Day3 
showed that glucagon is of benefit to 
patients with acute pancreatitis.
In a controlled double-blind ran­
domized manner this prospective 
study compares the effects of glu­
cagon and placebo on patients with 
acute pancreatitis admitted to the sur­
gical services of the Vancouver Gen­
eral Hospital. The study shows that 
glucagon has no effect on the clinic­
al course or on the outcome of acute 
pancreatitis.
Patients and Methods
Sixty-six patients with acute pan­
creatitis seen at the Vancouver Gen­
eral Hospital between Jan. 1, 1975 
and Dec. 31, 1977 were studied. The 
criteria for entry into the study were: 
the presence of typical symptoms 
and signs of acute pancreatitis as­
sociated with elevation of serum 
amylase to three times the normal 
level or operative findings of acute 
pancreatitis at the time of exploratory 
laparotomy. The arbitrary criterion of 
elevation of serum amylase to three 
times the normal value was adopted 
because this value is high enough to 
exclude most acute abdominal condi­
tions that cause hyperamylasemia 
simulating pancreatitis and low 
enough that we did not exclude too 
many patients with acute pancrea­
titis from the study. Once we decided 
to enter a patient into the study, the 
hospital pharmacy randomly assigned 
the patient into the study (group 1) 
or placebo group (group 2). The 
pharmacy then issued to the ward 
glucagon (1 mg) or placebo (saline) 
in 1-ml syringes. The patients re­
ceived 1 ml of glucagon or placebo 
every 3 hours by continuous intra­
venous infusion in 100 ml of 5% 
glucose in water. By this means we 
avoided deterioration of glucagon in 
the intravenous bottle. This would 
occur if the drug stayed in solution 
longer than 3 hours at room tem­
perature.
Baseline studies included a com­
plete history-taking and physical 
examination, estimation of the serum 
and urine amylase, the serum cal­
cium, phosphorus, fasting blood 
sugar, electrolyte and hemoglobin 
levels, the leukocyte count and dif­
ferential and performance of liver 
function tests. The same examiner 
who made the initial assessment 
(H.T.D. or R.J.H.) also performed 
subsequent daily clinical evaluation 
of the abdominal signs. The amount 
of fluid administered daily, the vol­
ume of nasogastric suction, the lowest 
blood pressure and highest pulse rate 
and temperature each day and the 24- 
hour narcotic requirement were also
recorded. In addition the following 
values were determined daily: blood 
hemoglobin, leukocyte count and 
differential, serum calcium, serum 
amylase and 24-hour urine amylase. 
Serum bilirubin, alkaline phospha­
tase, fasting blood glucose and elec­
trolyte levels were determined every 
2 days.
Studies were continued until the 
patient was free of pain and the 
serum amylase had returned to nor­
mal or, if the serum amylase level 
remained elevated, until the patient 
was pain free for 4 days. The total 
number of hospital days, the final 
etiologic diagnosis (e.g., biliary tract 
disease, alcoholism, trauma) and any 
side effects of treatment were also 
recorded.
Following the completion of the 
protocol, the code was given to the 
computer analyst who then applied 
the y2 test to evaluate any differences 
between the glucagon and the placebo 
groups. In instances where the blood 
levels of chemicals (e.g., sugar, cal­
cium) were compared, the signif­
icance of difference between the two 
groups was evaluated using Student’s 
r-test for unpaired values.
Results
Comparison of Patient Groups
Patients in the two groups were 
comparable in age, sex and initial 
serum amylase and calcium levels. 
Biliary tract disease and alcoholism 
as etiologic factors were also equally 
distributed (Table I). The severity of 
disease in the two groups as assessed 
by abdominal signs, tachycardia and 
blood pressure changes, was also 
similar.
Clinical Response
The clinical response in each group 
was assessed by resolution of ileus 
and abdominal tenderness and by the 
amount of analgesic required, as well 
as by the volume of nasogastric suc­
tion and intravenous fluids required 
(Table II). There were no statistically 
significant differences between the 
groups with respect to any of these 
variables.
Hematologic and Biochemical
Responses
There were no differences between 
the two groups with respect to daily 
changes in hemoglobin concentration, 
leukocyte count, liver function test 
results or electrolyte levels. Although 
the serum calcium concentration did 
not differ in the two groups at the
Table 1—Comparison of Patients in the Glucagon and 
Placebo Groups on Admission*
Feature
Group
1 2
No. of patients 33 33
Age, y r t 52.5 ±  19.6 53.6 ±  18.6
Sex
Male 23 18
Female 10 15
No. of patients with gallstones 13 14
No. of alcoholics 18 15
Serum amylase, IU/1 2463 ±  1481 2179 ±  1642
Serum calcium, m g/dlf 8.0 ±  2.4 9.0 ±  0.8
♦Differences were not significant.
(Mean ±  standard deviation.
Table I I - Clinical Course of Patients*
Group
Variable 1 2
Duration of tenderness, d 5 7
72-h narcotic requirement, mgf 505 ±  440 356 ±  367
72-h volume of nasogastric
suction, I f 1.7 ±  1.7 1.8 ±  1.7
72-h volume of fluid administered
intravenously, If 10.0 ±  2.3 8.7 ±  2.7
♦Differences were not significant. 
fM ean ±  SD.
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time of entry to the study, the con­
centration 1 day after the onset of 
treatment was significantly lower 
(P <  0.05) in group 1 (8.4 ±  0.2 mg/ 
dl [2.10 ±  0.05 p.mol/1]) than in 
group 2 (9.1 ±  0.1 mg/dl [2.27 ±  
0.02 p.mol/1]). This is in keeping 
with the known hypocalcemic effect 
of glucagon.
Figs. 1 and 2 compare daily con­
centrations of serum amylase and 
fasting blood sugar respectively in 
the two groups. It is clear that glu­
cagon did not decrease the duration 
of hyperamylasemia (Fig. 1). Plow- 
ever, patients in group 1 generally 
had a higher fasting blood glucose 
level (P <  0.05), which is again in 
keeping with the hyperglycemic ac­
tion of glucagon (Fig. 2).
Clinical Outcome
The mean hospital stay was 26 ±  5 
days for group 1 and 20 ±  3 days 
for group 2. Of the 66 patients 
studied 4 (6%) died. Of the four 
deaths, three were in group 1. There 
was no statistically significant dif­
ference with respect to either the 
length of hospital stay or mortality 
between the two groups. The cause of 
death in the patient in group 2 was 
cerebrovascular accident. Of the three 
patients in group 1, severe hemorrha­
gic pancreatitis verified at autopsy 
was the cause in two; the third, a 91- 
year-old man, died of congestive 
heart failure.
Side Effects
There were no identifiable side ef­
fects of treatment.
Discussion
Contrary to theoretical expect­
ations and to the results of earlier 
uncontrolled studies, this prospect­
ive, randomized, double-blind trial 
has shown that glucagon is of no 
value in improving either the course 
or the outcome of acute pancreatitis. 
Since the completion of our study, 
two similar randomized controlled 
trials have led to the same conclu­
sion. One of these studies was that 
by Olazabal and Fuller4 from Case 
Western Reserve University in which 
26 patients with pancreatitis due to 
alcoholism were randomized into the 
two groups. No differences were 
found between the two groups with 
respect to symptoms, signs, labora­
tory tests and requests for analgesia. 
A much larger multicentre trial of 
glucagon and aprotinin,5 concerned 
principally with death from acute 
pancreatitis, showed that the death
rate in 257 patients studies was 11% 
and that neither glucagon nor apro­
tinin diminished the risk of death.
These studies underline the im­
portance of controlled, prospective, 
double-blind trials. Condon, Knight 
and Day3 compared the 7% mor­
tality in their glucagon-treated pa­
tients with the 22% and 26% of 
most previously published series in
FID. 1— Serum amylase concentra­
tions in patients treated with glucagon 
(broken line) and placebo (solid line) 
(mean ±  standard deviation). Each 
point represents mean of 33 determina­
tions of serum amylase in 33 patients. 
Day 0 represents day before therapy 
began. Upper limit of normal for serum 
amylase in our laboratory is 300 IU/1.
FIG. 2— Fasting blood sugar values 
(mean ±  SD). Each point represents 
mean of 33 determinations in 33 pa­
tients. Solid line =  placebo, broken 
line =  glucagon.
Britain. There is little validity in such 
comparison since the mortality from 
acute pancreatitis is changing. Ag­
gressive management of blood-volume 
deficit and metabolic abnormalities, 
improved management of respiratory 
failure and better nutritional support 
with total parenteral nutrition have 
all helped to reduce mortality in 
acute pancreatitis. The patients in 
our study were mostly referred to 
the surgical service because they were 
considered to have an “acute abdo­
men” and, probably had a more sev­
ere form of the disease than those 
reported by Olazabal and Fuller.4 
Indeed, several of our patients were 
in hypovolemic shock on admission 
to the study.
The dosage of glucagon we used (1 
mg loading dose followed by conti­
nuous infusion of 1 mg every 3 hours) 
is comparable to that used by Con­
don, Knight and Day3 and by others. 
In this dosage it had demonstrable 
biologic activity since it caused appre­
ciable hyperglycemia and hypocal­
cemia. Whether a higher dosage might 
have been more effective in influen­
cing the course and outcome of acute 
pancreatitis is a matter of specula­
tion. In the absence of any trend in 
the present study, we doubt whether 
a higher dosage would be any more 
effective.
We conclude, therefore, that glu­
cagon is ineffective in improving 
either the course or outcome of acute 
pancreatitis whatever the cause or 
severity of the disease.
We thank all the members of the 
division of general surgery, Vancouver 
General Hospital who allowed us to 
study their patients, Ms. Ruth Kaplan 
and Ms. Margaret McKinney for co­
ordinating the data collection, Mirs. 
Eva Germann for processing the data 
and the nursing staff on the surgical 
wards of the Vancouver General Hos­
pital for their cooperation.
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Inadvertent Primary Vaginal Incision 
during Cesarean Section
B ruce  B ryan,
A previously undescribed complication 
of low transverse cesarean section— 
primary entry into the upper vagina— 
is reported in two women. The 
patient at risk is a parturient whose 
cervix is completely dilated and who 
has been pushing in second stage 
labour. Possible complications 
include bladder injury, vesical fistula, 
hemorrhage and laceration of adjacent 
ligamentous structures. Management 
requires meticulous hemostasis, 
careful search for bladder injury and 
anatomical closure of the vaginal 
defect. The postoperative course and 
prognosis of well managed cases 
are good.
La penetration de la partie superieure 
du vagin, une complication de la 
cesarienne transversale basse qui n'a 
pas ete decrite jusqu'a maintenant, 
est signalee chez deux femmes.
La patiente particulierement exposee 
est la parturiente dont le col uterin 
est completement dilate et qui a 
pousse durant la phase d'expulsion.
Les complications possibles incluent 
lesion de la vessie, fistule vesicate, 
hemorrhagie et laceration des struc­
tures ligamenteuses adjacentes. Le 
traitement requiert une hemostase 
meticuleuse, la recherche minutieuse 
des blessures de la vessie et la 
fermeture anatomique de la breche 
vaginale. L’evolution post-operatoire 
et le pronostic des cas bien traites 
sont bons.
A complication of low transverse ce­
sarean section not described in the 
English literature during the past 30 
years occurred twice during 458 pri­
mary cesarean sections performed at 
Barnes Hospital, St. Louis, between 
Sept. 1, 1977 and Jan. 31, 1979. In 
both cases, the transverse incision, 
which was thought to be through the 
lower uterine segment, actually en­
tered the anterior vaginal fornix leav­
ing the myometrium completely intact.
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The fetus and placenta were delivered 
through an intact, completely dilated 
cervix and the vaginal incision.
Case Reports
Case /
A 28-year-old primigravida presented 
at term following spontaneous rupture of 
the membranes in early active labour. 
Her past medical history and her ante­
natal course had been unremarkable. 
The cervix was dilated to 4 cm on ad­
mission and rapidly became fully dilated 
with the fetal vertex in an occipitopos- 
terior position. After 2 hours of pushing 
in second stage labour, the fetal vertex 
had descended to station spines + 2  (de­
scent 2 cm beyond the ischial spines) 
and remained in the occipitoposterior po­
sition. When attempted forceps rotation 
and vacuum extraction to correct the 
persistent occipitoposterior position were 
unsuccessful, primary low cesarean sec­
tion was performed, using a transverse 
uterine incision which inadvertently en­
tered the vaginal fornix. The woman was 
delivered, through the vaginal incision, 
of a living 3380-g infant whose Apgar 
scores were 8 and 9 at 1 and 5 minutes, 
respectively. The base of the bladder was 
lacerated during the delivery and there 
was profuse bleeding from the vesical 
venous plexus. The cystotomy was re­
paired in layers. Hemorrhage was con­
trolled using suture ligatures and pres­
sure. The anterior vaginal wall was re­
paired with a double layer of sutures. The 
woman was given broad spectrum anti­
biotics, received a 2-unit transfusion of 
whole blood and required drainage of the 
bladder through a urethral catheter for 
7 days. Her postoperative course was 
otherwise normal. She was discharged 8 
days after the operation and there have 
been no complications during a 2-year 
follow-up.
Case 2
A 27-year-old woman, gravida 3, para 
2, was admitted at term in early labour. 
Her cervix was dilated to 3 cm. Her 
history was unremarkable except that a 
pelvic fracture sustained in an automo­
bile accident had preceded her two 
previous uncomplicated vaginal deliveries. 
Her time-cervical dilatation curve was 
normal. An elective amniotomy was per­
formed when the cervix reached 9 cm 
dilatation. When cervical dilatation ar­
rested over the next hour, oxytocin was 
administered. A persistent anterior cer­
vical lip was manually retracted over the 
fetal vertex and an attempt manually 
to rotate the fetal vertex from a left
FRCSfc], FACOG
occipitotransverse position failed. After 
2 hours of pushing in second stage 
labour, fetal bradycardia that was un­
responsive to oxygen by mask and to 
lateral positioning prompted immediate 
delivery. The fetus was in a left occipito­
transverse position at station spines -f2. 
During the low transverse cesarean sec­
tion, the upper vagina was inadvertently 
incised. She was delivered through the 
vaginal incision of a 3490-g infant whose 
Apgar scores were 3 and 8 at 1 and 5 
minutes. The bladder was intact, but 
profuse bleeding from the vesical venous 
plexus was incompletely controlled by 
sutures and pressure. The vesicouterine 
space was drained onto the anterior ab­
dominal wall for 72 hours. She was given 
antibiotics. The postoperative recovery 
was smooth and she was discharged 7 
days after operation. Follow-up for 18 
months disclosed no complications.
Discussion
In both cases, the patients had 
pushed in the second stage of labour 
for approxim ately 2 hours and a 
vaginal m anipulation had been per­
form ed. A t the time of cesarean sec­
tion, the obstetrician entered the vesi­
couterine space immediately above the 
fold tha t identifies the superior m ar­
gin of the bladder. A fter reflecting 
the bladder downwards, the obste­
trician m ade an incision over the fetal 
head. The incision was thought to be 
through the lower uterine segment but 
actually entered the upper vagina, 
and this was not recognized until after
FIG. 1—Primary transverse vaginal incision following delivery of baby. Ce- phalad margin of incision, which re­tracts and becomes indistinct from an­terior lip of fully dilated cervix, has been exaggerated for clarity.
VOLUME 23, NO. 6, NOVEMBER 1980 /  THE CANADIAN JOURNAL OF SURGERY 581
In the
catheterized patient,
"NEOSPORIN
IRRIGATING
SOLUTION STERILE
(neomycin sulfate and polymyxin B sulfate)
Helps prevent the bacterial 
infection before it starts.
Neosporin* Irrigating 
Solution + Saline...
a proven effective 
combination for the 
prevention of 
catheter-induced 
bacteriuria
Bacteriuria used to be a 
“necessary evil” following 
catheterization. But 
Neosporin Irrigating 
Solution changes all that 
by helping to prevent 
bacteriuria and 
gram-negative rod 
bacteremia associated with 
indwelling catheters.
That’s because 
Neosporin Irrigating 
Solution has a broad, 
overlapping spectrum of 
activity against susceptible 
strains of gram-negative and gram-positive 
uropathogens (including most strains of 
Proteus and Pseudomonas). Resistance has 
not been a problem with this agent.
Neosporin can be used with three-way 
catheters or other catheter systems. Because 
Neosporin does not irritate the bladder, 
there is no need to interrupt continuous 
irrigation.
Neosporin is recommended in diluted 
solution for continuous bladder irrigation in 
short-term therapy (up to 10 days).
Neosporin is not for injection.
*Trade Mark
Calmic Medical Division 
Burroughs Wellcome Ltd.
LaSalle, Que.
“ Neosporin* Irrigating 
Solution
Neomycin Sulfate and 
Polymyxin B Sulfate Solu­
tion for Irrigation U.S.P.
A concentrated antibiotic 
solution to be diluted for 
urinary bladder irrigation
not for injection
Description: Each ml contains: neomycin sulfate equiv­
alent to neomycin base 40 mg, polym yxin B sulfate 
200 000 units, distilled water q.s.
Action: Polymyxin B sulfate is bactericidal to most 
gram -negative bacilli, including c lin ica lly  isolated 
strains o f Pseudomonas aeruginosa (B. pyocyaneus).
This organism is conspicuously absent from  the spectra 
of most other antibiotic agents, but it is highly suscep­
tible to polym yxin B sulfate, which is acknowledged to 
be an effective agent fo r the treatment and prophy­
laxis o f Pseudomonas infections.
Neom ycin sulfate is bactericidal against a wide range 
of gram -negative and gram-positive organisms. It is 
particu la rly  effective against many strains o f Proteus. 
W hen used topically  polym yxin B sulfate and neomy­
cin are rarely irrita ting, and absorption from  skin or 
mucous membranes is insignificant. The index of aller­
genicity o f this com bination has been shown over the 
years to be very low; and fina lly , since these antibiotics 
are seldom used systemically, the patient is spared sen­
sitization to those antibiotics which m ight later be 
required systemically.
Indications: To be used as a continuous irrig an t or 
rinse fo r short-term use (up to W days) in the urinary 
b ladder o f abacteriuric patients to help prevent bac- 
teriu ria  and gram-negative rod bacteremia, associated 
with the use o f indwelling catheters.
Contraindications: This product is contraindicated in 
those individuals who have shown hypersensitivity to 
any of its components.
Caution: Since the concentration o f neomycin used in 
this preparation is in the range known to cause renal 
toxicity, care should be exercised during the irrigation 
procedure to prevent reflux o f the solution up the 
ureters. As w ith other antib io tic  preparations, pro­
longed use may result in overgrowth o f non-susceptible 
organisms, including fungi. Appropria te  measures 
should be taken if this occurs. The safety and effective­
ness o f this preparation fo r use in the case o f patients 
with recent lower urinary tract surgery has not been 
established.
Dosage and Administration: This preparation is spe 
c ifica lly  designed fo r use with three-way catheters or 
with other catheter systems perm itting continuous irri 
gation o f the urinary bladder.
Using sterile precautions one (1) ml o f Neosporin Irri­
gating Solution Sterile should be added to a 1 000 ml 
bottle o f isotonic saline solution. This bottle should then 
be connected to the in flow  lumen o f the three-way 
catheter which has been inserted with fu ll aseptic pre­
cautions. The outflow  lumen should be connected, via 
a sterile disposable plastic hose, to a sterile disposable 
plastic collection bag.
Inflow  rate, fo r most patients, o f the 1 000 ml saline 
solution of neomycin and polym yxin B, should be 
ad|usted to a slow drip  to deliver about 1 000 ml every 
twenty-four hours. If the patient's urine output exceeds 
2 litres per day it is recommended that the in flow  rate 
should be ad|usted to deliver 2 000 ml o f the solution 
m a twenty-four hour period.
It is im portant that the rinse o f the b ladder be continu­
ous. The in flo w  of rinse solution should not be inter­
rupted fo r more than a few minutes.
Presentation:
Packings of 10 and 100 ampoules of 1 ml, and 
vials of 20 ml.
A d d itio n a l p roduct in fo rm a tio n  is a v a ila b le  on 
request.
’  Trade M a rk
PAAB
CCPP C 8025
Calm ic M ed ica l D iv is ion  
B urroughs W ellcom e Ltd.
LaSalle, Que
delivery, when the margins were iden­
tified for closure. In both cases, the 
caudad margin was clearly seen while 
the cephalad edge of the incision 
through the anterior vaginal fornix 
had apparently retracted to become 
indistinct from the anterior lip of the 
fully dilated cervix (Fig. 1). The re­
pair approximated the distinct caudad 
margin to the anterior lip of the cer­
vix, followed by a second imbrication 
layer of paravaginal and lower uterine 
segment tissues.
The two complications we encoun­
tered were bladder laceration which 
was repaired primarily and profuse 
venous bleeding from the base of the 
bladder. Injury to the bladder or ure­
thra, hematoma formation with pres­
sure necrosis or infection could pre­
dispose to fistula formation. Although 
this complication did not occur in our 
patients, vesicouterine and vesico­
vaginal fistulas were the subject of one 
report.1 The patient had been in labour 
for 18 hours and difficulty was en­
countered with the bladder.1 It is 
possible that a primary vaginal 
incision analogous to what we 
describe initiated that patient’s com­
plicated course. Other complications 
that might accompany primary entry 
of the vagina during cesarean section 
include extension of the incision into 
the cardinal ligament or cervix as the 
cut is curved cephalad with scissors 
and injury to the ureter or the de­
scending branch of the uterine artery.
When a low transverse cesarean 
section is performed on a woman 
whose cervix is fully dilated, who has 
pushed in second stage labour and in 
whom the presenting part has been 
delivered into the upper vagina, inad­
vertent primary vaginal incision is 
more likely. It should be possible to 
avoid surgical entry of the vagina 
rather than the uterus by incising the 
lower uterine segment at or above the 
reflection of the vesicouterine peri­
toneum. Since the position of the re­
flection onto the uterus is variable 
or may be distorted by traction onto 
the upper uterine segment, or both, 
identification of the transverse uterine 
muscle markings (as opposed to the 
longitudinal appearance of muscle 
forming the vaginal wall) is a further 
safeguard to correct placement of the 
uterine incision. Moreover, if the fetal 
head is tightly impacted into the pel­
vis, an assistant can provide upward 
pressure onto the vertex with gloved 
fingers in the vagina. This maneuver 
may promote correct placement of the 
lower segment incision over the fetal 
head, may reduce the transabdominal 
forces required to assist delivery and
should minimize extension of the in­
cision and its consequences. If vaginal 
entry has occurred, careful inspection 
of the bladder is mandatory so that 
primary repair of lacerations and 
prolonged drainage of the bladder 
can be effected. Hemostasis must be 
meticulous and surgical drainage of 
the vesicouterine space may be neces­
sary. Imbrication of the vaginal fornix 
with a two-layer closure using ab­
sorbable suture appears adequate. Al­
though both our patients received an­
tibiotics prophylactically, this may not 
be necessary. With proper surgical 
management the postoperative course 
is smooth and there appear to be no 
long-term sequelae.
We thank Drs. N. Muschany and J. 
Reed, who allowed us to report their 
patients.
Addendum
Since this manuscript was prepared 
two more cases of inadvertent vaginal in­
cision during cesarean section have 
occurred at our institution. The clinical 
features of these two cases mirrored 
those in this report.
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NOTICES
Course for General Surgeons
The annual refresher course for gen­
eral surgeons will be held at the 
Women’s College Hospital, University 
of Toronto, Toronto, Ont. from Feb. 
2-4, 1981. There will be symposia on: 
the biliary tract, esophageal problems, 
breast carcinoma, rectal carcinoma, 
pediatric surgery, what’s new, and 
how I manage, and workshops on 
fractures, thoracoabdominal trauma, 
gastroduodenal surgery, intensive 
care, vascular surgery, sepsis and nu­
trition, head and neck, and proctol­
ogy. For further information contact: 
Office of Continuing Medical Educa­
tion, Rm. 245, Fitzgerald Building, 
University of Toronto, Toronto, Ont. 
M5S 1A8 or phone (416) 978-2718.
Chemotherapy Congress
The 12th International Congress of 
Chemotherapy will take place July 
19-24, 1981 in Florence, Italy.
The topics will include antimicro­
bial, anticancer and antivral chem­
otherapy as well as mmunology and 
immunotherapy.
continued on page 587
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Cystic Adventitial Disease of the Popliteal Artery
Pierre Page, md* and F ernand Laurendeau, md, FRCs[c]f
Cystic degeneration of the popliteal 
artery is a rare vascular condition. 
The authors report on the third case 
recorded in Canada and provide a 
follow-up report of the first recorded 
case published in 1969. Observations 
made at operation on the anatomical 
relationship of the cyst give more 
information on the etiology of this 
curious entity. The clinical and 
roentgenologic aspects, the etiologic 
theories and treatment are briefly 
reviewed. The authors conclude that 
there are three principles of treatment 
applicable to this condition: (a) 
incision with evacuation of the cyst 
may be effective, (b) the lesion 
should be resected if evacuation is 
unsuccessful and (c) popliteal 
angioplasty should be avoided.
La degenerescence kystique de I’artere 
poplitee est une pathologie vasculaire 
rare. Les auteurs presentent ici le 
troisieme cas rapporte dans la lite ra ­
ture canadienne. Ms revisent egalement 
les donnees du premier cas publie en 
1969. Les constatations operatoires 
sur les relations anatomiques du 
kyste donnent des informations 
additionnelles pour aider a elucider 
letiologie mal connue. Ils ont 
revise brievement les aspects clini- 
ques et radiologiques du probleme, 
les theories etiologiques et les 
modalites de traitement. Les auteurs 
en arrivent a la conclusion qu’il existe 
trois principes de traitement appli- 
cables a cette pathologie: a) I'efficacite 
possible d'une incision pour 
I’evacuation du kyste, b) resequer 
la lesion si I’evacuation n'amene pas 
de bons resultats et c) eviter 
i'angioplastie poplitee.
In 1969, the senior author (F.L.) was 
the first to report a case of cystic ad­
ventitial disease of the popliteal artery 
in Canada.1 In 1975 Scobie and Curry2 
reported a second case.
' Resident, department of surgery, 
Maisonneuve-Rosemont Hospital, 
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•Head, department of surgery, 
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At the time the first Canadian case 
was published, 32 others had been 
recorded in the world literature. More 
recently, Flanigan and associates3 
studied this rare condition and found, 
by correspondence, a total of 115 
cases. The authors pointed out in 
their conclusion the need for further 
observations by surgeons to determine 
the cause of cystic adventitial disease.
Early in 1979 we treated a second 
patient with this rare vascular disease.
Case Report
A 29-year-old man was seen in March 
1979 at the outpatient clinic of the Mai­
sonneuve-Rosemont Hospital in Mont­
real. His chief complaint was of inter­
mittent claudication of the left calf which 
had begun suddenly on Dec. 19, 1978 
after mild direct external trauma to 
the left knee. There was no past his­
tory of any disease and in particular no 
manifestation of any other vascular dis­
ease.
The left knee appeared normal. There 
was no edema of the left lower limb, no 
trophic signs, no mass in the popliteal 
area. The distal pulses were normal but 
disappeared on active plantar flexion of 
the left ankle as well as the knee and 
after exercise. An arteriogram (Fig. 1) 
showed an extrinsic, smooth, localized, 
stenosis (50%) of the popliteal artery
FIG. 1— Arteriogram of left femoral 
artery showing localized smooth ex­
trinsic stenosis of proximal artery.
with poststenotic dilatation. The radiol­
ogist considered adventitial disease as the 
primary diagnosis, but could not rule 
out completely the diagnosis of popli­
teal entrapment syndrome, which was the 
surgeon’s preoperative diagnosis.
On Apr. 2, through a posterior ap­
proach, we isolated the artery and found 
a soft, pale, cystic mass (2.5 x  4 cm), 
which completely encircled the artery 
over a 4-cm segment (Fig. 2). Because 
we wanted to resect the whole mass we 
did not attempt to evacuate the cyst. 
By carefully dissecting the multiloculated 
cyst, we identified a pedicle continuous 
with the cyst cavities which led into the 
knee joint capsule.
After resecting the involved segment 
of the artery we cut the pedicle flush 
with the knee joint capsule then restored 
arterial continuity by a saphenous vein 
interposition graft.
A longitudinal incision through the 
resected specimen enabled us to see 
the intact intima, the clear mucoid sub­
stance in the cyst cavities and the en­
croachment of the lesion on the arterial 
lumen (Fig. 3).
Discussion
In 1957, Hiertonn, Lindberg and 
Rob4 described the principal features 
of the disease: (a) it occurs in young 
males, (b) it is associated with the 
sudden onset of cramps in the calf and
FIG. 2— LImbilical tape indicates nor­
mal popliteal artery, adjacent to which 
is cystic mass that completely encircles 
artery.
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development of typical intermittent 
claudication, (c) localized stenosis or 
occlusion of the popliteal artery is 
present but generalized arterial 
changes are not and (d) an intramural 
cyst, which contains a gelatinous sub­
stance and has a cyst wall suggestive 
of mucinous degeneration, forms be­
tween media and adventitia compres­
sing the arterial lumen.
On clinical grounds, it is difficult to 
distinguish this condition from popli­
teal entrapment syndrome. Ishikawa, 
Mishima and Kobayashi5 stressed that 
in cystic adventitial disease the distal 
pulse disappears when the knee is 
flexed, but in our case it disappeared 
also when the ankle was actively 
flexed, which is why the surgeon’s pre­
operative diagnosis was popliteal en­
trapment syndrome.
This disease has three arteriographic 
patterns depending on whether or not 
the arterial lumen is occluded. The 
most common pattern is that of ex­
trinsic smooth stenosis similar to what 
is reported here (Fig. 1). The second 
pattern is that of arterial occlusion as 
in the case we reported in 1969.1 The 
third pattern is that of a curvilinear 
scimitar sign produced by a cyst 
located medially or laterally in rela­
tion to the artery (Fig. 4).
In regard to the etiology, there are 
three theories. The first, which has 
the greatest support, is that the lesion 
originates from microtrauma. How- 
ever, this view has never been proved 
beyond doubt and, as stressed by 
Savage,6 it is difficult to understand 
why the condition is not more com­
mon. if trauma is the cause.
FIG. 3— Opened specimen shows in­tact intima compressed by mucoid sub­stance.
The embryologic theory has little 
support because the mucin of the cyst 
is more likely to be composed of 
ground substance breakdown products 
than epithelial cell secretions.3
The ganglion theory is most ac­
cepted. Shute and Rothnie7 demon­
strated the relation of the cyst with a 
neighbouring joint. The histochemical 
studies of De Laurentis and col­
leagues8 demonstrated that the cysts 
are rich in hyaluronic acid radicals. 
Flanigan and associates3 summarized 
the evolution of the pathologic change: 
“The joint capsular degeneration pro­
duces connective tissue change in 
which cells secrete a substance de­
rived from ground substance or col­
lagen which contains hydroxyprolene. 
These cells form cysts which invade 
adventitia. Later, as multiple cysts 
form, enlarge and coalesce with one 
another to form multilocular cavities, 
a sudden rupture of one cavity into 
another can produce rapid growth 
encroachment on the arterial lumen.”
The observations made in our case 
corroborate this theory. If one finds 
no relation between a cyst and the 
overlying knee joint it is probably 
because of degeneration of a part of 
the cyst with subsequent separation.
F ollow -U p o f First Case
Our first patient was operated on 
in June 1966. The arterial lumen was 
obstructed by the cyst, but there was 
no thrombosis. A gelatinous substance 
extruded when an incision was made 
through the adventitia and its evacua­
tion permitted the reappearance of a 
normal distal pulse in the popliteal 
artery. Thirteen years later this pa­
tient is asymptomatic.
Conclusions
The principles of treatment are 
simple:
FIG. 4— Scimitar sign-schematic re­
presentation.
1. Evacuation may be effective, as 
shown by the findings at the 13-year 
follow-up of our first case.
2. The lesion should be resected if 
arterial flow cannot be satisfactorily 
reinstituted by evacuation. A saphe­
nous vein bypass or an end-to-end an­
astomosis is done if technically fea­
sible.3. Popliteal angioplasty should be 
avoided.3
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NOTICEScontinued from page 583
The deadline for the submission of 
abstracts is Feb. 15, 1981.
For further information write to 
the Secretariat, 12th International 
Congress of Chemotherapy, Via della 
Scalla, 10, Florence, Italy, 50123 — 
Florence.
Clinical Application of Hyperbaric Oxygen
The sixth annual conference on the 
clinical application of hyperbaric 
oxygen is scheduled for June 10-12, 
1981 at the Memorial Hospital Medi­
cal Center of Long Beach, University 
of California, Irvine Center for Health 
Education. This clinically oriented 
conference will discuss the currently 
accepted uses of hyperbaric oxygen 
in plenary sessions, and will also in­
clude original papers, workshops, 
sound slides and scientific and com­
mercial exhibits.For further information, contact 
Dr. G.B. Hart, Director, baromedical 
department, Memorial Hospital Medi­
cal Center, 2801 Atlantic Ave., Long 
Beach, CA 90801.continued on page 589
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Treatment of Achalasia: Esophagomyotomy 
with Antireflux Procedure
J M B. N elems, md, frcs[c], J.D. Cooper, md, frcs[c] and F.G. Pearson, md, facs, frcs[c]
The results of Heller myotomy with 
Belsey fundoplication in the treatment 
of 32 patients with achalasia is 
reviewed. Eighteen who received 
no previous surgical treatment had 
good to excellent results. Fourteen 
patients who had undergone previous 
Heller myotomy without an antireflux 
procedure required further surgical 
treatment. Inadequate myotomy and 
reflux esophagitis were the causes of 
failure. In this group four patients 
who were treated by myotomy, Collis 
gastroplasty and the Belsey procedure 
still failed to achieve good to 
excellent results. The authors conclude 
that gastroplasty is contraindicated in 
patients with achalasia.
On examine les resultats chez 32 
patients du traitement de I'achalasie 
par la myotomie de Heller avec 
plicature du fundus de Belsey.
Dix-huit patients n'avaient eu aucun 
traitement chirurgica! precedemment 
et tous eurent d'excellents resultats. 
Quatorze malades, qui avaient subi 
precedemment une myotomie de 
Heller sans procedure anti-reflux, 
necessiterent une nouvelle intervention 
chirurgicale. Les causes d'echec 
furent une myotomie insuffisante et 
une oesophagite de reflux. Dans ce 
groupe, quatre patients traites par 
myotomie, gastroplastie de Collis et 
procedure de Belsey echouerent encore 
dans cette tentative pour obtenir de 
bons ou d'excellents resultats.
Les auteurs concluent que la 
gastroplastie est contre-indiquee 
chez les malades souffrant 
d'achalasie.
We recognize that classic achalasia 
may represent only a part of the spec­
trum of primary motor disorders of 
the esophagus, as suggested by Van-
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trappen and associates1 and Castell.2 
None the less, we wish to report our 
experience in the surgical management 
of 32 patients with a presumed diag­
nosis of achalasia. Investigators at the 
Mayo Clinic, in a series of excellent 
monograms,3'6 have made a compelling 
argument for treating this disorder by 
means of a left transthoracic longi­
tudinal esophagomyotomy extending 
from the esophagogastric junction dis- 
tally to the level of the inferior pul­
monary vein proximally, without 
causing undue traction on the esopha­
gus or unnecessary dissection of the 
esophageal hiatus and without an anti­
reflux procedure. Others,7-8 however, 
have reported that the routine use of 
an antireflux procedure in addition to 
the modified Heller procedure 
provides even better results. It is in 
support of the latter philosophy that 
we describe our experience.
Patients
Thirty-two patients underwent sur­
gical treatment of achalasia between 
1966 and 1976. They ranged in age 
from 14 to 80 years (median 46 years) 
at the time of operation. All com­
plained of dysphagia, 6 suffered epi­
sodes of pain, 12 had regurgitation of 
esophageal contents and 7 had respira­
tory symptoms. Fourteen of the 32 
patients had undergone previous eso­
phageal myotomy without an antire­
flux operation. Three of these 14 pa- 
tints had been operated on twice for 
achalasia. Seven patients had under­
gone previous pneumatic bag dila­
tation without improvement in their 
condition.
All patients had the radiologic fea­
tures of achalasia—a smooth tapered 
narrowing of the distal esophagus and 
no evidence of sequential peristalsis 
in the body of the esophagus. Various 
degrees of esophageal dilatation were 
reported; 20% had mild dilatation, 
60% had moderate dilatation and 
20% had the radiologic appearance of 
a megaesophagus. The radiologist re­
ported an associated hiatal hernia in 
three of the patients who had not 
undergone previous operation and in 
six of the patients who had.
Twenty-five patients were studied
preoperatively by esophageal man­
ometry. The other 7 patients were 
operated upon before this diagnostic 
method was available. Endoscopy re­
vealed esophagitis caused by food 
retention in all the patients not pre­
viously operated on and in six of those 
who had already undergone operation. 
In eight patients previously operated 
on there was evidence of reflux eso­
phagitis, two had ulcerative esopha­
gitis without stricture and six had 
stricture. All strictures were dilatable.
Operative Management
The 18 patients operated upon for 
the first time underwent left thora­
cotomy with esophagomyotomy that 
extended from the proximal part of 
the stomach to the level of the inferior 
pulmonary vein. Unlike the technique 
used by the Mayo Clinic investigators, 
the proximal stomach was mobilized 
intp the thorax to ensure that com­
plete esophageal myotomy was per­
formed. The hiatal hernia so created 
was then formally repaired using the 
Belsey technique. The lateral esopha­
geal sutures were placed on one side 
of the myotomized muscle.
Six of the 14 patients previously 
operated on were found to have had 
an incomplete distal esophageal myo­
tomy. The myotomy was completed 
and a Belsey repair performed.
The remaining eight patients who 
had undergone previous operation 
were found to have reflux esophagitis 
with some degree of esophageal short­
ening. They were treated by Collis 
gastroplasty with Belsey fundoplica­
tion.
Results
Of the 32 patients in our study, only 
1 was lost to follow-up. The mean 
length of follow-up was 52 months.
The criteria for evaluating the qual­
ity of the results obtained were the 
same as those used at the Mayo 
Clinic.6 An excellent result means that 
the patient became entirely asymp­
tomatic. A good result implies that the 
patients were markedly improved but 
that they still had esophageal symp­
toms occasionally. A fair result in-
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dicates that the patients continued to 
have moderate symptoms but that 
their overall condition was improved. 
A poor result signifies that the patient 
was unimproved or the symptoms 
were worse. Fair and poor results 
were considered unsatisfactory.
Of the 18 patients who underwent 
primary surgical treatment, 1 was 
lost to follow-up, 1 3 had excellent and 
4 had good results.
Of the 14 who had undergone myo­
tomy previously without an antireflux 
operation, 6 underwent repeat myo­
tomy with Belsey repair for incom­
plete myotomy and 8 underwent gas­
troplasty with Belsey repair for control 
of reflux esophagitis. Of the six with 
incomplete myotomy three had excel­
lent results and three good. How­
ever, of the eight who underwent 
the Collis gastroplasty procedure, 
one was graded as excellent, 
three as good, three as fair and one as 
poor. These four patients with un­
satisfactory results had persistent 
dysphagia not appreciably improved 
by dilatation.
Discussion
The Mayo Clinic series was large 
and the results were impressive. How­
ever, the reported results were ob­
tained for patients who were treated 
for the first time only. Of the 456 
patients operated upon for the first 
time at the Mayo Clinic between 
1949 and 1975 by esophagomyotomy 
alone, 15% had fair to poor results.6 
The authors make no reference to re­
peat operation for this condition. Ap­
proximately 40% of our cases were 
referred, for reoperation, the patients 
having failed to obtain satisfactory 
results from esophagomyotomy with­
out an antireflux procedure. Incom­
plete myotomy and reflux esophagitis 
were the major reasons for failure.
The one poor and the three fair 
results were in patients who had un­
dergone previous esophagomyotomy 
without antireflux operation. They 
all had reflux esophagitis and sub­
sequently underwent the Collis gas- 
troplasty-Belsey fundoplication. Of 
the 18 patients who had this combi­
nation of surgery, 4 had an unsatis­
factory outcome. Of the 24 patients 
who had esophagomyotomy with 
Belsey repair there were no unsatis­
factory results. A substantial group of 
patients were referred to us because 
of failure following simple esopha­
gomyotomy without an antireflux 
operation. These failures could prob­
ably have been prevented by complete 
myotomy with antireflux repair.
We advocate mobilization of the 
stomach to ensure adequate myotomy 
and a formal repair of the hiatal her­
nia so created. Partial fundoplication 
of the Belsey type is probably the 
repair of choice in the presence of a 
myotomized esophagus. Fundoplica- 
tionof the Nissen type may be too 
complete a barrier for the adynamic 
esophagus to overcome.
There are several reasons for the 
unsatisfactory results in the four pa­
tients who underwent gastroplasty with 
Belsey repair for severe reflux esopha­
gitis and stricture. It is possible that 
the presence of stricture predisposes 
to less satisfactory results. However, 
this was not the experience of Pearson 
and Henderson9 in their management 
of strictures by the combination of 
Collis gastroplasty and Belsey fundo­
plication. The more likely explanation 
lies in the observation that the gastro­
plasty tube functions in a fashion 
similar to the lower esophabeal sphinc­
ter.10 The longitudinal fibres of the 
esophagus, as they fan out in the sling 
fibres of the proximal stomach, are 
incorporated into the gastroplasty 
tube. Since the lower esophageal 
sphincter does not function normally 
in patients with achalasia, it is reas­
onable to presume that the neuromus­
cular function of the gastroplasty is 
likewise impaired. This is the most 
likely explanation for persistent dy­
sphagia in the gastroplasty tube even 
though a large bougie will traverse 
the gastroplasty tube without dif­
ficulty. The physiology of the gastro­
plasty segment is the focus of ongoing 
studies and until this is more clearly- 
defined it is recommended that gastro­
plasty should not be used in the man­
agement of patients with achalasia.
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NOTICES
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Symposium on Facial 
Plastic Surgery
The department of otolaryngology, 
division of facial plastic surgery, and 
extended programs in medical educa­
tion of the University of California 
School of Medicine at San Francisco 
will present an interdisciplinary sym­
posium in facial plastic surgery from 
Apr. 8-11, 1981 at The Stanford 
Court, San Francisco.
The course, designed for the sur­
geon who currently has an active 
reconstructive and facial plastic prac­
tice, will focus on current trends and 
techniques of facial contouring. En­
rolment will be limited to encourage 
and promote effective interaction with
the internationally known guest facul­
ty: Jack Anderson, M. Eugene Tardy 
and Richard C. Webster. Didactic 
lectures stressing new advances will 
be augmented by in-depth discussion 
to ensure adequate evaluation of the 
techniques presented. In addition, ca­
daver dissections will be offered to a 
limited number of course participants. 
Preference for inclusion in the labo­
ratory session will be given to early 
applicants.
Roger L. Crumley and Larry D. 
Schoenrock will be the program chair­
men.
For further information, please 
write Extended Programs in Medical 
Education, University of California, 
Rm. 569-U, San Francisco, CA 94143 
or phone (415) 666-4251.
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BOOK REVIEWS
ACTUALITES CHIRURGICALES. 79e 
congres franyais de chirurgie. I. Chi­
rurgie abdominale et digestive. (Pre­
miere partie). Edite par J-Cl. Patel. 
160 pp. Illust. Masson, Paris; Masson 
Publishing U.S.A. Inc., New York, 
1978. $21, broche. ISBN 2-225-70246- 
2.
ACTUALITES CHIRURGICALES. 79e 
congres francais de chirurgie. II. 
Chirurgie abdominale et digestive. 
(Deuxieme partie). Chirurgie experi- 
mentale. Edite par J-Cl. Patel. 161 pp. 
Illust. Masson, Paris; Masson Pub­
lishing U.S.A. Inc., New York, 1978. 
$21, broche. ISBN 2-225-70400-7.
ACTUALITES CHIRURGICALES. 79e 
congres franpais de chirurgie. III. 
Chirurgie vasculaire et thoraeique, 
orthopedic et trauinatologie. Edite par 
J-Cl. Patel. 156 pp. Illust. Masson, 
Paris; Masson Publishing U.S.A. Inc., 
New York, 1978. $21, broche, ISBN 
2-225-70411-2.
ACTUALITES CHIRURGICALES. 79e 
congres francais de chirurgie. IV. 
Chirurgie generate, urologie-neurochi- 
rurgie. Edite par J-Cl. Patel. 215 pp. 
Illst. Masson, Paris; Masson Pub­
lishing U.S.A. Inc., New York, 1978. 
$21, broche. ISBN 2-225-70422-8.
These four monographs are extensive 
and extremely didactic. For each sub­
ject there is an elaborate review of the 
anatomy and surgical technique but very 
few schematic representations. For in­
stance, the section on the anal canal 
contains four pages on anatomy but no 
drawings.
The first book covers abdominal sur­
gery. In a section on the treatment of 
cancer of the stomach the authors con­
sider the controversy between total gas­
trectomy and proximal or distal gastrec­
tomy. In their hands, total gastrectomy 
for early cancer gave better results than 
the less extensive procedures.
The surgical treatment of pancreatic 
pseudocyst is reviewed. The authors 
had good results with proximal pancre­
atectomy but believe external drainage 
procedures still have a place in the 
treatment of this condition.
Anal fistulas and their problems are 
covered. In the appropriate section left 
colonic esophagoplasty is recommended.
The techniques and problems of an­
astomosis in low anterior abdominal 
resections are presented but unfortunately 
the use of end-to-end anastomosis with 
a stapling device, which has solved many 
of these problems and probably also has 
saved a few colostomies in some cases 
of low-lying cancers of the rectum, is 
not mentioned. Another unsolved prob­
lem is the surgical treatment of acute 
hemorrhagie gastritis.
In a discussion of severe, diffuse peri­
tonitis, an interesting technique of conti­
nuous irrigation of the abdominal cavity 
is presented.
Also in this first book is a discussion 
of sphincterectomy of the Oddi sphincter. 
This appears at a time when most sur­
geons avoid this technique because of 
the high complication rate associated with 
its use.
In the second book splenectomy, trau­
matic and nontraumatic, is discussed and 
its surgical complications and hema­
tologic problems are reviewed. Although 
the review of the complications is ex­
haustive, no mention is made of 
partial splenectomy and more conser­
vative approaches to treatment in cases 
of trauma.
A chapter on chemotherapy is in­
cluded.
With respect to plication, the methods 
of Noble and Childs-Phillips are re­
viewed but no mention is made of other 
types of plication, such as the Baker tube 
plication which possibly gives a better 
result.
The technique of highly selective vago­
tomy is described but no representative 
illustration is offered.
Many other techniques are also dis­
cussed in this book, including colostomy, 
ileostomy, and Whipple and esophageal 
resections.
An interesting discussion is presented 
on the treatment of perforated duodenal 
ulcer. The authors’ method consists of 
a very aggressive, nonsurgical approach 
with suction, antibiotic therapy and care­
ful monitoring of the patient as opposed 
to traditional suturing of the ulcer or 
vagotomy and drainage.
The Kraske (Localio) approach for 
carcinoma of the rectum is discussed. 
Choledochoscopy is described and the 
advantages of this technique are con­
sidered. The last portion of this second 
volume is reserved for experimental sur­
gery.
The third book presents discussions on 
various vascular surgical techniques. 
There is an extensive and interesting dis­
course on lymphedema of the arm after 
mastectomy, the treatment being pallia­
tive.
Orthopedic trauma is covered in chap­
ters that discuss shoulder dislocation, 
fracture of the distal third of the radius 
and dislocation of the cervical spine.
In the last volume, ablative surgery and 
hormonal therapy for breast cancer are 
put together. The concept of reducing 
the tumour mass to allow for better 
chemotherapy is considered.
Important topics such as thrombo­
phlebitis and gas gangrene are covered 
in detail.
The treatment of anuria, urethral rup­
ture and emergencies in neurosurgery are 
also thoroughly discussed in interesting 
fashion.
In summary, these books contain a 
pot-pourri of good review articles that 
are worth reading. Although most of the 
topics discussed are of interest to gen­
eral surgeons and to general practition­
ers, I recommend these four volumes 
particularly to surgical residents.
Jacob Garzon, md, frcs[c]
Ste. 150,
6000 Cote-des-Neiges Rd.,
Montreal, PQ
ADVANCES IN SURGERY. Volume 
13, 1979. Edited by George L. Jordan, 
Jr., James I). Hardy, William P. Long- 
mire, Jr. and others. 329 pp. Illust. 
Year Book Medical Publishers, Inc., 
Chicago, 1979. Price not stated. ISBN 
0-8151-4917-4.
The editors of this volume of “Advances 
in Surgery” continue to maintain their 
standard of excellence in presenting a 
variety of topics of interest to surgeons 
by authors who are authorities in their 
fields. The lead article by Professor 
J.C. Goligher on sphincter-saving exci­
sion for carcinoma of the rectum is 
written in his usual lucid style and based 
on extensive experience. He is objective 
and honest in his approach to this con­
troversial area. His paper is well illus­
trated with clear sketches. He discusses 
in detail the use of the end-anastomotic 
stapler and comments on local coagula­
tion, radiotherapy and local excision.
The article on the treatment of me­
tastatic disease attempts to deal with too 
many disease states in one short paper 
and would have been of greater benefit 
to the reader if it had included some 
tabular data. The authors cover a lot 
of detail in a superficial way. A table 
of chemotherapeutic agents, their applica­
tions, doses and toxic effects would have 
been helpful. The described therapeutic 
benefits and low mortality associated 
with hepatic resection for metastatic 
disease to the liver do not represent the 
common experience.
J.F. Birk concisely updates burn thera­
py and deals with various practical 
aspects; this paper should be particu­
larly helpful to surgical residents and 
surgeons who occasionally treat burns.
The paper on prophylaxis of throm­
boembolism is an excellent review of the 
classic and new approaches to this prob­
lem. It includes a critical analysis of the 
benefits of low-dose heparin administra­
tion. The bibliography is extensive and
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will be of value to those who wish to 
study in this area further.
In updating colonoscopy, William I. 
Wolf describes the historical aspects, 
and advantages of and indications for 
colonoscopy, but his main concern seems 
to be colonic disease and the cancer- 
polyp controversy. Those readers who 
hope to obtain technical tips from the 
vast experience of the author may be 
disappointed.
A fine cookbook approach to the treat­
ment of traumatic wounds is given by 
R.F. Edler and associates. It will prove 
helpful to emergency physicians and resi­
dents. Many of the principles outlined 
are also of value in treating nontraumatic 
wounds.
J.V. Town and R.E. Condon, in a 
logical, well written article entitled 
“Lower extremity amputations for is­
chemic disease” advance the concept of 
carrying out, whenever possible, below- 
knee amputation for end-stage ischemia 
of the lower extremity. Perhaps, they 
will convert those who still believe that 
above-knee amutation is the best treat­
ment for this condition.
The discussion of diagnoses and treat­
ment of obstetric and gynecologic emer­
gencies will act as a refresher course for 
surgeons who will be faced with these 
problems and will also be helpful to sur­
gical residents.
F.H. Ellis, Jr. concisely reviews the 
anatomy, pathophysiology, medical and 
surgical treatment for esophageal hiatus 
hernia. He describes the classic methods 
and assesses the current approaches to 
treatment with an overview based on 
his own expertise.
In summary, the volume is well edited
and collated, providing a balanced ap­
proach to a number of current prob­
lems in surgery .It will be a valuable 
addition to any surgeon’s library.
Harvey H. Sigman, md, frcs[c]
3755 Cote Ste-Catherine Rd.,
Montreal, PQ
CHEMOSURGERY. Microscopically 
Controlled Surgery for Skin Cancer. 
Frederic E. Mohs. 378 pp. Illust. 
Charles C Thomas, Publisher, Spring- 
field, 111., 1978. $43.75. ISBN 0-398- 
03725-6.
This long monograph represents the 
life’s work of a man dedicated to a tech­
nique that will find limited acceptance 
by most physicians involved in the treat­
ment of skin cancer. Introductory chap-
1980 DAVIS & GECK SURGICAL ESSAY AWARD
The presentation of the 1980 Davis & Geek Surgical Essay Award took place in Toronto on Oct. 1, 1980.
The winner of this year’s award was Dr. Leonard Makowka (second front right), who submitted a paper entitled “Stu­
dies into the mechanism of reversal of experimental acute hepatic failure by hepatocyte transplantation”. Dr. Makowka 
is a resident in general surgery at the University of Toronto.
Mr. John W. Ployart (second from left), marketing manager of Davis & Geek, presented the award. Also present are 
Dr. C. Barber Mueller (right), coeditor of the CanadianJournal of Surgery and Mr. F.J. Miller (left), teaching hos­
pital representative of Davis & Geek.
The editorial board and the coeditors of the Canadian Journal of Surgery thank Davis & Geek for providing this 
award. They extend their congratulations to Dr. Makowka and their thanks to those who participated in the 1980 
competition.
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LUNGS
HEART
Ls th e treatment of the pa p  
~ent in shock has progressed 
in recent years, various organ 
systems have, in turn, been 
the “ weak link’’ limiting 
recovery. The deterioration 
often becomes apparent first 
in the kidney where disrup­
tion of cellular metabolism 
causes acute tubular swelling 
Ljsputpnesulting oligurE jl
Soon, the pulmonary vascu­
lature begins to exhibit a  
pattern of interstitial oedema, 
pooling of blood in the stag­
nant microcirculation and 
aggregation of the formed ele­
ments of the blood. Diffusion 
of oxygen from the alveoli is 
greatly decreased, commonly 
resulting in arteriovenous 
shunting -  a phenomenon in 
which blood passes through 
the lung without oxygenation.
If the shock state continues, 
lysosomal enzymes in the 
anoxic pancreas trigger the 
release of myocardial depres­
sant factor (MDF), a vaso­
active peptide which can 
cause further deterioration of 
the microcirculation.
severe shock threatens each link in the 
body’s chain of organ systems
Although cerebral blood flow 
is maintained early in shock 
at the expense of the other 
organs, this state of adequate^ 
perfusion does not persist for 
long. Relatively soon, avail- « 
able oxygen becomes crit- ^  
ically low, and the brain, too, 
turns to anaerobic metabo­
lism. Lactate acid levels rise 
and fluids leakjjitp the in-  ^
testitial spaces. Continued y 
oxygen deprivation threatens 
both the cellular integrity of ~  
the brain and the central ner­
vous system function.
Once shock has progressed > 
beyond its early stage, fluid 
administration alone is usu- -
Solu-Medrol exerts a protective effect on the cell 
to preserve tissue function and increase survival rates
ally  rio t s u ffic ie n t t o  reverse! The actions o f Solu-Medrol •  Pancreatic lysosomes are
4-1 1_________ J  ____________J  ^ .^1 ffnA* nil n f  kn/li^c c«rc4nmc< cfaKllirvorl lio ltin n  tilO nrni ^the haemodynamic and cel- affect all o f the body’s systems: 
lular disruptions. • in  the kidney, increased per-Avum  WAOi * £11 m IV1UUCJ, l l l t l  C43CU |JC 1“
Solu-Medrol, administered in fusion reverses the anoxic state 
- * ’“I—u * -  * 4’ --1—1—4— and improves organ function
as evidenced clinically by an __L
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Solu-Medrol
(methylprednisolone sodium succinate)
Action:
Solu-Medrol, like other corticosteroids, exerts its action 
by its anti-inflammatory effect.
Indications and Clinical Uses:
Intravenous administration of Solu-Medrol is indicated 
in situations in which a rapid and intense hormonal 
effect is required.
Shock:
In severe shock adjunctive use of intravenous methyl­
prednisolone sodium succinate (Solu-Medrol) may aid 
in achieving hemodynamic restoration. Corticoid 
therapy should not replace standard methods of 
combating shock, but present evidence indicates that 
concurrent use of large doses of corticoids with other 
measures may improve survival rates. In particular, 
large pharmacological doses of Solu-Medrol have been 
proven useful in bacteremic or endotoxin shock, 
hemorrhagic shock, traumatic shock, and cardiogenic 
shock.
Contraindications:
Except when used for short-term or emergency therapy 
as in acute sensitivity reactions, Solu-Medrol is 
contraindicated in patients with arrested tuberculosis, 
herpes simplex keratitis, acute psychoses, Cushing’s 
syndrome, peptic ulcer, vaccinia and varicella.
Precautions:
Existence of diabetes, osteoporosis, chronic psychoses, 
active tuberculosis, renal insufficiency or predisposition 
to thrombophlebitis requires that Solu-Medrol be 
administered with extreme caution. In the presence of 
infection, the causative organism must be brought 
under control with appropriate anti-bacterials, or 
therapy with Solu-Medrol should be discontinued. 
While therapy with corticoids does not appear to be 
contraindicated in pregnancy, caution is recommended, 
particularly during the first trimester. Also, newborn 
infants of mothers who received such therapy during 
pregnancy should be observed for signs of hypo- 
adrenalism and appropriate measures instituted if such 
signs are present. Since Medrol, like prednisolone, sup­
presses endogenous adrenocortical activity, it is highly 
important that the patient receiving Solu-Medrol be 
under careful observation, not only during the course 
of treatment but for some time after treatment is 
terminated. Adequate adrenocortical supportive 
therapy including ACTH, must be employed promptly 
if the patient is subjected to any unusual stress such as 
surgery, trauma, or severe infection. Patients should be 
advised to inform subsequent physicians of the prior 
use of Solu-Medrol.
There have been a few reports of cardiovascular 
collapse associated with the rapid intravenous admini­
stration of large doses of Solu-Medrol (greater than
0.5 grams) in organ transplant recipients. The cause 
and relation to other medications (i.e., diuretics) is not 
known at this time, but physicians should be alert to 
this possibility.
Adverse Reactions:
Adverse reactions are not likely to result from short­
term intravenous administration of Solu-Medrol, but 
may be anticipated if continued therapy with oral or 
intra-muscular corticosteroid preparations is to follow. 
Medrol has less tendency than prednisolone to induce 
retention of sodium and water, and in some cases has 
been observed to produce diuresis and an increased 
excretion of sodium. Likewise, therapy with Medrol 
appears to produce less nervousness and psychic 
stimulation than that produced by prednisolone. While 
epigastric distress has not been totally lacking in 
patients receiving Medrol, the incidence and severity of 
this side reaction to date suggest that although Medrol 
has an enhanced anti-inflammatory potency when com­
pared with prednisolone on a weight basis, the so- 
called ulcerogenic potential of this corticosteroid is no 
greater, and may even be less, than that of 
prednisolone.
With the exception of the differences noted in the 
preceding paragraph, Medrol is similar to hydro­
cortisone and prednisolone in regard to the kinds of 
adverse reactions and metabolic alterations to be 
anticipated when treatment is intensive or prolonged. 
Negative nitrogen balance is usually counteracted by a 
high protein intake. In patients with diabetes mellitus, 
Solu-Medrol may increase insulin requirements during 
the period of administration. Ecchymotic manifesta­
tions, while noted only rarely during the clinical 
evaluation of Medrol, may occur. Excessive loss of 
potassium is not likely to be induced by effective 
maintenance doses of Medrol. If such reactions are 
serious or distressing to the patient, reduction in 
dosage or discontinuance of corticoid therapy may be 
indicated. While a retardant effect on wound healing is 
seldom encountered, except in high doses, it should be 
a matter of consideration when Solu-Medrol is admin­
istered in conjunction with surgery.
Symptoms and Treatment of Overdosage:
Single large doses of Solu-Medrol do not have any 
apparent toxic effect and require no specific therapy. 
Continuous overdosage would require careful gradual 
reduction of dosage in order to prevent the occurrence 
of acute adrenal insufficiency.
Dosage and Administration:
In treating severe shock there is a tendency in current 
medical practice to use massive (pharmacological) 
doses of corticosteroids. The following are Solu-Medrol 
doses suggested by various authors:
Author Dose Repeat
Oaks 100 mg Every 2-6 hours
Weil 200 mg 100 mg. every 4-6 hours
Melby 250 mg Every 4-6 hours
Cavanagh 15 mg/kg Every 24 hours
Dietzman 30 mg/kg In 4 hours if needed
Therapy is initiated by administering Solu-Medrol 
intravenously over a period of at least 10 minutes. In 
general high dose corticosteroid therapy should be 
continued only until the patient’s condition has 
stabilized; usually not beyond 48 to 72 hours.
Although adverse effects associated with high dose 
short term corticoid therapy are uncommon, peptic 
ulceration may occur.
In other indications initial dosage will vary from 10 to 
500 mg depending on the clinical problem being 
treated. The larger doses may be required for short­
term management of severe, acute conditions. The 
initial dose usually should be given intravenously over 
a period of at least 10 minutes. Subsequent doses may 
be given intravenously or intramuscularly at intervals 
dictated by the patient’s response and clinical 
condition.
Availability:
As Solu-Medrol (methylprednisolone sodium succinate) 
in 40 mg and 125 mg Mix-O-Vial; 500 mg and 1 g vials 
with water for injection.
Product monograph is available on request.
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ters are devoted to a description of the 
technique and its applications. Chemo- 
surgery is defined as the removal of 
malignant, gangrenous or infected tissue 
by chemical fixation, followed by ex­
cision of that tissue in layers, comple­
mented by the concurrent examination of 
microscopic frozen sections to ensure 
complete removal. The technique is 
based on the premise that the surface 
extent of skin cancers and other cuta­
neous lesions bears no relation to their 
surface appearance and dimensions.
The author coined the term “chemo- 
surgery” in 1936, and the first of his 
more than 60 publications on the subject 
appeared in 1941. The concept is entirely 
empirical and originated while he was 
doing experimental work on the dif­
ference between inflammatory response 
of normal and malignant tissue in rats. 
One of the inflammation-inciting agents, 
20% zinc chloride, was observed to 
produce fixation in situ of tissues with 
preservation of histologic architecture. 
The author adapted this work to the field 
of clinical dermatopathology and thus 
set the stage for a career devoted to 
chemosurgery.
Following the introduction, the use of 
chemosurgery in treating basal cell car­
cinoma, squamous cell carcinoma and 
malignant melanoma is described in an 
unnecessarily ritualistic and detailed 
manner. Application of the technique to 
such benign conditions as cutaneous gan­
grene and various dermatoses is also 
covered. The author’s theoretical basis 
for this rather controversial form of 
therapy is not clear.
Any surgeon familiar with the man­
agement of basal cell carcinoma would 
be put off by the description of the 
primary management of a 1-cm basal 
cell carcinoma of the nasal bridge. The 
painstaking and protracted procedure 
involving multiple quick sections takes 
approximately IV2 hours. The author 
then describes healing by second inten­
tion of the large defect over a period of 
several weeks and notes that the patient 
is free of recurrence 4 years later. The 
cosmetic result is illustrated by a photo­
graph taken at what can only be termed 
a “questionable angle”. Plastic surgeons 
can only sympathize with the unfortunate 
patient who might have undergone exci­
sion and reconstruction with a small 
glabellar flap taking less than 20 minutes 
of the patient’s time.
Dr. Moh’s thesis appears to be that 
because a small percentage of malignant 
cutaneous lesions have an “iceberg” con­
figuration, and therefore tend to recur 
if not adequately excised, all should be 
treated by his time-consuming, laborious 
and therefore expensive technique. The 
fact that the chapter on the treatment 
of gangrene of the extremities by chemo- 
surgical techniques was left to the end 
may be no accident. Had it appeared 
earlier, readers with the most rudi­
mentary knowledge of modern concepts 
of wound healing and surgical technique 
would have read no further.
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The book is not without merit. The 
chapter on modes of spread of cancer 
demonstrates the author’s familiarity with 
the unpredictable tendency of certain 
cutaneous malignant lesions to spread 
along or be turned aside by various 
tissue planes. The chapter on nonchemo- 
surgical management of nonmalignant 
growths, while of interest, would seem 
to be outside the scope of this book.
The bibliography contains 177 ref­
erences of which more than one third are 
to works of Dr. Mohs himself.
G. A llan  T aylor, dds, m d , fr c s[c]
Plastic surgeon,
Ottawa Civic Hospital.
Ottawa, Ont.
MODERN HOSPITAL. International 
Planning Practice. Ervin Putsep. 668 
pp. Illust. Lloyd-Luke Ltd., London, 
1979. Price not stated. ISBN 0-85342- 
141-4.
Despite the constraints of budgetary 
controls, hospitals continually strive to 
maintain the three basic principles: provi­
de good patient care, promote of 
medical education and foster clinical and, 
if possible, basic research. In a new hos­
pital milieu, improvement in all these 
areas can best be promoted by expert 
planning in hospital design and function. 
Furthermore, planning must take into 
consideration the community in which 
the hospital will be built and the needs 
it must satisfy.
Ervin Putsep’s opus is a comprehen­
sive and almost encyclopedic resource in 
the field of hospital planning. His great 
experience and knowledge in the field
are obvious from the factors taken into 
account in his detailed recommendations. 
All aspects of health care—economics, 
patient needs, medical roles, etc. are de­
scribed according to the needs of a 
modern institution, demanded by conti­
nuing advances of medicine in a modern 
society. The book covers almost all 
aspects that must be considered in to­
day’s hospital design, such as hospital 
infection, environment, installations, tech­
nology, to mention but a few. Data 
processing methods in laboratories and 
patient areas are discussed and described 
as necessary adjuncts to efficient adminis­
tration, not only for present needs but 
also future developments which must 
anticipate obsolescence.
The author has taken into considera­
tion the newer concepts of hospital care 
—so-called general care and specialized 
care of a comprehensive university hos­
pital type. In his discussions, Putsep 
has consulted an extensive bibliography 
supporting his thoughts and considera­
tions. His discussions of the economics of 
health care and attitudes to health and 
preventive medicine are most interesting 
and thought-provoking. The paragraphs 
on nursing are most timely in that they 
criticize constructively the role of the 
nurse, a role that she is trying to define 
in the midst of her own identity crisis.
Planning, design, statistics, norms and 
so on are explored in fair detail. Cost- 
benefit construction and function, trans­
portation systems for patients and goods 
are discussed and evaluated. Routes of 
hospital infection and preventive meas­
ures are described in detail. The author 
presents general considerations but goes 
into detail where necessary, for example, 
in the description of operating theatres,
intensive care areas and laboratories. 
Various types of illumination are de­
scribed and compared. The importance 
of noise abatem ent and background 
music in various hospital areas are 
discussed and  the effects considered. The 
importance o f proper ventilation is 
stressed.
Apart from his excellent recommenda­
tions regarding present and future tech­
nical needs in the hospital, the author 
comments in some detail on the patient 
as an individual and on necessity of 
planning for his privacy and comfort. 
Quality of care  must be appreciated in 
all planning considerations.
Laboratory services, surgical centres 
and radiology facilities, including radio­
therapy and scanning, are treated in ex­
cellent detail and contain much valuable 
information for the hospital planning 
team.
Emergency and outpatient areas are 
described and delineated with recom­
mendations for traffic control, trans­
portation and other factors.
This volume is an excellent compen­
dium of facts and information. Almost 
all aspects of hospital planning and de­
sign are covered. The author’s great 
knowledge, research and experience are 
evident throughout this impressive book 
which will be valuable not only to hos­
pital planners and administrators but 
also to those charged with the repon- 
sibility of designing and constructing 
a modern facility. This book would 
be an important addition to the hos­
pital library.
W illia m  R. Sl a t k o ff , md
156 Melbourne Ave.,
Montreal, PQ
Critique of Items 539-542 (SESAP III)
Distinctive antigens and chemical products are identified with growing and metastatic neoplasms, and 
increasingly sensitive and accurate assays permit quantitation of these substances. Correlating their 
values and directional change with the size (bulk) and activity of the related neoplasms has improved 
the ability to predict how successfully operation, radiation, or adjunctive chemotherapy are control­
ling the progress of the disease.
a-Fetoprotein levels have been correlated with both hepatoma and malignant teratomas. Calcitonin 
levels are directly related to the activity of medullary carcinoma of the thyroid gland, which occur in 
conjunction with pheochromocytomas (MEA-II syndrome). Excretion of 3-methoxy-4-hydroxymandelic acid 
(VMA) is an established screening test for pheochromocytoma, and urinary or serum catecholamine levels 
can be specific in this diagnosis. 5-HIAA is a metabolite of serotonin which can be elevated in metastatic 
carcinoid. As additional means are sought to chart the course of neoplastic disease, and as we discover more 
about the altered chemistry of neoplastic cells, other products that may be predictive of specific cell activity 
will be added to this list.
539 E  540 B  541 E  542 E
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THE UNIVERSITY OF BRITISH COLUMBIA 
Faculty of Medicine 
DEPARTMENT OF SURGERY
With the expansion of the medical school 
undergraduate enrollment, and the comple­
tion of the Acute Care Unit of the Health 
Sciences Centre Hospital on this campus, 
positions w ill become available within the 
Department of Surgery during 1981. Appli­
cants should have obtained their Fellowship 
of the Royal College of Physicians and 
Surgeons of Canada, or hold a comparable 
qualification; be eligible for registration by 
the College of Physicians and Surgeons of 
British Columbia; and have demonstrated 
an ability for research and clinical care of 
patients, as well as experience in teaching. 
Appointments w ill be either Geographic fu ll­
time. or part-time. Rank and salary will be 
according to experience and qualifications.
With the expansion of the medical school 
undergraduate enrollment, and the comple­
tion of the new Children's Hospital, a 
position w ill become available within the 
Department of Surgery during 1981. Appli­
cants should have obtained their Fellowship 
in the Royal College of Physicians and 
Surgeons of Canada in Cardio-vascular and 
Thoracic Surgery, and be eligible for regis­
tration by the College of Physicians and 
Surgeons of British Columbia. The applicant 
must have a proven record in clinical re­
search and a strong interest in pediatric 
and adult cardio-vascular and thoracic inten­
sive care organization and applied research. 
Rank and salary w ill be according to expe­
rience and qualifications.
Applications, accompanied by a curriculum vitae, and 
requests for further information should be sent to:
The Head, Department of Surgery
Faculty of Medicine 
700 West 10th Avenue 
Vancouver, B.C. V5Z 1L5
— S80-004
G E N E R A L  S U R G E O N
FELLOWSHIP GENERAL SURGEON 
needed in Vanderhoof, BC
Get away from the competition of city 
practice. Come to a small town in the out­
door paradise of the interior of British 
Columbia. Practise your science with chal­
lenge and commitment.
This is a well-established practice with a 
wide ranging area. New 65-bed hospital with 
a well-equipped operating room. Partnership 
is available.
If you are interested please contact:
Dr. C. H. Stephen or Dr. G. C. Joly
R.R. #2 , Vanderhoof, BC V0J 3A0 
or telephone: (604) 567-2201
CARDIOVASCULAR THORACIC 
SURGEON
Applications are invited for appointment 
to the University of Western Ontario, Depart­
ment of Surgery, Division of Cardiovascular 
and Thoracic Surgery.
Applicants must have a record of special 
competence in cardiovascular research and 
arrythmia surgery. Certification by the Royal 
College of Physicians and Surgeons of 
Canada, and eligibility for licensure in Onta­
rio are essential. This geographic full-time 
appointment w ill be at the University Hospi­
tal. London, Ontario, Canada.
Applications should be submitted to the: 
Chairman, Department of Surgery, The Uni­
versity of Western Ontario, London, Ontario, 
Canada, N6A 5A5. Closing date for receipt of 
applications is December 31. 1980
— S80-001
SACKVILLE MEMORIAL HOSPITAL 
Sackville, New Brunswick, Canada
GENERAL SURGEON
Applications are invited from medically qualified 
Practitioners to serve as a General Surgeon and to 
associate with six General Practitioners and an Intern­
ist, in a University town having a 60 bed accredited 
hospital, serving a population of 12,000. Vacancy due to 
recent death of surgeon. Duties would commence as 
soon as possible. Submit resume, credentials, refer­
ences and telephone contact to:
Dr. B. E. W. Barnhill, Secretary, Medical Staff 
P.O. Box 29
Sackville, New Brunswick, Canada, E0A 3C0 
Telephone: (506) 536-0128 — T017
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